QuickLinksTable of Contents-- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.          )

Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

o

 

Preliminary Proxy Statement

o

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ý

 

Definitive Proxy Statement

o

 

Definitive Additional Materials

o

 

Soliciting Material under §240.14a-12

 

Bruker Corporation

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

ý

 

No fee required.

o

 

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1) Title of each class of securities to which transaction applies:
         
  (2) Aggregate number of securities to which transaction applies:
         
  (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
         
  (4) Proposed maximum aggregate value of transaction:
         
  (5) Total fee paid:
         

o

 

Fee paid previously with preliminary materials.

o

 

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

 

(1)

 

Amount Previously Paid:
        
 
  (2) Form, Schedule or Registration Statement No.:
         
  (3) Filing Party:
         
  (4) Date Filed:
         

Table of Contents


BRUKER CORPORATION
40 Manning Road
Billerica, MA 01821
(978) 663-3660

Dear Stockholder:

        On behalf of the boardBoard of directorsDirectors and management of Bruker Corporation, I would like to invite you to attend our Annual Meeting of Stockholders to be held on Friday,Monday, May 20, 20162019 at 9:30 a.m., Local Time, at the offices of Nixon Peabody LLP, 100 Summer53 State Street, Boston, Massachusetts.

        The Notice of Annual Meeting of Stockholders and Proxy Statement, which describe the formal business to be conducted at the meeting, and Proxy Card accompany this letter. The Company'sOur Annual Report to Stockholders is also enclosed for your information.

        All Stockholders are invited to attend the Meeting. To ensure your representation at the Meeting, however, you are urged to vote by proxy by completing, dating and returning the enclosed Proxy Card. A postage-paid envelope is enclosed for that purpose. Regardless of the number of shares you own, your careful consideration of, and vote on, the matters before the Stockholders is important.

        I look forward to your participation and thank you for your continued support.

  Sincerely,

 

 


GRAPHIC

 

 

Frank H. Laukien, Ph.D.
Chairman, President and Chief Executive Officer

Table of Contents


BRUKER CORPORATION
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Our Stockholders:

        Notice is hereby given that the Annual Meeting of the Stockholders of Bruker Corporation will be held on Friday,Monday, May 20, 2016,2019, at 9:30 a.m., Local Time, at the offices of Nixon Peabody LLP, 100 Summer53 State Street, Boston, Massachusetts, for the following purposes:

1.
To elect the Class I nominees for director named in the accompanying proxy statement to hold office until the 20192022 Annual Meeting of Stockholders and the Class IIIII nominee for director named in the accompanying proxy statement to hold office until the 20172021 Annual Meeting of Stockholders.

2.
To hold an advisory vote to approve the adoption of the Bruker Corporation 2016 Incentive Compensation Plan.compensation paid to our named executive officers.

3.
To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year 2019.

4.
To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

        The boardBoard of directorsDirectors has fixed the close of business on March 24, 201625, 2019 as the record date for the determination of stockholders entitled to notice of and to vote at this Annual Meeting and at any adjournment or postponement thereof.

  By order of the board of directors

 

 


GRAPHIC

 

 

Frank H. Laukien, Ph.D.
Chairman, President and Chief Executive Officer

Billerica, Massachusetts
April 22, 201617, 2019

        All stockholders are invited to attend the meeting. Whether or not you plan to attend, you can ensure that your shares are represented at the meeting by promptly voting and submitting your proxy by telephone or byvia the internet, or by completing, dating and returning the enclosed Proxy Card in the enclosed postage-paid envelope. Your shares cannot be voted unless you vote by telephone or internet, date, sign and return the enclosed Proxy Card, or attend the meeting in person. Regardless of the number of shares you own, your careful consideration of, and vote on, the matters before the stockholders is important. Even if you have given your proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you will not be permitted to vote in person at the meeting unless you first obtain a proxy issued in your name from the record holder.

**************

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 20, 2016:2019:

This Proxy Statement and the accompanying Annual Report are available via the Interneton our website at:http:https://ir.bruker.com


Table of Contents


BRUKER CORPORATION

2019 ANNUAL MEETING OF STOCKHOLDERS
PROXY STATEMENT TABLE OF CONTENTS

GENERAL INFORMATION ABOUT THE 2019 ANNUAL MEETING AND VOTING MATTERS

1

PROPOSAL NO. 1 ELECTION OF DIRECTORS


3

CORPORATE GOVERNANCE


4

DIRECTOR COMPENSATION


13

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT


15

EXECUTIVE OFFICERS


18

COMPENSATION DISCUSSION AND ANALYSIS


21

COMPENSATION COMMITTEE REPORT


44

SUMMARY OF EXECUTIVE COMPENSATION


45

RELATED PERSONS TRANSACTIONS


53

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE


55

AUDIT COMMITTEE REPORT


56

PROPOSAL NO. 2 ADVISORY VOTE ON EXECUTIVE COMPENSATION


57

PROPOSAL NO. 3 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


58

OTHER INFORMATION


60

Table of Contents


BRUKER CORPORATION
PROXY STATEMENT

        ThisWe are furnishing this proxy statement and the enclosed proxy card are furnished in connection with the solicitation of proxies by the boardour Board of directors of Bruker CorporationDirectors (the "Company""Board") for use at the 2016our 2019 Annual Meeting of Stockholders (the "2016"2019 Annual Meeting") to be held on May 20, 2016,2019, at the time and place set forth in the notice of the meeting and at any adjournments thereof. The approximate date on whichof the meeting. We are first sending this proxy statement and form of proxy are first being sent to stockholders ison April 22, 2016.17, 2019.


GENERAL INFORMATION ABOUT THE 2019 ANNUAL MEETING AND VOTING MATTERS

        The holders of a majority in interest of all of the Company'sour common stock, par value $.01 per share, ("Common Stock") issued, outstanding and entitled to vote are required to be present in person or be represented by proxy at the 20162019 Annual Meeting in order to constitute a quorum for the transaction of business. Each share of Common Stockour common stock outstanding on the record date of March 25, 2019 will be entitled to one vote on all matters.

        For Proposal No. 1, the candidates for election as Class I directors and Class II director at the 2016 Annual Meeting who receive the highest number of affirmative votes will be elected to serve in the respective class. For Proposal No. 2, approvalA description of the 2016 Incentive Compensation Plan, the affirmative votevoting requirements and related effect of holders of a majority of the shares of Common Stock represented in person or by proxyabstentions and entitled to votebroker non-votes on the proposal will be requiredeach item proposed for approval.

        Because abstentions with respect to any matter are treatedstockholder action is as shares present or represented and entitled to vote for the purposes of determining whether that matter has been approved by the stockholders, abstentions have the same effect as negative votes for Proposal No. 2. Additionally, "withhold" votes for any of the nominees for election as a director will have no effect on the election of the nominees.follows:

Proposal

Voting Options

Board
Recommendation


Vote Required
to Adopt
the Proposal


Effect of
Abstentions,
"Withhold"
Votes and
Broker Non-Votes

Item 1—Election of 4 Directors Identified in the Proxy Statement"For" all nominees or "Withhold" from all nominees or "Withhold" from one or more nominees"For" all nomineesPlurality: the individuals who receive the greatest number of votes cast "For" will be elected.No impact on election outcome.
Item 2—Advisory Vote to Approve the 2018 Compensation of our Named Executive Officers"For," "Against," or "Abstain""For"Majority of shares present and entitled to voteAbstentions are treated as votes "against." Broker non-votes have no effect.
Item 3—Ratification of the Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for 2019"For," "Against," or "Abstain""For"Majority of shares present and entitled to voteAbstentions are treated as votes "against." Brokers have discretion to vote on this item, so broker non-votes have no effect.

        If the enclosed proxy card is properly executed and returned, it will be voted in the manner instructed by the stockholder. If a proxy card is properly submitted but contains no instructions, the shares represented thereby will be voted FOR theall nominees for director in Proposal No. 1 and FOR approval of the 2016 Incentive Compensation Plan in ProposalProposals No. 2.2 and 3. In addition, if other matters come before the meeting, the persons named in the accompanying proxy and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. Any person signing the enclosed form of proxy has the power to revoke it by voting in person at the meeting or by giving written notice of revocation to the Secretary of the CompanyBruker at any time before the proxy is exercised. Please note, however, that if your shares are held of record by a broker, bank or nominee and you wish to vote at the meeting, you will not be permitted to vote in person unless you first obtain a proxy issued in your name from the record holder.

        If your shares are held in the "street name" of a broker or other nominee, the broker or nominee may not be permitted to exercise voting discretion with respect to certain of the proposals to be acted


Table of Contents

upon. If the broker or nominee is not given instructions as to how to vote such shares, the broker does not have discretionaryhas authority under New York Stock Exchange rules to vote those shares for or against "routine" matters, such as Proposal No. 3. Brokers cannot vote on their customers' behalf on "non-routine" matters such as the election of directors in Proposal No. 1 and the approval of the 2016 Incentive Compensation Plan in Proposal No. 2. These rules apply notwithstanding the fact that shares of the Company's Common Stock are traded on the NASDAQ Global Select Market. If you provide voting instructions to the broker or nominee holder of your shares for either Proposal No. 1 or Proposal No. 2, but2. If you do not provide voting instructions for botheach of these proposals, yourthis will result in a "broker non-vote" with respect to the matters for which you did not provide voting instructions. If the brokerage firm lacks discretionary voting power with respect to an item that is not a routine matter and you do not provide voting instructions, those shares will be counted for purposes of establishing a quorum to conduct business at the 20162019 Annual Meeting, will be voted in accordance with your instructions on the particular matters for which you have provided instructions, and will result in a "broker non-vote" with respect to the matters for which voting instructions have not been provided. If you do not provide voting instructions to the broker or nominee holder of your shares for at least one of the proposals to be considered at the 2016 Annual Meeting, your shares will not be represented by proxy and thereforebut will not be counted for purposes of establishing a quorum to conduct business at the 2016 Annual Meeting or determining whether stockholder approval of any particular matter has been obtained.


        The CompanyWe will bear the cost of theany proxy solicitation. Although it is expectedwe expect that the solicitation will be primarily by mail, regular employees or our representatives of the Company (none of whom will receive any extra compensation for their activities) may also solicit proxies by telephone, facsimile and in person and arrange for brokerage houses and other custodians, nominees and fiduciaries to send proxies and proxy materials to their principals at the expense of the Company.our expense.

        The Company's 2015We will hold the 2019 Annual Meeting at the offices of Nixon Peabody LLP, 53 State Street, Boston, Massachusetts. You can obtain directions to the meeting by contacting Investor Relations at (978) 663-3660, extension 1479.

        We are mailing our 2018 Annual Report, including the Company'sour audited financial statements for the fiscal year ended December 31, 2015, is being mailed2018, to stockholders concurrently with this proxy statement.

        The Company'sOur principal executive offices are located at 40 Manning Road, Billerica, Massachusetts 01821, and itsour telephone number is (978) 663-3660.


RECORD DATE AND VOTING SECURITIES
Record Date and Voting Securities

        Only stockholders of record at the close of business on March 24, 201625, 2019 are entitled to notice of and to vote at the 20162019 Annual Meeting. On March 24, 2016, the Company had25, 2019, 156,814,676 shares of Bruker Corporation common stock were outstanding and entitled to vote 162,754,756 shares of Common Stock.vote. Each outstanding share of Common Stockour common stock entitles the record holder to one vote. Broadridge Financial Solutions, Inc. will tabulate all votes that are received prior to the date of the 20162019 Annual Meeting. The inspector of elections, who will be one of our employees or one of our attorneys, will receive Broadridge's tabulation, tabulate all other votes, and certify the voting results.



CORPORATE INFORMATION

        Bruker Corporation was incorporated in Massachusetts as Bruker Federal Systems Corporation. In February 2000, we reincorporated in Delaware as Bruker Daltonics Inc. In July 2003, we merged with Bruker AXS Inc., and we were the surviving corporation in that merger. In connection with that merger, we changed our name to Bruker BioSciences Corporation and formed two operating subsidiaries, Bruker Daltonics and Bruker AXS, into which we transferred substantially allTable of their respective assets and liabilities, except cash. We acquired Bruker Optics Inc. in July 2006 and the Bruker BioSpin group of companies in February 2008. In connection with the Bruker BioSpin acquisition, we changed our name to Bruker Corporation. Our four principal operating segments are Bruker BioSpin, Bruker CALID, Bruker Nano and Bruker Energy & Supercon Technologies, or BEST.Contents


PROPOSAL NO. 1
ELECTION OF DIRECTORS

        The first proposal on the agenda for the 2016 Annual Meeting is the election of Frank H. Laukien, John Ornell, Richard A. Packer and Robert Rosenthal to serve as Class I directors for three-year terms beginning at the 2016 Annual Meeting and ending at our 2019 Annual Meeting of Stockholders or until a successor has been duly elected and qualified and the election of Cynthia M. Friend to serve as a Class II director for a one-year term beginning at the 2016 Annual Meeting and ending at our 2017 Annual Meeting of Stockholders or until a successor has been duly elected and qualified. The Company'sOur Certificate of Incorporation, as amended, provides that the board of directors shallour Board will consist of three classes of directors with overlapping three-year terms. One class of directors is to be elected each year for a three-year term. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the board of directors,Board, each class consisting, as nearly as possible, of one-third the total number of directors. There are currently fourteenten members of our board of directors,Board, consisting of sixfour Class I directors serving terms expiring at the 2016 Annual Meeting of Stockholders in 2019, four Class II directors serving terms expiring at the Company'sour 2020 Annual Meeting of Stockholders in 2017 and fourtwo Class III directors serving terms expiring at the Company'sour Annual Meeting of Stockholders in 2018.2021. The four Class I directors whose terms expire at the 2019 Annual Meeting are Frank H. Laukien, John Ornell, Richard A. Packer and Robert Rosenthal.


        The first proposal on the agenda for the 2019 Annual Meeting is the election of Frank H. Laukien, John Ornell and Richard A. Packer to serve as Class I directors for three-year terms beginning at the 2019 Annual Meeting and ending at our 2022 Annual Meeting of Stockholders and the election of Robert Rosenthal to serve as a Class III director for a two-year term beginning at the 2019 Annual Meeting and ending at our 2021 Annual Meeting of Stockholders, or in each case, until a successor has been duly elected and qualified.

        Effective as of the 20162019 Annual Meeting, in conjunction with the expiration of the terms of the sixfour current Class I directors, the classes will be adjusted to consist of fourthree Class I directors, fivefour Class II directors and fourthree Class III directors. At the 20162019 Annual Meeting, fourthree nominees will be elected as Class I directors to serve for terms expiring at the 20192022 Annual Meeting of Stockholders. Additionally, although our bylaws provide that vacancies may remain unfilled or may be filled by a majority vote of the directors then in office,Stockholders and one nominee will be elected as a Class IIIII director to serve for a term expiring at the 20172021 Annual Meeting of Stockholders to fill the vacancy in the class of Class II directors.

Stockholders. Each of the nominees for Class I director, Frank H. Laukien, John Ornell and Richard A. Packer, was previously elected by our stockholders and Robert Rosenthal, is currently serving as a Class I director. The nominee for Class III director, Robert Rosenthal, is currently a Class I director and we are proposing to elect him as a Class III director at this Annual Meeting to more evenly balance the classes. All nominees were unanimously approved by our board of directors,Board, including unanimous approval by our independent directors, upon the unanimous recommendation of the Nominating Committee which is comprised of three independent directors.Committee.

        Wolf Dieter-Emmerich and Brenda J. Furlong,Joerg C. Laukien, who have served as a Class I directorsIII director since 2007, have not been nominated for re-election and, accordingly, their service on the board of directors will terminate at the 2016 Annual Meeting.2003, retired in November 2018.

        Unless marked otherwise, proxies received will be votedFOR the election of each of the nominees for the office ofas director. If any such nominee is unwilling or unable to serve as a nominee for the office of director at the time of the 20162019 Annual Meeting, the proxies may be voted for a substitute nominee who shallwill be designated by the present board of directorsBoard to fill such vacancy. Alternatively, if no such nominee is designated, a vacancy will be created in Class I or Class II,III, as applicable. The board of directorsBoard has no reason to believe that any of the nominees will be unwilling or unable to serve if elected as a director.

        The Board of Directors recommends a vote FOR the election of Frank H. Laukien, John Ornell and Richard A. Packer and Robert Rosenthal to serve as Class I directors and FOR the election of Cynthia M. FriendRobert Rosenthal to serve as a Class IIIII director.


Table of Contents


CORPORATE GOVERNANCE

Certain Information Regarding Directors and Nominees

        The biographies of the nominees and each of our continuing directors are below contain information regarding each person's service as a director, business experience, director positions held currently or at any time during the last five years, information regarding involvement in certain legal or administrative proceedings, if applicable, and include the experiences, qualifications, attributes or skills that caused the board of directorsBoard to determine that the person should serve as a director of the Company.Bruker.


Nominees for Election to a Three-Year Term Expiring at the 20192022 Annual Meeting

PHOTO

Frank H. Laukien, Ph.D.Ph.D. Age 5659 Director Since 1991

Dr. Frank H. Laukien has been the Chairman, President and Chief Executive Officer of the Company since February 1991 and is the Company's largest shareholder. Dr. Laukien also serves as a director of various subsidiaries of the Company. He served as executive chairman of the former public company Bruker AXS Inc. and its predecessor companies from August 2002 until the merger of Bruker Daltonics Inc. and Bruker AXS Inc. in July 2003. In addition, from October 1997 to August 2002, he served as the Chairman of the Board of Directors and, from October 1997 to March 2000, as the Chief Executive Officer, of Bruker AXS Inc. Until February 2010, Dr. Laukien also served as Co-Chief Executive Officer of the Bruker BioSpin Group. Dr. Laukien is the brother of Joerg C. Laukien, a director of the Company and Executive Chairman of Bruker BioSpin Corporation. Dr. Laukien served as a director of ALDA (Analytical Life Science & Diagnostics Association), an industry association formerly known as Analytical & Life Sciences Systems Association, or ALSSA, for several terms in the last ten years, and was ALDA Chairman from 2002 to 2003. Dr. Laukien holds a B.S. degree from the Massachusetts Institute of Technology, as well as a Ph.D. in chemical physics from Harvard University. Dr. Laukien was a member of the Dean's Advisory Committee of the MIT School of Science until 2014, and served as a Trustee of the Rivers School in Weston, Massachusetts from 2006 to mid-2013. As the Company's largest shareholder and based on his long history of leading the growth of the Company, Dr. Laukien brings to the board the perspective of a significant stakeholder with an in-depth knowledge of all aspects of the Company's operations. He also provides extensive executive experience in organizational management, strategic planning, finance, global business development and life-science tools markets, as well as the scientific and technical background required for a deep understanding of the Company's key technologies and industry dynamics.

John Ornell


Age 58


Director Since 2015

Mr. Ornell is retired from Waters Corporation, where he served as Vice President, Finance and Administration and Chief Financial Officer from 2001 to 2013. During this time at Waters, he was also responsible for information technology, investor relations and the TA Instruments Division. Mr. Ornell joined Waters in 1994 and served there in a variety of operational and financial leadership roles before assuming the position of Waters' Chief Financial Officer. During 2014, Mr. Ornell continued to serve Waters on a part-time, transitional basis. Prior to joining Waters, Mr. Ornell progressed through a series of roles of increasing responsibility at a number of multinational corporations, primarily in operational finance functions. Mr. Ornell holds a Master of Business Administration degree from Southern New Hampshire University. Mr. Ornell brings to the board a depth of knowledge in the life sciences and analytical instruments industry, as well as a global perspective with significant experience managing the operational, strategic and financial matters of life sciences companies.

Mr. Ornell serves on the Company's Audit Committee.

Dr. Frank H. Laukien has been our Chairman, President and Chief Executive Officer since February 1991 and is our largest stockholder. Dr. Laukien also serves as a director of various subsidiaries of Bruker, none of which are publicly-traded companies. Dr. Laukien served as a director of ALDA (Analytical, Life Science & Diagnostics Association), an industry association formerly known as Analytical & Life Sciences Systems Association, or ALSSA, for several terms in the past, and was ALSSA Chairman from 2002 to 2003. Dr. Laukien holds a Bachelor of Science degree in physics from the Massachusetts Institute of Technology ("MIT"), as well as a Ph.D. in chemical physics from Harvard University. Dr. Laukien was a member of the Dean's Advisory Committee of the MIT School of Science until 2014, and a Trustee of the Rivers School in Weston, Massachusetts until 2013. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. As our largest stockholder and based on his long history of leading the profitable growth at Bruker, Dr. Laukien brings to the Board the perspective of a significant stakeholder with an in-depth knowledge of all aspects of our operations. He also provides extensive executive experience in organizational management, strategic planning, finance, global business development and life science tools markets, as well as the scientific and technical background required for a deep understanding of our key technologies, markets and industry dynamics.


PHOTO


Richard A. Packer


Age 58


Director Since 2007

Mr. Packer is a Primary Executive Officer of Asahi Kasei Corporation and co-leader of Asahi Kasei's healthcare business unit. Mr. Packer also serves as the non-executive Chairman of ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions that was publicly traded until it was acquired by Asahi Kasei Corporation in April 2012. From November 1999 to April 2016, Mr. Packer was the Chief Executive Officer and a director of ZOLL. He served as Chairman of ZOLL from 1999 until November 2010. From 1996 until his appointment as Chairman and Chief Executive Officer in 1999, Mr. Packer served as ZOLL's President, Chief Operating Officer and director. From 1992 to 1996, he served as Vice President of Operations of ZOLL and also served as Chief Financial Officer and Head of North American Sales of ZOLL from 1995 to 1996. Prior to joining ZOLL, Mr. Packer served for five years as Vice President of various functions for Whistler Corporation, a consumer electronics company. Before joining Whistler in 1987, Mr. Packer was a manager with the consulting firm of PRTM/KPMG, specializing in operations of high technology companies. Mr. Packer is the past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He currently serves as a board member of Surgical Specialties Corporation, a surgical instruments manufacturer, the Medical Device Manufacturers Association and the ZOLL Foundation. Mr. Packer holds a M.B.A. from the Harvard Business School, as well as B.S. and M. Eng. degrees from Rensselaer Polytechnic Institute. Mr. Packer has extensive financial, operations and management experience in the medical devices industry. He also brings to the board significant experience in corporate governance, strategic planning and public company compensation matters.

Mr. Packer serves on the Company's Audit Committee and is the chairman of the Company's Nominating Committee.

Robert Rosenthal, Ph.D.


Age 59


Director Since 2015

Dr. Rosenthal currently serves as Chief Executive Officer of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, a position he has held since joining Taconic Biosciences in June 2014. Dr. Rosenthal previously served since 1995 in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, where he is chair of the Capital Management Committee and a member of the Audit and Compensation Committees. He also currently serves as a director of Taconic Biosciences and Galvanic Applied Sciences,  Inc., a privately held Canadian company. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph. D. from Emory University and a Master of Science degree from the State University of New York. Dr. Rosenthal brings to the board an extensive understanding of corporate governance due to his public company board experience as well as an entrepreneurial perspective due to his success as an entrepreneur.


Nominee for Election to a Term Expiring at the 2017 Annual Meeting

Cynthia M. Friend, Ph.D.John Ornell


Age 61

 


Dr. Friend currently serves as Director of the Rowland Institute at Harvard University, a non-profit organization whose goal is to support the high risk/high reward research of early career scientists. In 2014, she became Director of the Energy Frontier Research Center for Sustainable Catalysis at Harvard University, a Department of Energy-funded multi-institution effort focused on the design of efficient catalytic processes, where her responsibilities include management of the fiscal health of the Center and strategic scientific planning. Dr. Friend became the Theodore Williams Richards Professor of Chemistry in 1998 and a Professor of Materials Science in 2002 at Harvard University. Since joining the Harvard University Department of Chemistry in 1982, Dr. Friend has served in a variety of senior faculty and leadership rules at Harvard, including member of the Advisory Board to the Dean of Faculty of Arts and Sciences from 1999 to 2012, Associate Director of the Harvard Materials Research Science and Engineering Center from 2001 to 2011 and Chair of the Harvard University Department of Chemistry and Chemical Biology from 2004 to 2007. Dr. Friend has received numerous awards for her scientific research and scholarship and has served on a number of research and scientific advisory boards and panels. Dr. Friend holds a Ph. D. in Chemistry from the University of California, Berkeley. Dr. Friend brings to the board extensive technical expertise and significant experience in the investment strategy and infrastructure in academic as well as government research markets. Further, Dr. Friend has substantial management experience in non-profit scientific institutions and brings to the board valuable insight into science policy and scientific research funding priorities.

Directors Continuing in Office until the 2017 Annual Meeting

Stephen W. Fesik, Ph.D.


Age 62


Director Since 2008

Dr. Fesik is currently a Professor in the Department of Biochemistry at Vanderbilt University School of Medicine. He is also a member of the Vanderbilt-Ingram Cancer Center, the Institute of Chemical Biology and the Center for Structural Biology. Prior to joining the Vanderbilt faculty in May 2009, Dr. Fesik was the Divisional Vice President of Cancer Research of Abbott Laboratories, a global, broad based health care company. Dr. Fesik joined Abbott Laboratories in 1983 and served in various research and scientific capacities. From 2003 to 2006, Dr. Fesik served as a member of the Scientific Advisory Board of the Bruker BioSpin Group. In 2003 he was awarded a lifetime achievement award in nuclear magnetic resonance by the Eastern Analytical Society and also was named a Distinguished Research Fellow of Abbott Laboratories' Volwiler Society. Dr. Fesik has received numerous awards for his scientific research and scholarship and currently serves on a number of research and scientific advisory boards. Dr. Fesik holds a Ph.D. in Medicinal Chemistry from the University of Connecticut and has postdoctoral training at Yale University. Dr. Fesik brings both scientific and executive expertise to the board, with extensive life-science research and pharmaceutical drug discovery experience, including at various pharmaceutical, academic and institute laboratories.

Dr. Fesik serves on the Company's Compensation Committee.2015

Mr. Ornell is retired from Waters Corporation, where he served as Vice President, Finance and Administration and Chief Financial Officer from 2001 to 2013. During his time at Waters, he was also responsible for information technology, investor relations and the TA Instruments Division. Mr. Ornell joined Waters in 1994 and served there in a variety of operational and financial leadership roles before assuming the position of Waters' Chief Financial Officer. During 2014, Mr. Ornell continued to serve Waters on a part-time, transitional basis. Prior to joining Waters, Mr. Ornell progressed through a series of roles of increasing responsibility at a number of multinational corporations, primarily in operational finance functions. Mr. Ornell holds a Bachelor of Science degree in Business Administration and a Bachelor of Arts degree in Economics from the University of New Hampshire, as well as a Master of Business Administration degree from Southern New Hampshire University. He is a Certified Management Accountant and a Certified Public Accountant. Mr. Ornell brings to the Board a depth of knowledge in the life sciences and analytical instruments industry, as well as a global perspective with significant experience managing the operational, strategic and financial matters of life sciences companies.

Mr. Ornell serves as Chair of our Audit Committee.


Table of Contents

PHOTO


MarcRichard A. Kastner, Ph.D.Packer


Age 7061

 

Director Since 2015

Dr. Kastner currently serves as President of the Science Philanthropy Alliance, a non-profit organization whose goal is to increase private funding for fundamental research. In January 2016 he became Donner Professor of Science Emeritus at Massachusetts Institute of Technology ("MIT"), having held the Donner Chair since 1989. Since joining the MIT Department of Physics in 1973, Dr. Kastner has served in a variety of senior faculty and leadership roles at MIT, including as Dean of the MIT School of Science from July 2007 to December 2014, Head of the MIT Department of Physics from 1998 to 2007, Director of MIT's Center for Materials Science and Engineering from 1993 to 1998 and as Associate Director of MIT's Consortium for Superconducting Electronics from 1989 to 1992. Dr. Kastner previously served a term on the Company's board of directors from February 2013 to May 2014. Dr. Kastner has received numerous awards for his scientific research and scholarship and currently serves on a number of research and scientific advisory boards. Dr. Kastner holds a Ph.D. in Physics from the University of Chicago. Dr. Kastner brings to the board significant expertise in recent and emerging scientific, technological and research funding trends, as well as in academic and government research markets, from which the Company derives approximately half of its revenues. Moreover, Dr. Kastner has extensive organizational and management experience in non-profit institutions and insights into U.S. government research management and priorities.

Dr. Kastner serves on the Company's Nominating Committee.

Gilles G. Martin, Ph.D.


Age 52


Director Since 2014

Dr. Martin is Chairman and Chief Executive Officer of the Eurofins Scientific Group, a Luxembourg-based international life sciences company with approximately 20,000 employees in laboratories located in 37 countries. The Eurofins Scientific Group provides a range of analytical testing services to clients across multiple industries. Dr. Martin is also a director of Eurofins Scientific SE, Analytical Bioventures SCA and certain of their affiliates. Dr. Martin founded the original Eurofins Scientific Nantes food authenticity laboratory in 1988 and is a past President of the French Association of private analytical laboratories, or APROLAB, and the North American Technical Committee for Juice and Juice Products. Dr. Martin holds a Ph.D. in Statistics and Applied Mathematics from Ecole Centrale, Paris, and a Master of Science from Syracuse University. As Chairman and Chief Executive Officer of Eurofins Scientific, the largest group of independent food testing laboratories in the world, Dr. Martin is and has been involved throughout his career with many generations of analytical instruments and their suppliers. Dr. Martin brings extensive international business and management experience in the life-science and analytical testing industries to the board, including specialized expertise in the environmental testing, food safety analysis, pharmaceutical research and clinical markets. Dr. Martin also brings an entrepreneurial perspective to the board.

Mr. Packer is a Primary Executive Officer of Asahi Kasei Corporation and co-leader of Asahi Kasei's healthcare business unit. Mr. Packer also serves as the non-executive Chairman of ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions that was publicly traded until it was acquired by Asahi Kasei Corporation in April 2012. From November 1999 to April 2016, Mr. Packer was the Chief Executive Officer and a director of ZOLL. He served as Chairman of ZOLL from 1999 until November 2010. From 1996 until his appointment as Chairman and Chief Executive Officer in 1999, Mr. Packer served as ZOLL's President, Chief Operating Officer and director. From 1992 to 1996, he served as Vice President of Operations of ZOLL and also served as Chief Financial Officer and Head of North American Sales of ZOLL from 1995 to 1996. Prior to joining ZOLL, Mr. Packer served for five years as Vice President of various functions for Whistler Corporation, a consumer electronics company. Before joining Whistler in 1987, Mr. Packer was a manager with the consulting firm of PRTM/KPMG, specializing in operations of high technology companies. Mr. Packer has served as a director of Teleflex Incorporated, a publicly traded provider of medical devices, since May 2017 and is a member of the Teleflex Incorporated governance committee. Mr. Packer is the past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He also currently serves as a board member of the Medical Device Manufacturers Association and the ZOLL Foundation. Mr. Packer holds a Master of Business Administration from the Harvard Business School, as well as Bachelor of Science and Master of Engineering degrees from Rensselaer Polytechnic Institute. Mr. Packer has extensive financial, operations and management experience in the medical devices industry. He also brings to the Board significant experience in corporate governance, strategic planning and public company compensation matters.

Mr. Packer serves on our Nominating Committee and is the Chair of our Compensation Committee.

Nominee for Election to a Term Expiring at the 2021 Annual Meeting


PHOTO


Hermann Requardt,Robert Rosenthal, Ph.D.


Age 6162

 

Director Since 2015

Dr. Requardt currently serves as an independent strategic advisor to a number of European public and private life science and healthcare technology companies. From 2009 to February 2015 he served as Chief Executive Officer of the healthcare division of Munich, Germany-based Siemens AG. He also served as Chief Technology Officer of Siemens AG from 2008 through 2011. Additionally, from 2006 through January 2015 he was a member of the Siemens AG Managing Board, during which time he also held a variety of regional and operational responsibilities at Siemens and its affiliates. Dr. Requardt joined Siemens Medical Solutions in 1984 and served there in roles of increasing responsibility before assuming global responsibility for the magnetic resonance business unit in 1994. Dr. Requardt is an honorary Professor of Physics at the University of Frankfurt and serves on several academic and industrial boards in Germany, including, among other positions, serving as Vice Chairman of Fraunhofer-Gesellschaft, Europe's largest application-oriented research organization, and as a member of the Executive Board of Acatech, the National Academy of Science and Engineering. He also is a member of the Advisory Board of Dekra SE, headquartered in Stuttgart, Germany, and the Supervisory Board of Sivantos Group, which was Siemens Audiology Solutions prior to its spin-off from Siemens AG in early 2015. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt. In addition to his global and technical industry expertise, Dr. Requardt brings to the board significant experience in the management and strategic planning of life sciences companies.

Dr. Requardt serves on the Company's Compensation Committee.

Directors Continuing in Office until the 2018 Annual Meeting

Richard D. Kniss


Age 75


Director Since 2003

Mr. Kniss joined the Company's board of directors in July 2003 in connection with the merger of Bruker Daltonics and Bruker AXS, having served on the Bruker AXS board of directors since June 2001. Mr. Kniss was Senior Vice President and General Manager for Agilent Technologies, Chemical Analysis Group, a producer of gas and liquid chromatographs, mass spectrometers and spectrophotometers, from August 1999 until March 2001. Prior to the spin-off of Agilent from the Hewlett Packard Company, from 1995 to 1999, Mr. Kniss was Vice President and General Manager of the Chemical Analysis Group for Hewlett Packard. From 2004 to 2008, Mr. Kniss served as chairman of the board of directors of AviaraDx, Inc. (formerly Arcturus Bioscience, Inc.), a life-science tools company acquired by BioMerieux. Mr. Kniss holds a B.S. from Brown University and a M.B.A. from Stanford University. Mr. Kniss has a strong executive background in the life sciences and analytical instruments industries, as well as experience in corporate governance and public company executive compensation matters.

Mr. Kniss is the chairman of the Company's Compensation Committee.

Joerg C. Laukien


Age 62


Director Since 2005

Mr. Joerg Laukien has served as Executive Chairman of Bruker BioSpin Corporation since 2010. Until December 2013, Joerg Laukien was a Managing Director of Bruker BioSpin MRI GmbH since 1997 and a Managing Director of Bruker Elektronik GmbH from 1991 until its merger with Bruker BioSpin GmbH in 2010, as a director and President of Bruker BioSpin MRI, Inc. from 1997 to 2010 and as a director of Bruker Energy & Supercon Technologies, Inc. from 2008 through March 2013. Joerg Laukien is the brother of Dr. Frank H. Laukien, the Chairman, President and Chief Executive Officer of the Company. Joerg Laukien serves as a member of the regional advisory council of Deutsche Bank AG in Germany. He holds a B.A. from the Verwaltungs- und Wirtschafts-Akademie in Karlsruhe, Germany. Joerg Laukien brings extensive executive experience within the Company to the Board, as well as experience in financial and strategic planning.

Dr. Rosenthal serves as Chairman of the Board of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2018 he also served as Chief Executive Officer. Dr. Rosenthal previously served since 1995 in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of its board of directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company, and as a director of The ECHO Group, a privately-held information management company. Dr. Rosenthal holds a Ph.D. from Emory University and a Master of Science degree from the State University of New York. Dr. Rosenthal brings to the Board an extensive understanding of corporate governance due to his public company board experience as well as an entrepreneurial perspective due to his success as an entrepreneur.

Dr. Rosenthal serves on our Audit Committee.


Table of Contents

Directors Continuing in Office until the 2020 Annual Meeting

PHOTO

Cynthia M. Friend, Ph.D.Age 64Director Since 2016

Dr. Friend currently serves as Director of the Rowland Institute at Harvard University, a non-profit organization whose goal is to support the high risk/high reward research of early career scientists. In 2014, she became Director of the Energy Frontier Research Center for Sustainable Catalysis at Harvard University, a Department of Energy-funded multi-institution effort focused on the design of efficient catalytic processes, where her responsibilities include management of the fiscal health of the Center and strategic scientific planning. Dr. Friend became the Theodore Williams Richards Professor of Chemistry in 1998 and a Professor of Materials Science in 2002 at Harvard University. Since joining the Harvard University Department of Chemistry in 1982, Dr. Friend has served in a variety of senior faculty and leadership roles at Harvard, including member of the Advisory Board to the Dean of Faculty of Arts and Sciences from 1999 to 2012, Associate Director of the Harvard Materials Research Science and Engineering Center from 2001 to 2011 and Chair of the Harvard University Department of Chemistry and Chemical Biology from 2004 to 2007. Dr. Friend has received numerous awards for her scientific research and scholarship and has served on a number of research and scientific advisory boards and panels. Dr. Friend holds a Ph.D. in Chemistry from the University of California, Berkeley. Dr. Friend brings to the Board extensive technical expertise and significant experience in the investment strategy and infrastructure of academic as well as government research markets. Further, Dr. Friend has substantial management experience in non-profit scientific institutions and brings to the Board valuable insight into science policy and scientific research funding priorities.

Dr. Friend serves on our Compensation Committee.

PHOTO

Marc A. Kastner, Ph.D.Age 73Director Since 2015

Dr. Kastner currently serves as President of the Science Philanthropy Alliance, a non-profit organization whose goal is to increase private funding for fundamental research, a position he has held since March 2015. In January 2016 he became Donner Professor of Science Emeritus at Massachusetts Institute of Technology ("MIT"), having held the Donner Chair since 1989. After joining the MIT Department of Physics in 1973, Dr. Kastner served in a variety of senior faculty and leadership roles at MIT, including as Dean of the MIT School of Science from July 2007 to December 2013, Head of the MIT Department of Physics from 1998 to 2007, Director of MIT's Center for Materials Science and Engineering from 1993 to 1998 and as Associate Director of MIT's Consortium for Superconducting Electronics from 1989 to 1992. Dr. Kastner previously served a term on our board of directors from February 2013 to May 2014. Dr. Kastner has received numerous awards for his scientific research and scholarship and currently serves on a number of research and scientific advisory boards. Dr. Kastner holds a Ph.D. in Physics from the University of Chicago. Dr. Kastner brings to the Board significant expertise in recent and emerging scientific, technological and research funding trends, as well as in academic and government research markets, from which we derive approximately half of our revenues. Moreover, Dr. Kastner has extensive organizational and management experience in non-profit institutions and insights into U.S. government research management and priorities.

Dr. Kastner is the Chair of our Nominating Committee.


Table of Contents

PHOTO

Gilles G. Martin, Ph.D.Age 55Director Since 2014

Dr. Martin is Chairman and Chief Executive Officer of the Eurofins Scientific Group, a Luxembourg-based international life sciences company with approximately 45,000 employees in laboratories located in 45 countries. The Eurofins Scientific Group provides a range of analytical testing services to clients across multiple industries. Dr. Martin is also a director of Eurofins Scientific SE, Analytical Bioventures SCA and certain of their affiliates. Dr. Martin founded the original Eurofins Scientific Nantes food authenticity laboratory in 1988 and is a past President of the French Association of private analytical laboratories, or APROLAB, and the North American Technical Committee for Juice and Juice Products. Dr. Martin holds a Ph.D. in Statistics and Applied Mathematics from Ecole Centrale, Paris, and a Master of Science from Syracuse University. As Chairman and Chief Executive Officer of Eurofins Scientific, the largest group of independent food and environment testing laboratories in the world, Dr. Martin is and has been involved throughout his career with many generations of analytical instruments and their suppliers. Dr. Martin brings extensive international business and management experience in the life-science and analytical testing industries to the Board, including specialized expertise in the environmental testing, food safety analysis, pharmaceutical research and clinical markets. Dr. Martin also brings an entrepreneurial perspective to the Board.

PHOTO

Hermann Requardt, Ph.D.Age 64Director Since 2015

Dr. Requardt currently serves as an independent strategic advisor to a number of European public and private life science and healthcare technology companies. From 2009 to February 2015 he served as Chief Executive Officer of the healthcare division of Munich, Germany-based Siemens AG. He also served as Chief Technology Officer of Siemens AG from 2008 through 2011. Additionally, from 2006 through January 2015 he was a member of the Siemens AG Managing Board, during which time he also held a variety of regional and operational responsibilities at Siemens and its affiliates. Dr. Requardt joined Siemens Medical Solutions in 1984 and served there in roles of increasing responsibility before assuming global responsibility for the magnetic resonance business unit in 1994. Dr. Requardt is an honorary Professor of Physics at the University of Frankfurt and serves on several academic and industrial boards in Germany, including, among other positions, Vice President of acatech, the National Academy of Science and Engineering. He also is a member of the Advisory Board of Dekra SE, headquartered in Stuttgart, Germany, and the Supervisory Board of Sivantos Group, which was Siemens Audiology Solutions prior to its spin-off from Siemens AG in early 2015. In 2018, Dr. Requardt was nominated non-executive director of Sphere Medical Ltd., Cambridge, United Kingdom. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt. In addition to his global and technical industry expertise, Dr. Requardt brings to the Board significant experience in the management and strategic planning of life sciences companies.

Dr. Requardt serves on our Compensation Committee.


Table of Contents

Directors Continuing in Office until the 2021 Annual Meeting

PHOTO

William A. Linton, Ph.D.

Age 6871

 

Director Since 2000

Dr. Linton serves as the lead director of our Board. He was appointed lead director in March 2004 by the independent members of the Board. As lead director, Dr. Linton performs customary responsibilities of a lead director including acting as a liaison between management and the Board. Since 1978, Dr. Linton has served as the Chairman, President and Chief Executive Officer of Promega Corporation, Madison, Wisconsin, a privately-held life science supply company founded by Dr. Linton. Dr. Linton received a Bachelor of Science degree from University of California, Berkeley in 1970 and honorary doctorate degrees from Hannam University (Korea) in 2004 and the University of Wisconsin Madison in 2015. Dr. Linton is a director of ALDA (Analytical, Life Science & Diagnostics Association), a director of Heffter Research Institute (a non-profit research institute), a member of the Supervisory Board of Eppendorf AG, Hamburg (a private life sciences company), founder and Executive Director of Usona Institute (a non-profit medical research organization) and President of the BioPharmaceutical Technology Center Institute (a non-profit organization). Dr. Linton brings to the Board extensive executive, international operations management and technical expertise in the life sciences industry, as well as significant experience in strategic planning, corporate governance, and executive compensation matters.

Dr. Linton serves on our Nominating Committee.

PHOTO


Dr. Linton serves as the lead director of our board of directors. He was appointed lead director in March 2004 by the independent members of the board of directors. As lead director, Dr. Linton performs the usual responsibilities of a lead director including acting as a liaison between management and the board of directors. Since 1978, Dr. Linton has served as the Chairman, President and Chief Executive Officer of Promega Corporation, Madison, Wisconsin, a privately held life science supply company founded by Dr. Linton. Dr. Linton received a B.S. degree from University of California, Berkeley in 1970 and an honorary Ph.D. from Hannam University (Korea) in 2004. Dr. Linton has been a director of the Wisconsin Technology Council since 2001 and also serves as a director of ALDA (Analytical, Life Science & Diagnostics Association), an industry association formerly known as Analytical & Life Sciences Systems Association, or ALSSA, and Heffter Research Institute, a non-profit medical research organization, and is President of the BioPharmaceutical Technology Center Institute. Dr. Linton brings to the board extensive executive, international operations management and technical expertise in the life sciences industry, as well as significant experience in strategic planning, corporate governance, and public company executive compensation matters.

Chris van IngenAdelene Q. Perkins


Age 6959

 

Director Since 2012

Chris van Ingen has served as an advisor to various life sciences and analytical technology companies since 2007, including Bruker and certain of its subsidiaries from 2008 until 2011. Mr. van Ingen also served as a director of Bruker Energy & Supercon Technologies, Inc. from 2009 through March 2013, including as chairman of the board of directors and member of the Compensation Committee from 2010 to March 2013. From 2001 until October 2007, he was President of the Life Sciences and Chemical Analysis Group at Agilent Technologies, Inc. Prior to joining Agilent, Mr. van Ingen was Vice President of Sales and Marketing at Hewlett Packard's Chemical Analysis Group and held other senior management positions at Hewlett Packard's Avondale Division and Netherlands Country Operation. Mr. van Ingen currently serves on the board of directors of Trinean N.V., a privately-held life sciences instrumentation company based in Belgium and also serves on the board of directors of Lifeonics Limited, a privately held life sciences company based in New Zealand. Mr. van Ingen previously served as chairman of the board of directors and as a member of Audit Committee of Accelrys, Inc. from 2010 to 2014 and served on the board of directors and Compensation Committee of Promega Corporation, a privately-held biotechnology company, from 2010 to 2015. He also served on the board of directors and Compensation Committee of ProteinSimple, a privately-held life sciences company, from March 2014 until July 2014. Mr. van Ingen holds a B.S. degree in analytical chemistry. Mr. van Ingen brings to the board financial, sales and marketing, and general management experience in the analytical and life sciences industries, as well as significant experience in corporate governance, strategic planning and public company compensation matters.

Mr. van Ingen serves on the Company's Audit Committee.2017

Ms. Perkins currently serves as Chief Executive Officer of Infinity Pharmaceuticals, Inc., a publicly traded clinical-stage biopharmaceutical company, a position she has held since January 2010. Ms. Perkins also has served as Chair of Infinity Pharmaceuticals, Inc.'s board of directors since November 2012. Within Infinity Pharmaceuticals, Inc., Ms. Perkins served as President and Chief Business Officer from October 2008 through December 2009, and as Executive Vice President and Chief Business Officer from June 2002 to October 2008. Ms. Perkins served from 2000 to 2002 as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, now a unit of Pfizer. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain & Company, a management consulting firm. Ms. Perkins currently serves on the board of directors of Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council and two biotechnology industry trade organizations. She is also the Vice Chairman of the board of Project Hope, a not-for-profit social service agency. She previously served on the board of Padlock Therapeutics, Inc., a privately-held biotechnology company, prior to its acquisition by Bristol-Myers Squibb Company in 2016. Ms. Perkins holds a Master of Business Administration from the Harvard Business School, as well as a Bachelor of Science degree in chemical engineering from Villanova University. Ms. Perkins has more than 30 years of international business and corporate strategy experience and brings to the Board a valuable understanding of the pharmaceutical and life sciences industries, as well as significant experience in various aspects of public company management and governance.

Ms. Perkins serves on our Audit Committee.


Table of Contents

BOARD LEADERSHIP STRUCTURE
Board Leadership Structure

        Under our bylaws, the chairman of the Company's board of directorsour Board has the power to preside at all meetings of the board.Board. Dr. Frank Laukien, our Chief Executive Officer and President, serves as the Chairman of our board of directorsBoard and has done so throughout the time we have been a public company. Although the boardBoard believes that the combination of the Chairman and Chief Executive Officer roles is appropriate in the current circumstances, the boardBoard does not have a fixed policy regarding the combination or separation of the offices of Chairman and Chief Executive Officer. Our board of directorsBoard believes that it should have the flexibility to make these determinations at any given point in time in the way that it considers best to provide appropriate leadership for the CompanyBruker at that time.

        The Chief Executive Officer is appointed by our boardBoard to manage the Company'sour daily affairs and operations. Dr. Laukien's extensive industry knowledge and long history of direct involvement in the Company'sour operations make him best suited to serve as Chairman in order to (i) leadto:

        While we believe that having a unified Chairman and Chief Executive Officer is appropriate and in the best interests of the Company and its stockholders at this time, our boardOur Board structure also fosters strong oversight by independent directors. Since 2004, an independent lead directorDr. William Linton has been appointed as our lead independent director by the independent directors to ensure an independent leadership contact.leadership. The lead independent director's responsibilities include: (i) consulting

Board Meetings and Board Committees


BOARD MEETINGS, COMMITTEES AND COMPENSATION

        There are currently fourteenten members of our board of directors. TwelveBoard. All of our current directors namely Wolf-Dieter Emmerich, Stephen W. Fesik, Brenda J. Furlong, Marc A. Kastner, Richard D. Kniss, William A. Linton, Gilles J. Martin, John Ornell, Richard A. Packer, Hermann Requardt, Robert Rosenthal and Chris van Ingen,director nominees, other than Frank Laukien, our Chief Executive Officer, meet the independence requirements of the NASDAQNasdaq Stock Market, LLC, or NASDAQ,Nasdaq, listing standards. AllOur former director Richard Kniss, whose term expired in May 2018, was also determined to be independent when serving as a member of our Board. Our former director nominees, other than Dr. FrankJoerg Laukien, arewho retired in November 2018, was not an independent under such standards.director. In making its independence determinations, the board of directorsBoard considered, among other things, relevant transactions between the CompanyBruker and entities associated with the independent directors, as further described in this proxy statement under the


heading "Transactions with Related Persons," and determined that none have


Table of Contents

any relationship with the CompanyBruker or other relationships that would impair the directors' independence. The Board meets in executive session during each regularly scheduled Board meeting.

        Following the 2019 Annual Meeting, the Board will consist of ten members, nine of whom are independent.

        During 2015,2018, the board of directors of the CompanyBoard held six meetings.five meetings and acted by unanimous written consent three times. Our incumbent directors, on average, attended 97 percent95% of boardBoard and committee meetings during 2015.2018. No director attended less than 75 percent75% of the total number of 20152018 meetings of the board of directorsBoard and boardBoard committees of which he or she was a member. It is the policy of our board of directorsBoard that at least two directors, including at least one independent director, attend our Annual Meeting, either in person or by telephonic conference. Two directors, including one independent director, attended our 20152018 Annual Meeting.

        As described below, the board of directorsBoard has three standing committees: an Audit Committee, a Compensation Committee and a Nominating Committee. Each Committee's charter is available on our website at https://ir.bruker.com under the "Corporate Governance" section.

        Audit Committee.    The Audit Committee of the board of directors is currently comprisedconsists of Brenda J. Furlong, John Ornell, Richard A. Packer,Adelene Q. Perkins and Chris van Ingen,Robert Rosenthal, each of whom satisfies the applicable independence requirements of the rules and regulations of the SEC and NASDAQ.Nasdaq. Under these rules, we are required to have an Audit Committee consisting of at least three independent members. The Audit Committee met seven times during 2015. Each of Ms. Furlong,2018. Mr. Ornell, Chair of the Audit Committee, and Mr. Ornell qualifies as an audit committee financial expert pursuant to applicable SEC rules and regulations.

The Audit Committee providesCommittee:

        None of the members of the Audit Committee has participated in the preparation of anyour financial statements of the Company at any time during the last three fiscal years. The Audit Committee's charter is available on the Company's website at http://ir.bruker.com under the "Corporate Governance" section.

        Compensation Committee.    The Compensation Committee is comprisedcurrently consists of Wolf-Dieter Emmerich, Stephen W. Fesik,Cynthia Friend, Richard D. KnissPacker and effective as of April 1, 2016, Hermann Requardt, all of whom meet the independence requirements of the NASDAQ Listing Rules.Nasdaq. The Compensation Committee met teneight times and acted by unanimous written consent three times during 2015.2018. Mr. KnissPacker is the ChairmanChair of the Compensation Committee. The Compensation Committee (i) administers the Company'sCommittee:

and discusses the recommendations with our Chief Executive Officer and, as appropriate, our Chief Financial Officer. In some cases, these discussions may lead to adjustments to an executive officer's performance evaluation and compensation recommendation. In other cases in which the Compensation Committee deems it appropriate, the evaluations and management recommendations may be approved by the Compensation Committee with little or no change.        Our Chief Executive Officer, Chief Financial Officer, General Counsel and our Corporate Vice President—Senior Director of Human Resources may routinely attend meetings of the Compensation Committee to provide information relating to matters the Compensation Committee is considering. The Compensation


Table of Contents

Committee may, from time to time, meet in executive session without any executive officers or other members of management present. The Compensation Committee's charter is available on the Company's website at http://ir.bruker.com under the "Corporate Governance" section.

        Nominating Committee.    The Nominating Committee is comprisedcurrently consists of Wolf-Dieter Emmerich, Marc A. Kastner, and Richard A. Packer and William A. Linton, all of whom meet the independence requirements of the NASDAQ Listing Rules. Mr. PackerNasdaq. Dr. Kastner is the ChairmanChair of the Nominating Committee. The purpose ofNominating Committee:

        The Nominating Committee met four times during 2015.2018. In addition, to these meetings, members of the Nominating Committee communicated periodically throughout the year regarding candidates for director and director nomination matters. At a meeting held in February 2016,2019, the Nominating Committee unanimously recommended each of the current nominees for director to the full board of directors.

        In addition to the standing committees described above, in 2013 the board of directors established a temporary BEST Special Committee, comprised of Chris van Ingen, Frank Laukien and Joerg Laukien, to focus on key issues relating to the Company's Bruker Energy and Supercon Technologies division. The BEST Special Committee was terminated effective April 1, 2016.Board.


DIRECTOR NOMINATIONS
Director Nominations

        On March 3, 2004, the Company adopted a policy by board resolution governing the nomination of directors, according to which the full board of directors approves all nominees for board membership. All nominees must also be approved by a majority of the Company's independent directors.        Upon recommendation of the Nominating Committee, the qualifications of candidates will be reviewed by at least a majority of theour independent directors, of the Company, as well as the full board of directors.Board. Stockholders may recommend director candidates for inclusion by the board of directorsBoard in the slate of nominees which the boardBoard recommends to stockholders for election as described below.

        The process followed to identify and evaluate potential candidates includes requests to boardBoard members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates and interviews of selected candidates by the members of the Nominating Committee, the independent directors and the board.Board. The Nominating Committee, the independent directors and the boardBoard are each authorized to retain advisers and consultants and to compensate them for their services. NoWe retained no such advisers or consultants were retained for this purpose during 2015.2018.


        The Company doesWe do not have a formal policy with regard to the consideration of diversity in identifying director nominees, but striveswe strive to identify and recruit director candidates with a variety of complementary skills, expertise and backgrounds so that, as a group, the boardBoard will possess the appropriate talent, skills and expertise to oversee the Company'sour business. The Committee seeks to promote through the nominations process an appropriate diversity in boardBoard composition, recognizing that the Corporation'sour businesses and operations are diverse and global in nature. In considering individual director candidates, the Committee takes into account such factors as diversity in professional experience, skills and background, as well as diversity in gender, race and ethnicity. Search firms retained to assistWhen we search for new directors, the Committee are advisedadvises our search firms to actively seek to identify qualified, diverse candidates, including women and minorities. As a global company with worldwide operations, we also strive to maintain geographic and international diversity on our Board by ensuring an appropriate mix of directors with experience operating international businesses in other geographies.

        In considering whether to recommend any candidate for inclusion in the board'sBoard's slate of recommended director nominees, including any candidate recommended by a stockholder, the boardBoard and the independent directors apply the criteria which are set forth in a resolution of the board approved and adopted on March 3, 2004.

        These criteria include, but are not limited to, the following:following criteria:


Table of the Company;Contents

        The boardBoard and the independent directors may also consider the following for some of the director nominees:

        In evaluating candidates recommended by the Nominating Committee, the boardBoard and the independent directors do not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. We believe that the backgrounds and qualifications of the directors, considered as a group, should provide a significant composite mix of experience, knowledge, backgrounds and abilities that will allow the boardBoard to fulfill its responsibilities.

        Although the Company does not have a specific policy with respect to the nomination of directors by stockholders, the Nominating Committee will consider nominations made by stockholders. The Company believes that it is not necessary to have a policy for director nominations by stockholders because the board of directors, including the Nominating Committee and the independent directors, is able to effectively locate and evaluate potential candidates for nomination to the board of directors due


to the directors' intimate knowledge of the Company and the life science industry. However, stockholders        Stockholders may communicate directly with the Nominating Committee of the board of directors by written communication submitted to Richard M. SteinKristin S. Caplice at the address set forth below under "Stockholder Communications." Mr. Stein shall be primarily responsible for monitoring the communications and providing summaries or copies of such communications to the Nominating Committee or the board of directors as he deems appropriate, and, as described below, will submit communications to the Nominating Committee or the board of directors, as appropriate, relating to corporate governance matters and long-term corporate strategy.Stockholder Communications." Stockholders may use this process to suggest potential nominationsnominees to the board of directors. SuchBoard. We forward suggested nominations shall be forwardednominees to the Nominating Committee and the proposed candidates shall beare evaluated using substantially the same process and applying the same criteria as used and appliedwe apply in evaluating candidates submitted by boardBoard members. NominationsWe must be received by the Companyreceive nominations within the timeframe set forth hereinbelow under "Time"Time for Submission of Stockholder Proposals.Proposals."

        At the 2016 Annual Meeting, stockholders will be asked to consider the re-election of Frank H. Laukien, John Ornell, Richard A. Packer and Robert Rosenthal to serve as Class I directors and the election of Cynthia M. Friend to serve as a Class II director. EachRole of the nominees is standing for election following the unanimous recommendation for nomination first by the Nominating Committee, and then by the full board of directors, including the unanimous approval of all of the Company's independent directors.


ROLE OF THE BOARD IN RISK OVERSIGHT
Board in Risk Oversight

        Our board of directorsBoard considers general oversight of the Company'sour risk management efforts to be a responsibility of the entire board.Board. The Audit and Compensation Committees assist the boardBoard in carrying out this responsibility by focusing on specific key areas of risk that our business faces. The board'sBoard's role in risk oversight includes receiving regular reports from members of senior management on areas of material risk to the Company,Bruker, or to the success of a particular project or endeavor under consideration, including operational, financial, legal and regulatory, strategic and reputational risks. The full board of directors,Board, the Audit Committee in the case of financial and compliance risks that are within the oversight of the Audit Committee or the Compensation Committee in the case of matters relating to our compensation policies and practices, receivesreceive these reports from members of management to enable the boardBoard or the Audit or Compensation Committee, as applicable, to understand the Company'sour risk identification, risk management, and risk mitigation strategies. To facilitate this process and assist the Audit Committee in fulfilling its responsibility for monitoring legal and compliance risks, our senior director of internal audit, who reports directly to our Chief Financial Officer, also has a dotted line reporting relationship to the chairpersonchairman of the Audit Committee. The Audit Committee chairpersonchairman is authorized to give instructions and assignments directly to the senior director of internal audit as to which assignmentsand the senior director of


Table of Contents

internal audit reports directly and only to the Audit Committee chairperson.chairman on these matters. When a report is evaluated at the Audit Committee level, the chairpersonchairman of the Audit Committee subsequently reports on the matter to the full boardBoard to ensure coordination of the board'sBoard's risk oversight activities. Our board of directorsBoard also believes that risk management is an integral part of our strategic planning process, which addresses, among other things, the risks and opportunities facing the Company.our business.


DIRECTOR COMPENSATION OF DIRECTORS

        We pay the non-employee members of our board of directorsBoard a mix of cash and share-based compensation based on the determination of the Compensation Committee. Employee directors, includingOur employee director, Dr. Frank Laukien, and Mr. Joerg Laukien, receivereceives compensation only as employeesan employee of the CompanyBruker and receivereceives no additional compensation for service as a director. Directors are reimbursed


for reasonable out-of-pocket expenses incurred in attending meetings of the boardBoard or boardBoard committees.

Components of Director Compensation

        During 2015, directors other than employee2018, non-employee directors were paid cash compensation according to the following schedule:


 2015 Director Cash
Compensation
  2018 Director Cash
Compensation
 

Board Service

 $40,000  $60,000 

Audit Committee Service

 $18,000  $18,000 

Audit Committee Chair

 $15,000  $15,000 

Compensation Committee Service

 $8,000  $8,000 

Compensation Committee Chair

 $5,000  $10,000 

Nominating Committee Service

 $2,000  $3,000 

Nominating Committee Chair

 $3,000  $6,000 

BEST Special Committee Service

 $9,000 

BEST Special Committee Chair

 $6,000 

Attendance Fees per Board meeting

 $1,500 

Lead Director Service

 $10,000 

        In addition to the cash component of director compensation, our directors participate in the Company's 2010 Incentive Compensation Plan (the "2010 Plan"), which permits the grant of stock options and restricted stock awards. Directors will be eligible to participate in the Company's 2016 Incentive Compensation Plan (the "2016 Plan"), assuming our stockholders approve the 2016 Plan at the 2016 Annual Meeting. It is currently our policy towe grant non-employee directors an annual equity award as a component of their compensation an annual equity award consisting of an option to purchase 10,000 shares of common stock, with an exercise price equal to the fair marketcompensation. The value of the awards of restricted stock units, or RSUs, we grant our common stockdirectors is $125,000. RSU awards to non-employee directors vest in full on the datefirst anniversary of the grant and vest over a three-year period in approximately equal annual increments.date. Additionally, it is our policy towe grant a stock optionan equity award to each newly-elected non-employee director, effective upon commencement of service on the board,Board, upon terms consistent with those of the annual awards to incumbent non-employee directors. Effective August 2015, theThe number of shares underlying such optionnew director awards are determined as follows: 10,000 shares100% of the annual director equity award amount if elected to service commencing in the first quarterquarter; 75% of the calendar year; 7,500 sharesannual director equity award amount if elected to service commencing in the second quarterquarter; 50% of the calendar year; 5,000 sharesannual director equity award amount if elected to service commencing in the third quarterquarter; and 25% of the calendar year; and 2,500 sharesannual director equity award amount if elected to service commencing in the fourth quarter of the calendar year. Such awards to newly-elected non-employee directors are granted effective upon commencement of service on the board and upon terms consistent with those of the annual awards to incumbent non-employee directors.quarter.

        On January 5, 2015, the Company2018, we granted each non-employee director an annual equity award consisting of an option to purchase 10,000 shares of common stock. The 2015 option grants vest ratably3,474 RSUs, which vested in annual installments over three years on the anniversary of the grant date, beginningfull on January 5, 2016. Mr. Ornell and Drs. Kastner, Requardt and Rosenthal each received an award of stock options upon initial election to our board of directors in 2015. On January 5, 2016, annual equity awards were again granted to all non-employee directors. The 2016 grants to non-employee directors consisted of an option to purchase 10,000 shares of common stock, which option vests ratably in annual installments over three years on the anniversary of the grant date, beginning on January 5, 2017.2019.

        The following table provides information concerning the compensation paid by us to each of our non-employee directors for the fiscal year ended December 31, 2015.2018. The compensation paidwe pay to Dr. Frank Laukien, our President and Chief Executive Officer, is shown in the Summary Compensation Table on page 4745 of this proxy statement. The compensation paid in 2015 to Mr. Joerg Laukien as an


employeeTable of the Company is described in this proxy statement under the heading "Transactions with Related Persons."Contents


20152018 Director Compensation Table

Name
 Fees Earned
or Paid in Cash
 Option Awards(1) Total 

Wolf-Dieter Emmerich

 $59,000 $82,400 $141,400 

Stephen W. Fesik

 $57,000 $82,400 $139,400 

Brenda J. Furlong

 $82,000 $82,400 $164,400 

Chris van Ingen

 $82,000 $82,400 $164,400 

Marc A. Kastner(2)

 $29,115 $76,400 $105,515 

Richard D. Kniss

 $60,500 $82,400 $142,900 

William A. Linton

 $51,000 $82,400 $133,400 

Gilles J. Martin

 $49,000 $82,400 $131,400 

John Ornell(3)

 $22,777 $34,000 $56,777 

Richard A. Packer

 $72,000 $82,400 $154,400 

Hermann Requardt(4)

 $18,978 $34,000 $52,978 

Robert Rosenthal(5)

 $5,543 $19,300 $24,843 
Name
 Fees Earned
or Paid in Cash
($)
 Equity
Awards(1)
($)
 Total ($) 

Cynthia M. Friend

  65,121  125,029  190,150 

Marc A. Kastner

  66,841  125,029  191,870 

Richard D. Kniss(2)

  30,429  125,029  155,458 

Joerg C. Laukien(3)

  60,000  125,029  185,029 

William A. Linton

  73,000  125,029  198,029 

Gilles G. Martin

  60,000  125,029  185,029 

John Ornell

  93,000  125,029  218,029 

Richard A. Packer

  90,566  125,029  215,595 

Adelene Q. Perkins

  75,750  125,029  200,779 

Hermann Requardt

  68,000  125,029  193,029 

Robert Rosenthal

  78,000  125,029  203,029 

(1)
Reported amounts reflect the grant date fair value of stock optionsRSUs granted to each director in 2015,2018, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. Assumptions used in the calculations of these amounts may be found in Note 2 to our 20152018 audited financial statements included in the Company'sour Annual Report on Form 10-K filed with the SEC on February 29, 2016.March 1, 2019. The actual amount realized by the director will likely vary based on a number of factors, including our performance, stock price fluctuations and applicable vesting.

As of December 31, 2015,2018, our non-employee directors held the following aggregate vested and unvested options to purchase common stock of the Company:and unvested RSUs:

Name
 Number of
Vested Options
 Number of
Unvested Options
 

Wolf-Dieter Emmerich

  47,900  20,100 

Stephen W. Fesik

  21,900  20,100 

Brenda J. Furlong

  44,900  20,100 

Chris van Ingen

  19,900  20,100 

Marc A. Kastner

    10,000 

Richard D. Kniss

  39,900  20,100 

William A. Linton

  39,900  20,100 

Gilles J. Martin

  3,300  16,700 

John Ornell

    5,000 

Richard A. Packer

  39,900  20,100 

Hermann Requardt

    5,000 

Robert Rosenthal

    2,500 
Name
 Number of
Vested Options
 Number of
Unvested Options
 Number of
Unvested RSUs
 

Cynthia M. Friend

  4,950  2,550  3,474 

Marc A. Kastner

  16,600  3,400  3,474 

Richard D. Kniss

       

Joerg C. Laukien

       

William A. Linton

  54,600  3,400  3,474 

Gilles G. Martin

  26,600  3,400  3,474 

John Ornell

  11,600  3,400  3,474 

Richard A. Packer

  54,600  3,400  3,474 

Adelene Q. Perkins

      3,474 

Hermann Requardt

  11,600  3,400  3,474 

Robert Rosenthal

  9,100  3,400  3,474 
(2)
Dr. Kastner was elected toMr. Kniss' term of service on the board of directors effectiveBoard expired May 20, 2015.21, 2018.

(3)
Mr. Ornell was elected toJoerg Laukien retired from the board of directors effective August 19, 2015.

(4)
Dr. Requardt was elected to the board of directors effective August 6, 2015.

(5)
Dr. Rosenthal was elected to the board of directorsBoard effective November 11, 2015.5, 2018.

Table of Contents


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

        The following table sets forth certain information regarding beneficial ownership of the Company'sour common stock as of April 4, 20162, 2019 by (i) each person who is known by the Companyus to own beneficially more than 5% of the Company'sour common stock, (ii) each of our directors and nominees for director, (iii) each named executive officer, of the Company, as defined under the heading "Summary of Executive Compensation," and (iv) all directors and executive officers who served as directors or executive officers as of April 4, 2016 as a group. Unless otherwise noted, the address of each beneficial owner is c/o Bruker Corporation, 40 Manning Road, Billerica, Massachusetts 01821.

Beneficial Owners
 Amount and Nature of
Beneficial Ownership(1)
 Percent
of Class(1)
 

Named Executive Officers, Directors and Director Nominees

       

Frank H. Laukien(2)

  40,443,597  24.9%

Anthony L. Mattacchione(3)

  51,166  * 

Mark R. Munch(4)

  89,767  * 

Juergen Srega(5)

  117,056  * 

Michael G. Knell(6)

  33,284  * 

Charles F. Wagner, Jr. 

    * 

Thomas Bachmann

    * 

Wolf-Dieter Emmerich(7)

  57,900  * 

Stephen W. Fesik(8)

  31,900  * 

Cynthia M. Friend

    * 

Brenda J. Furlong(9)

  55,900  * 

Chris van Ingen(10)

  29,900  * 

Marc A. Kastner(11)

  3,300  * 

Richard D. Kniss(12)

  86,076  * 

Joerg C. Laukien

  17,208,795  10.6%

William A. Linton(13)

  96,650  * 

Gilles J. Martin(14)

  9,900  * 

John Ornell

    * 

Richard A. Packer(15)

  68,900  * 

Hermann Requardt

    * 

Robert Rosenthal

    * 

All executive officers and directors as a group (19 persons)(16)

  58,384,091  35.8%


Beneficial Owners
 Amount and Nature of
Beneficial Ownership(1)
 Percent
of Class(1)
 

5% Beneficial Owners

       

T. Rowe Price Associates, Inc.(17)

  28,072,588  17.3%

100 E. Pratt Street

       

Baltimore, MD 21202

       

FMR LLC(18)

  
16,257,703
  
10.0

%

245 Summer Street

       

Boston, MA 02210

       
Beneficial Owners
 Amount and Nature of
Beneficial Ownership(1)
 Percent
of Class(1)

Executive Officers, Directors and Director Nominees

     

Frank H. Laukien(2)

  40,774,683 26.0%

Gerald N. Herman(3)

  6,237 *

Falko Busse(4)

  14,901 *

Mark R. Munch(5)

  113,750 *

Juergen Srega(6)

  232,980 *

Anthony L. Mattacchione(7)

   

Cynthia M. Friend(8)

  15,551 *

Marc A. Kastner(9)

  28,051 *

William A. Linton(10)

  124,801 *

Gilles G. Martin(11)

  38,051 *

John Ornell(12)

  23,051 *

Richard A. Packer(13)

  107,158 *

Adelene Q. Perkins

  6,230 *

Hermann Requardt(14)

  23,051 *

Robert Rosenthal(15)

  20,551 *

All executive officers and directors as a group (16 persons)(16)

  41,546,800 26.5%

5% Beneficial Owners

  
 
 

 

Joerg C. Laukien(17)

  12,715,769 8.1%

Markgrafenstrasse 34
Baden-Baden Germany

     

T. Rowe Price Associates, Inc.(18)

  
29,443,500
 

18.8%

100 E. Pratt Street
Baltimore, MD 21202

     

The Vanguard Group(19)

  
10,495,889
 

6.7%

100 Vanguard Blvd.
Malvern, PA 19355

     

*
Less than one percent

(1)
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options held by that person that are currently exercisable, or become exercisable within 60 days from the date hereof,

    are deemed outstanding. However, such shares are not deemed outstanding for purposes of computing the percentage ownership of any other person.



(2)
Includes options to purchase 49,303181,963 shares of common stock that are currently exercisable, or become exercisable within 60 days of the date hereof and 154,10516,305 shares of restricted common stock. Also includes: 1,846,499 shares owned by Robyn Laukien, his former spouse, as to which

Table of Contents

    Dr. Laukien has sole voting power; 336,607 shares held by each of his adult children, as to which Dr. Laukien has sole voting power and shared investment power; and 201,702224,522 aggregate shares held as custodian for the benefit of ahis minor child of his,children, as to which Dr. Laukien has sole voting and investment power. 1,340,0445,000,000 shares have been pledged by Dr. Laukien to secure a personal loan. Dr. Laukien retains voting power of all such pledged shares. Does not include 6,920 shares held in trust for Dr. Laukien's adult daughter, 7,400 shares held by Dr. Laukien's adult son or 1,042 shares held by his spouse, in each case as to which Dr. Laukien disclaims beneficial ownership.

(3)
Includes options to purchase 38,0614,002 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(4)
Includes options to purchase 12,535 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(5)
Includes options to purchase 92,100 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof and 13,1054,857 shares of restricted common stock.

(4)(6)
Includes options to purchase 38,190166,089 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof and 44,1183,469 shares of restricted common stock.

(5)
Includes options to purchase 60,343 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof and 32,464 shares of restricted common stock.

(6)
Includes options to purchase 33,284 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(7)
Includes options to purchase 57,900 sharesAmount reported is based on information provided by Mr. Mattacchione as of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.April 2, 2019. Mr. Mattacchione left Bruker on March 16, 2018.

(8)
Includes options to purchase 31,9007,500 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(9)
Includes options to purchase 54,90020,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(10)
Includes options to purchase 29,90058,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(11)
Includes options to purchase 3,30030,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(12)
Includes options to purchase 49,90015,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(13)
Includes options to purchase 49,90058,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(14)
Includes options to purchase 9,90015,000 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(15)
Includes options to purchase 49,90012,500 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.

(16)
Includes options to purchase 556,681687,084 shares of common stock that are currently exercisable, or become exercisable, within 60 days of the date hereof.


(17)
Amount reported is based on information provided by Mr. Joerg Laukien as of February 16, 2019. Joerg Laukien retired from the Board on November 5, 2018.

(18)
According to a Schedule 13G filed February 10, 2016,14, 2019, T. Rowe Price Associates, Inc. ("Price Associates") beneficially owns, or may be deemed to beneficially own, 28,072,58829,443,500 shares as a result of acting as investment advisor to various investment companies, including the T. Rowe Price Mid-Cap Growth Fund, Inc. (the "Fund"), and institutional clients. Price Associates reported sole

Table of Contents

    power to dispose of 28,072,58829,443,500 shares and sole power to vote or direct the voting of 6,916,2638,644,940 shares. The Fund reported sole power to vote or direct the voting of 9,400,0009,434,500 shares.

(18)(19)
According to a Schedule 13G filed February 12, 2016, FMR LLC11, 2019, The Vanguard Group ("FMR"Vanguard") and certain of its affiliates, subsidiaries and other companies beneficially own, or may be deemed to beneficially own, 16,257,70310,495,889 shares. FMRVanguard reported sole power to dispose of 16,257,70310,440,585 shares, andshared power to dispose of 55,304 shares, sole power to vote or direct the voting of 2,086,17850,778 shares and shared power to vote or direct the voting of 14,151 shares.

Table of Contents


EXECUTIVE OFFICERS

        Our executive officers are designated annually by the board of directors. In February 2016, our board of directors designated theBoard. The persons listed below are serving as the Company'sour executive officers for the fiscal year ending December 31, 2016. Each of these executive officers, other than2019. Dr. Lenggenhager who joined the Company in November 2015,Laukien, Dr. Munch and Mr. Srega served as executive officers of the Company throughout the fiscal year ended December 31, 2015.2018. Dr. Prause was appointed an executive officer in February 2018, Mr. Herman was appointed an executive officer in March 2018 and Dr. Busse was appointed an executive officer in May 2018.

Name
 Age Position

Frank H. Laukien, Ph.D. 

  5659 

Chairman, President and Chief Executive Officer

Anthony L. MattacchioneGerald N. Herman

  5361 

Senior Vice President and Chief Financial Officer

Michael G. KnellFalko Busse, Ph.D. 

  3952 

Vice President, of Finance and Chief Accounting OfficerBruker BioSpin Group

Mark R. Munch, Ph.D. 

  5457 

Executive Vice President, President of Bruker Nano Group and Bruker Nano Surfaces Division

Burkhard Prause, Ph.D. 

52

President and Chief Executive Officer, Bruker Energy & Supercon Technologies, Inc.

Juergen Srega

  6164 

President, Bruker CALID Group and Bruker Daltonics Division

René Lenggenhager, Ph.D. 

56

President, Bruker BioSpin Group

        For biographical information relating to Dr. Laukien, who serves as both an executive officer and a director, of the Company, please see "Certain Information Regarding Directors and NomineesNominees"" above. BiographicalWe present biographical information relating tofor our current non-directorother executive officers is presented below. As previously reported in our Current Report on Form 8-K filed with the SEC on February 21, 2018, Mr. Anthony Mattacchione, our former Chief Financial Officer and a "named executive officer" resigned effective March 16, 2018.

PHOTO

        Anthony L. Mattacchione.Gerald N. Herman.    Mr. MattacchioneHerman has served as the Company's Senior Vice President andour Chief Financial Officer since February 2016. Mr. Mattacchione served as the Company'sJune 2018, after being named Interim Chief Financial Officer from June 2015 until his appointmentin March 2018. Mr. Herman joined Bruker in 2016 as Chief Financial Officer. Mr. Mattacchione joined the Company as Senior Vice President and Corporate Finance and Accounting in February 2013, with responsibility for the Company's global finance and accounting functions, including financial planning and analysis, corporate accounting, treasury, tax, shared financial services, internal controls and audit and global ERP business processes.Controller. Prior to joining the Company,Bruker, Mr. MattacchioneHerman had served in senior executive positions with various publicly traded companies, including as Chief Financial OfficerCorporate Vice President—Clinical Operations of EMD Millipore Corporation, a subsidiary of Merck KGaA,PAREXEL International from 2014 to February 2016, and as Corporate Vice President & Controller-Finance of PAREXEL from 2008 to 2013. Prior to 2008, Mr. Herman was Vice President—Corporate Controller and Chief Accounting Officer of Millipore Corporation from April 2006 until his appointment as Chief Financial Officer of EMD Millipore following the acquisition of Millipore by Merck KGaA. From 1990 to April 2006, Mr. MattacchionePresstek, Inc. He also served in various financial, consulting and accounting roles at Gerber Scientific, Inc.,various organizations, including as Treasurer, Corporate Controller and Chief Accounting Officer. Mr. Mattacchione was a senior auditorSenior Manager at Price WaterhouseArthur Andersen LLP from 19881979 to 1990.1987. Mr. MattacchioneHerman is a Certified Public Accountant in the State of Connecticut(CPA) and holds a M.B.A. in financeMaster of Business Administration degree from the University of ConnecticutChicago, and a B.S.Master of Science in accountingTaxation from Central Connecticut StateBentley University.


Table of Contents

PHOTO

        Michael G. Knell.Falko Busse, Ph.D.    Mr. KnellDr. Busse has served as President of the Company'sBruker BioSpin Group since May 2018, with responsibility for management of its global operations. Dr. Busse served as Deputy President of the Bruker BioSpin Group from October 2017 until his appointment as President. From March 2017 to September 2017, Dr. Busse served as Executive Vice President of FinanceResearch and Chief Accounting Officer since March 2012.Development, Operations and Marketing at the Bruker BioSpin Group. Dr. Busse joined the Bruker BioSpin Group in June 2015 and served as Executive Vice President of Research and Development until February 2017. Prior to joining the Company, Mr. Knell was with Ernst & Young LLP in its Boston office, where since 1998 heBruker BioSpin Group, Dr. Busse served in various managerial roles at Philips Healthcare and its subsidiaries from August 1994 until May 2015, including most recently as Partner-Assurance ServicesGeneral Manager Radiology Solutions, from January 2014 to May 2015, and as a senior manager of Assurance ServicesGeneral Manager MR-Therapy, from 2006 until his promotionAugust 2009 to partner in July 2011. Mr. Knell's audit experience at Ernst & Young included service for a variety of clients in the retail, consumer products and manufacturing industries. Mr. Knell is a Certified Public Accountant in Massachusetts andDecember 2013. Dr. Busse holds a Bachelor of Science degreeB.A. and a Ph.D. in Business AdministrationPhysics from the State University of New York at Buffalo.Rheinische Friedrich-Wilhelms-Universität Bonn.


PHOTO

Mark R. Munch, Ph.D.    Dr. Munch has served since September 2012 as President, Bruker Nano Group, with responsibility for management of theits global operations of our Bruker Nano Group, which manufactures and distributes the Company's advanced analytical X-ray technologies and spark-optical emission spectroscopy, atomic force microscopy and stylus and optical metrology instrumentation used in non-destructive molecular, materials and elemental analysis.operations. He has also served, since July 2015, as an Executive Vice President of the Company,Bruker, and in that capacity is responsible for providing oversight to the Company'sour global information technology function and enterprise resource planning, as well as other strategic management development and business process initiatives. Dr. Munch has also served as President of Bruker Nano, Inc., a wholly-owned subsidiary of the Company,Bruker, since October 2010. Prior to joining Bruker Nano, Inc., from February 2008 to October 2010, Dr. Munch was Executive Vice President of Veeco Instruments Inc. Dr. Munch also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006. Dr. Munch's background includes over 2329 years of experience in marketing, product development, operations and sales, as well as experience in managing significant business units of multi-national corporations. Dr. Munch holds a Bachelor of Science degree in Chemical Engineering from the University of Colorado and a Master of Science degree and Ph.D. in Chemical Engineering from Stanford University.

PHOTO

Burkhard Prause, Ph.D.    Dr. Prause has served as President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc., or BEST, since April 2008, with responsibility for management of its global operations. Dr. Prause also was a director of BEST from April 2012 to February 2013. Additionally, he has served as a director of Hydrostatic Extrusions Ltd. since April 2013, and as a Managing Director of Bruker EAS GmbH and Bruker HTS GmbH since January 2005, RI Research Instruments GmbH since December 2008, and Bruker ASC GmbH since March 2009. Prior to that time, Dr. Prause served as Product Manager for Bruker BioSpin MRI GmbH. Before joining Bruker BioSpin MRI GmbH in 2002, Dr. Prause was a senior staff scientist at the Max-Planck Institute in Tubingen, Germany. Dr. Prause currently is a director of CCAS (the Coalition for the Commercial Application of Superconductors), and from 2006 to 2010, Dr. Prause was Chairman of ivSupra, a German superconductor industry coalition. Dr. Prause holds a Ph.D. in Physics from the University of Notre Dame.


Table of Contents

PHOTO

Juergen Srega.    Mr. Srega has served as President of the Bruker CALID Group since January 2013, with responsibility for management of theits global operations of our Bruker CALID Group, which manufactures and distributes the Company's mass spectrometry and chromatography instruments for life science and applied markets, as well as analytical instruments for chemical, biological, radiological, nuclear and explosives detection and research and process instruments based on infrared and Raman molecular spectroscopy technologies.operations. Mr. Srega also serves as a Managing Director of Bruker Daltonik GmbH, an indirect wholly-owned subsidiary of the CompanyBruker located in Germany. Prior to joining the Company,us, Mr. Srega served since 1996 in a variety of senior management roles at Thermo Fisher Scientific Inc., a global provider of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics headquartered in Waltham, Massachusetts.diagnostics. At Thermo Fisher Scientific, Mr. Srega led a number of significant operating divisions, including as Vice President and General Manager Biomarkers, BRAHMS GmbH, from 2011 to 2012, Vice President and General Manager Scientific Instruments Division Global Products from 2005 to 2011 and Vice President and General Manager Advanced MS from 1996 to 2004. Prior to 1996, Mr. Srega was with Badenwerk AG, a German power utility company located in Karlsruhe, Germany, from 1988 to 1995 and an employee of Bruker GmbH from 1980 to 1988. Mr. Srega holds a B.A.Bachelor of Arts degree in Finance from Nord Akademie in Hamburg, Germany and a B.A.Bachelor of Arts degree in Engineering from Karlsruhe University of Applied Science in Karlsruhe, Germany.


        René Lenggenhager.

    Dr. René Lenggenhager serves as PresidentTable of the Bruker BioSpin Group. From 2004 until he joined the Company in November 2015, Dr. Lenggenhager served as General Manager for Laboratory Weighing at Mettler-Toledo International Inc. ("MTD"). From 2000 until 2003, he was the Head of R&D of Laboratory & Weighing Technologies at MTD. Prior to joining MTD, he worked at the Siemens Building Technologies SBT Cerberus Division, at Cerberus AG, at Landis & Gyr AG and at Metrohm AG. Dr. Lenggenhager holds a Ph.D. and a Master of Science ETH in Physics from the Swiss Federal Institute of Technology, a Bachelor of Science in Electronics from the University of Applied Sciences NTB in Buchs, Switzerland and an Executive MBA from the University of St. Gallen in Switzerland.Contents


COMPENSATION DISCUSSION AND ANALYSIS

        This Compensation Discussion and Analysis ("CD&A") describes the principles, objectives, and features of our executive compensation program, which is generally applicable to each of our senior officers. However, this CD&A focuses primarily on the program as applied toofficers, including our Chief Executive


Officer and the other executive officers listed below and included in the Summary Compensation Table, whom we refer to collectively in this proxy statement as the "named executive officers."

Mr. Wagner, our former Chief Financial Officer,Mattacchione resigned from the CompanyBruker effective June 2015. Additionally, Mr. Bachmann, former President of the Bruker BioSpin Group, resigned from the Company effective July 2015. These former executive officers areMarch 16, 2018. He is included as a named executive officersofficer in this proxy statement pursuant to applicable rules of the SEC.SEC rules.

Executive Overview

        Our executive compensation program is designed to attract, motivate, retain and reward the individuals thatwho lead the CompanyBruker and thatwho are responsible for developing and executing theour overall business strategy. Our approach to compensation for our executive officers targets a mix of competitive salaries, performance-based cash incentive awards linked to corporate and individual objectives and long-term equity incentive awards. The majority of our executive officers' pay opportunities are in the form of incentives, rather than base salary,is at risk, with a significant amount of those opportunities tied to long-term equity incentive awards.awards, thereby strongly linking the interests of our overall pay program with those of our stockholders. We provide limited perquisites and no excise tax gross ups. We also have a recoupment ("clawback") provision under our 2015 cash incentive plans that allows us to seek reimbursement of short-term incentive payments to the extentand repayment of the excess of what would have been paid to the participantstock award gains in the event of a restatement, due to material noncompliance with any financial reporting requirements, that is required to be prepared at any time during the three-year period following such payment.certain circumstances.

        We believe that our compensation policies and practices are effectively designed to motivate and reward performance, and that the mix of compensation elements creates incentives that are closely aligned with increasing shareholderstockholder value without encouraging excessive or unnecessary risk-taking.

        Our business strategy is to create value for our stockholders based on our ability to innovate and generate revenue growth, both organically and through acquisitions. Achieving improvements in our grossrevenue growth, operating profit, margins, operating marginsearnings per share and cash flowworking capital levels are also criticalimportant to our success. In 2015, our revenues declined by approximately 10% to $1.62 billion from $1.81 billion, reflecting primarily the unfavorable impact of changes in foreign exchange rates and the divestitureReflecting these objectives, a significant portion of our former Chemicalexecutive officers' cash compensation is based on our performance relative to goals linked to currency-adjusted revenue growth, non-GAAP gross profit and/or non-GAAP operating profit, working capital ratio reduction and Applied Markets (CAM) division. Includednon-GAAP earnings per share.

        In 2018, we exceeded our corporate level goals linked to currency-adjusted revenue growth and increasing our non-GAAP operating profit and non-GAAP earnings per share. We did not achieve our goal of reducing our working capital ratio. Our underlying business results also were generally favorable, with the Bruker CALID Group overachieving with respect to its Group level currency-adjusted revenue growth, non-GAAP gross profit improvement and non-GAAP operating profit improvement metrics, and almost achieving its Group level goals related to reducing the working


Table of Contents

capital ratio. The Bruker Nano Group overachieved its currency-adjusted revenue growth target and almost achieved its non-GAAP gross profit target but did not achieve its non-GAAP operating profit or working capital ratio goals. The Bruker BioSpin Group did not achieve its Group level financial objectives in 2015 revenues were a decrease of approximately $184.4 million from the impact of foreign exchange due to the strengthening2018. Reflecting these results, Dr. Munch, President of the U.S. Dollar versusBruker Nano Group, and Dr. Busse, President of the Euro, Japanese YenBruker BioSpin Group, received cash incentive awards below target award levels. Based on strong Corporate and other currenciesGroup level performance, Dr. Laukien and Mr. Herman received cash incentive awards slightly above target levels and Mr. Srega, President of the Bruker CALID Group, received a decreasecash incentive award significantly above his target award level.

        Additional information regarding our use of approximately $37.1 million attributable to divestitures, which was partially offset by the acquisitionnon-GAAP financial measures is included in Part II, Item 7—Management's Discussion and Analysis of Jordan Valley Semiconductors, Ltd. Adjusted for changes in foreign exchange ratesFinancial Condition and Results of Operations of our recent acquisitions and divestitures, our 2015 revenues increased by $36.4 million, or 2.1%. While our gross profit declined, our gross profit margin for fiscal 2015 rose to 43.6% from 42.2% for fiscal 2014. On a non-GAAP basis, excluding the effects of acquisition-related costs and restructuring charges totaling, in the aggregate, $42.4 million and $44.4 millionAnnual Report on Form 10-K for the year ended December 31, 2015 and 2014, respectively, our gross profit margins


increased approximately 150 basis points to 46.2% for fiscal 2015, compared to 44.7% for fiscal 2014. Our operating income for fiscal 2015 increased to $145.7 million, or 9.0% of revenues, from $105.4 million, or 5.8% of revenues, for fiscal 2014. Adjusted for acquisition-related costs and other non-recurring charges totaling, in the aggregate, $69.5 million and $79.0 million in 2015 and 2014, respectively, our non-GAAP operating margin improved by approximately 310 basis points, to 13.3% in 2015 from 10.2% in 2014. Additionally, as a result of a combination of improvements in our inventory management programs and the favorable effects of foreign exchange on our operating costs, our working capital ratio improved significantly, with working capital per dollar of revenue of $0.360 in 2015 compared to $0.384 in 2014.

        Overall, we significantly over-achieved on all our financial metrics at the Corporate level. While our underlying business results were mixed,2018 filed with the Bruker CALID Group overachieving, but the Bruker BioSpin and Bruker Nano Groups underachieving, we significantly exceeded our Corporate level goals linked to increasing our non-GAAP revenue, operating profit and earnings per share, and reducing our working capital ratio. Our management team also made significant progressSEC on a number of strategic initiatives aimed at reducing our operating costs and improving our operating efficiency, which we believe will benefit the Company and ultimately contribute to positive shareholder value creation in the long-term. Consequently, consistent with our pay for performance philosophy, the 2015 cash incentive awards approved for our executive officers reflects these results at the Corporate and Group levels.March 1, 2019.

        Highlighted below are some of the key actions and decisions with respect to our executive compensation programs for fiscal year 2015,2018, as approved by the Compensation Committee:


Table of Contents





CEO & CFOGroup/Segment PresidentsAll Executive Officers

Financial Goals   70% of Total Target Cash Incentive Plan Opportunity


Potential Payout Amounts
​ ​ ​ 

Corporate Financial Performance Goals

Currency-Adjusted Revenue Growth (15%)

Non-GAAP Operating Profit Improvement (20%)

Non-GAAP Earnings Per Share Growth (Non-GAAP EPS) (15%)

Working Capital Improvement (20%)

Non-GAAP EPS (10%)

Commensurate with performance on linear scale relative to achievement of each goal, subject to maximum aggregate payout of 200% of target amount linked to financial goals for each executive officer

Group/Segment Financial Performance Goals

Currency-Adjusted Revenue Growth (15%)

Non-GAAP Gross Profit Improvement (15%)

Non-GAAP Operating Profit Improvement (15%)

Working Capital Improvement (15%)


Individual Goals   30% of Total Target Cash Incentive Plan Opportunity


Potential Payout Amounts
​ ​ ​ 

Individual strategic and organizational objectives

Individual strategic and organizational objectives

0 - 125%, subject to adjustment at the discretion of the Compensation Committee

Long-Term Incentive Awards.  In 2015,2018, the Compensation Committee approved long-term incentive awards to our named executive officers and senior management team, including awards of stock options and restricted stock, in each case subjectRSUs, which vest ratably over four years from the date of grant. Our Compensation Committee selected time-based awards for our long-term incentives as an appropriate complement to time-based vesting.the strong performance component of our short-term incentive awards. The value of such awards to our Chief Executive Officer approximated 2.53.7 times his base salary and 50%almost 61% of his total direct compensation, which includes base salary, target bonus and long-term equity incentives, thus linking a significant portion of his total compensation to shareholderstockholder value. Our continuing Group presidents, Dr. MunchPresidents and Mr. Srega,our Chief Financial Officer also hadwere awarded significant equity stakes awarded, approximating 1.65in amounts representing, on average, 1.2 times their base salaries, and similar to the Chief Executive Officer had long-term incentives compriseor approximately 50% of their total direct compensation. On balance, the continuing named executive officers had approximately 45%42% (on average) of their total direct compensation delivered in the format target levels.

Table of equity awards. Contents

20142018 Say on Pay Vote

        At the Company's 2011 Annual Meeting of Stockholders, our stockholders voted on a proposalWe hold annual advisory votes on the frequency of future stockholder advisory votes regarding the compensation of the Company'spaid to our named executive officers. A frequency of once every three years received the highest number of votes cast, as well as a majority of the votes castofficers, or "say on the proposal. Accordingly, we hold an advisory say on pay vote every three years. In May 2014, our stockholders cast the most recent advisory vote on the Company's executive compensation decisions and policies as disclosed in the proxy statement for the 2014 Annual Meeting of Stockholders.pay" votes. Over 98%99% percent of the shares voted on the matter"say on pay" at the 2014our 2018 Annual Meeting of Stockholders approved theour named executive officer compensation decisions and policies described in the 2014our 2018 proxy statement. The Compensation Committee considered this result in 20142018 and determined that it was not necessary to make any material changes to the Company'sour compensation policies and practices in response to the most recent advisory vote. However, the Compensation Committee regularly reviews the compensation programs of our executive officers to ensure that they achieve our objectives. Our stockholderspractices. We will next be askedask our stockholders to cast a vote on the frequency of future stockholder advisory"say on pay" votes regarding executive compensation and an advisory vote regarding executive officer compensation at the Company's 2017our 2023 Annual Meeting of Stockholders.

Executive Compensation Philosophy and Process

        Our key objectives in structuring and determining executive compensation are to:

        To achieve these objectives, we have embraced a compensation philosophy that seeks to align compensation with our strategic objectives and reward our executive officers for meeting or exceeding certain pre-determined performance goals. Executive compensation at Bruker is based in large part on a pay-for-performance philosophy, through annual incentive bonus awards which emphasize both company and individual performance measures that correlate closely with the achievement of our short and long termshort-and long-term strategic performance objectives. To motivate our executive officers, we focus on cash compensation in the form of salary and annual performance incentives, a portion of which is tied to the individual's performance, and we augment this cash compensation with equity grants. In structuring executive compensation, the Compensation Committee focuses on our goal of long-term enhancement of shareholder value through grants of equity incentive awards with extended multi-year vesting schedules.

        Our Compensation Committee oversees management's administration of our executive compensation program, is administered by the Compensation Committee of the board of directors. The Compensation Committee oversees the Company's equity incentive plan, including determiningincluding:


Table of Contents

        The Compensation Committee conducts the annual performance evaluation of our Chief Executive Officer. Generally, the process begins with the Chief Executive Officer completing a self-evaluation, which is submitted to the Compensation Committee for review and discussion. As part of this review, the ChairmanChair of the Compensation Committee may solicit views from other members of our board of directors,Board, after which the ChairmanChair of the Compensation Committee provides feedback to the Chief Executive Officer. The Compensation Committee uses this evaluation along with market data comprised of peer group and salary survey information in setting the Chief Executive Officer's compensation.

        For executive officers other than our Chief Executive Officer, the Compensation Committee relies primarily on input and recommendations from our Chief Executive Officer in the case of our Chief Financial Officer and Group presidents. In the case of our other executive officers who report directly to our Chief Financial Officer, the Compensation Committee relies primarily on the input and recommendations from our Chief Financial Officer. Our Chief Executive Officer and our Corporate Vice President of Human Resources also may contribute input to the Compensation Committee in connection with its evaluation of executive officers' performance objectives and performance of the executive officers against those objectives to assist it in making appropriate decisions regarding salary and incentive awards. The Corporate Vice President of Human Resources may also provide market analyses and other relevant market intelligence to the Compensation Committee as part of its evaluation and deliberations.

Prior to the end of the first quarter of each fiscal year, the Compensation Committee reviews and approves changes to our executive officers' total target cash compensation, including base salary and target incentive compensation. During the first quarter of each fiscal year,Also during this time, the Compensation Committee also reviews recommendations from management on the most recently completed fiscal yearprior year's short-term incentive compensation programs relative to anticipated corporate and individual performance. Additionally, during the first quarter of each fiscal year, the Compensation Committee reviews and makes recommendations to the full board of directorsBoard regarding any changes to board compensation. The Compensation Committee generallyBoard compensation and reviews recommendations for long-term equity incentive awards during the second and third quarters of the fiscal year.awards.

        The Compensation Committee assesses competitive market compensation for our executive officers using a variety of external sources, including cash and long-term incentive compensation data derived from independent sources, including market surveys and proxy information, for a reference group of publicly-traded companies in the same or similar industries. Although individual pay is driven largely by individual and corporate performance considerations, the Compensation Committee has historically used reference group data as a "market check" to help ensure that individual cash compensation levels remain reasonable and competitive. The Company has retained independent consulting firm Radford Consulting, or Radford, since September 2013 to provide support in evaluating the Company's executive compensation levels and practices, particularly with respect to total direct compensation, internal pay equity, pay for performance alignment, and long-term incentive award levels, and types of equity vehicles and processes, including the impact of overall stockholder dilution resulting from equity awards.

        The Compensation Committee retains the discretion to approve awards in excess of those calculated to have been earned under the pre-established cash incentive plans of our executive officers in recognition of exceptional individual performance or contributions to Company performance. Additionally, the Compensation Committee may exercise its discretion not to approve cash incentive plan awards calculated to have been earned under a pre-established cash incentive plan of an executive officer in the event the Compensation Committee determines that such executive officer has violated CompanyBruker policies or has failed to meet minimum performance expectations of an executive officer in that executive's position.expectations. The Compensation Committee may also recoup incentive compensation payments if it determines that a recipient has engaged in activities detrimental to our business, as well as excess payments made


resulting from before a financial restatement which resultsresulting from material non-compliance with accepted financial requirements or reporting standards.


Table of Contents

        The Chief Executive Officer, with the assistance of the Chief Financial Officer, is responsible for making recommendations to the Compensation Committee for our Company-wide financial performance goals and their respective weightings. He is also responsible for making recommendations to the Compensation Committee for the individual incentive goals and weightings for the Company'sour other executive officers. The Chief Executive Officer is also responsible for developing and providing a proposal to the Compensation Committee for his own cash incentive plan, including the goals, weightings and target levels. The Compensation Committee reviews the recommendations of the Chief Executive Officer and Chief Financial Officer and determines the final incentive plan structure and goals for each of the executive officers, including threshold performance and target incentive paymentperformance levels. After the close of the fiscal year, the Chief Executive Officer, assisted by the Corporate Vice PresidentChief Financial Officer and the Senior Director of Human Resources, provides the Compensation Committee with his assessment of the performance of the other executive officers against their respective bonus goals and proposed cash incentive plan payout. When determining the cash incentive plan payout for our executive officers, the Compensation Committee, while considering the recommendations of the Chief Executive Officer, makes the final determination based on its assessment of each executive officer's performance relative to his or her performance-based goals.

        The Chief Executive Officer and the Corporate Vice PresidentSenior Director of Human Resources participate in Compensation Committee meetings, at the request of the Compensation Committee, to provide background information and explanations supporting compensation recommendations, including the results of annual performance evaluations for our Chief Executive Officer,named executive officers. The Chief Financial Officer may participate in Compensation Committee meetings to provide perspective and supplemental information related to our financial goals and other named executive officers.financial plan topics.

        In light of the growth and evolution in recent years in theour size and complexity of the Company and itsour global operations, changes in the competitive landscape as a result of industry consolidation and changes in the Company'sour own organizational and management structure, the Compensation Committee and management have worked with independent consulting firm Radford Consulting, or Radford, to, among other things, providereview market surveys, observations and recommendations regarding our executive compensation program relative to other similarly situated public companies and providereceive external perspectiveperspectives on evolving trends related to executive compensation program design, and best practices and changes in the changing regulatory landscape.

        Since September 2013, Company management has engaged Radford to provideprovides support to management and the Compensation Committee, including the selection of a peer group of companies and development of peer group survey data, as well as analysis and advice on the Company'sour executive compensation structure, program design and market practices. Services provided during fiscal 20152018 by Radford under its engagement with the Company included working with the Companyus to assess the current peer group for reasonableness and various compensation analyses and assessments.assessments, including with respect to the 2018 CEO pay ratio analysis. The analyses and recommendations provided by Radford were among the inputs considered in the evaluation of the Company'sour compensation process, program design and executive compensation determinations for 2015.2018. The selected peer group is generally used for compensation assessments and analyzing the Company'sour executive compensation pay levels and practices, including the Company'sour share allocation and utilization for employee equity awards as compared with peer companies. Additionally, in 2015, the Company retained Radford to perform an assessment of the Company's 2010 Incentive Compensation Plan, performing modeling based on shareholder advisory firm guidelines, such as those of ISS and Glass Lewis, and also assessing the Plan against evolving standards of governance and best practice provisions. The recommendations from Radford were considered in the Company's development of its 2016 Incentive Compensation Plan that is proposed for stockholder approval at the 2016 Annual Meeting.


        Aon and Aon Hewitt, affiliates of Radford, also provided insurance consulting services to the Company in 2015 for which services they received aggregate fees of $50,000 in 2015.        For its services as anour executive compensation consultant, to the Company, Radford received aggregate fees of approximately $76,000$74,000 in 2015,2018, as well as approximately $34,000$57,000 for non-executive compensation consulting and surveys. The Committee has evaluated Radford's independence by considering each of the independence factors adopted by NASDAQNasdaq and the SEC. Based on such evaluation, the Committee determined that no conflicts of interest existed during fiscal 20152018 or exist currently. The Compensation


Table of Contents

Committee has the authority to retain, compensate and terminate any consultants or advisers it deems necessary to assist it in the fulfillment of its responsibilities.

        In establishing and evaluating fiscal 20152017 compensation for our executive officers, the Compensation Committee utilized survey market data and peer group analysis provided by Radford. The Compensation Committee believes that it is important to consider compensation practices of companies that are comparable to us in terms of revenue, market capitalization, employees, global reach, scale and complexity along withand industry. Radford generally targeted companies in the range of 1/1/2 to 3three times the size of the CompanyBruker across various categories, taking into accountconsidering the global complexity and reach of the Company.Bruker. The market data provided by Radford was based on published survey sources, including Radford's Global Technology Survey and Aon Hewitt's Total Compensation Management Database, as well as recent proxy statements of the Company'sour peer group companies. The Compensation Committee references ranges of the market data provided, including the 10th, 25th, 50th,10th, 25th, 50th, and 75th75th percentiles, considering all of these sources in determining the appropriate level of compensation for our executive officers.

        For fiscal 20152018 compensation evaluations, the Compensation Committee determined that certain changes were needed to better align the 2017 peer group's revenue levels and total market value to the 50th percentile. This new peer group identified by Radford and referencedapproved by the Compensation Committee was comprised of 17 other companies in the scientific tools, instruments, and services industries. The Compensation Committee believes that a peer group consisting of competitors of various sizes provides useful insight for its consideration of compensation levels, including information about the range and median of competitive salaries, cash bonuses and long-term incentives. In addition to industry, complexity and size characteristics, the Compensation Committee also considers the extent to which our selected peer group companies consider us a peer, how other third partythird-party organizations categorize the Company, such(such as the Standard and Poor's GICS methodology,methodology) categorize Bruker and other companies which shareholder advisory firms such(such as ISS,ISS) consider comparable to us. The Committee also strives for consistency in the peer group from year to year, in order to maintain consistency of results. The same peer group has generally been used since 2013, with minor modifications generally due to industry consolidation. In 2015,2018, at the time Radford compiled data for the peer group companies, the companies in our new selected peer group ranged in size on a revenue basis from approximately $1.5$0.96 to $2.8$2.1 billion, at the 25th and 75th percentiles, respectively, with a median of $2.2$1.8 billion, compared to our 2014trailing twelve-month revenue of $1.80$1.77 billion, and a range of 3,542 to 7,412 employees at the 25th and 75th percentiles, respectively, with median number of employees of 6,8005,218 compared to our 6,100 as of December 31, 2014.6,300. The peer group considered by the Compensation Committee for its evaluation of 20152018 executive compensation levels and practices included:

AMETEK, Inc.Analogic Corporation

 

KLA-Tencor CorporationMKS Instruments,  Inc.

Bio-Rad Laboratories,  Inc.

 

Mettler-Toledo International Inc.National Instruments Corporation

C.R. Bard,Charles River Laboratories International, Inc.

 

OSI Systems,  Inc.

Charles River Laboratories International,Coherent,  Inc.

 

Pall CorporationPerkinElmer,  Inc.

FEI CompanyFLIR Systems,  Inc.

 

PerkinElmer,Teradyne Inc.

FLIR Systems, Inc.Haemonetics Corporation

 

Sigma-Aldrich CorporationVeeco Instruments Inc.

HaemoneticsKLA-Tencor Corporation

 

Varian Medical Systems, Inc.Waters Corporation

Hologic, Inc.Luminex Corporation

 

Waters CorporationWatts Water Technologies,  Inc.

IlluminaMettler-Toledo International Inc.

  

        In general, in light of our relative market position, the Compensation Committee considered the range and median compensation levels of the companies in the peer group to be appropriate and reasonable competitive comparisons for our executive officers when evaluating and approving 20152018 compensation packages.


Executive Compensation Components and 2015 Compensation DeterminationsTable of Contents

        Consistent with our compensation objectives and philosophy, when setting compensation for our named executive officers the Compensation Committee focuses on providing a competitive and complementary mix of components, including base salary, annual incentive compensation and long-term equity incentive awards, designed to work together to reward performance and create incentives that encourage behavior consistent with the overall interests of the Company.

        In determining compensation packages for our named executive officers, the Compensation Committee seeks to strike an appropriate balance between fixed and variable compensation and between short-and long-term compensation. We believe that making a significant portion of our named executive officers' compensation variable and long-term supports our pay-for-performance executive compensation philosophy, while also mitigating potential excessive risk-taking behavior.

Components of Executive Compensation

        Total direct compensation consists of cash compensation in the form of annual base salary and annual incentive bonus awards, as well as long-term incentive compensation in the form of stock option and restricted stock unit grants.

        Annual Base Salary.    Base salaries are determined based on a variety of factors, including each officer's level of responsibility, scope of the role, experience and potential, performance and a comparison of salaries paid to peers within the CompanyBruker and to those with similar roles at other similarly situated companies, including those found in the market surveys and peer group data reviewed by the Compensation Committee. Base salaries are set at levels that the Compensation Committee believes are reasonably competitive to allow us to attract and retain qualified executives. Base salaries are reviewed annually and may be adjusted after considering the various factors described above.

        Annual Cash Incentive Awards.    Annual incentive awards in the form of performance-based cash incentive bonuses for the Chief Executive Officer and our other executive officers are based upon management's success in meeting our financial and strategic goals. Specific criteria for these awards are based onachieving a combination of quantitative financial and individual measures established each year by the Compensation Committee after consultation with management. The specific goals vary for each executive officer based on responsibilities and role within our CompanyBruker and may include financial or strategic measures, including, among others, revenue growth, gross profit and operating profit margin improvement, working capital ratio improvements, achieving return on invested capital goals, meeting earnings per share targets, identifying and developing new product and market opportunities and furthering or achieving other strategic initiatives. The individualmeasures. Individual goals are intended to reward performance which results in our CompanyBruker meeting or exceeding its financial or operational goals.

        The Compensation Committee also considers the mix of performance goals in order to balance the incentives created to mitigate risks that may be associated with a particular performance goal. In 2015, for example, the cash incentive plans established for our corporate level officers, including our Chief Executive Officer and Chief Financial Officer, consisted of a revenue target goal along with targets for non-GAAP operating profit improvement, working capital and non-GAAP earnings per share, such that the combination of goals emphasized profitable revenue growth and cash flow improvements as well based on the business plan approved by our board of directors. For our Group presidents, the financial metrics included revenue growth, increases in non-GAAP operating and gross profit, improvements in working capital, and linkage to the overall Bruker profit results to ensure alignment and teamwork


across the leadership team. Through a mix of quantitative financial metrics and individual goals, cash incentive awards reflect both the individual's contributions compared to his or her specific performance goals for the year and the overall performance of our CompanyBruker or the particular operations under the executive officer's leadership.

        Long-Term Incentive Awards.    Equity incentive compensation in the form of stock optionsoption and restricted stock unit (RSU) awards is designed to provide long-term incentives to executive officers and other employees, to encourage the executive officers and other employeesthem to remain with us and to enable recipients to develop and maintain a long-term stock ownership position in our common stock, which in turn motivates the recipientthem to focus on creating long-term enhancement to shareholderstockholder value. The Company's 2010

        Our 2016 Incentive Compensation Plan, or the 2016 Plan, is the vehicle used for grants of stock options and restricted stockequity incentive awards to our executive officers and other employees. CompanyThe 2016 Plan provides for the grant of awards of options, including nonqualified stock options or incentive stock options, restricted stock, unrestricted stock, restricted stock units, stock appreciation rights, performance shares and performance units, as well as cash-based awards. We primarily use RSU awards to provide a more tax-effective equity vehicle for our international employees and additional flexibility for us to deliver awards in the form of stock or cash. Our management evaluates the efficacy of our long-term incentive compensation on an ongoing basis and provides input and recommendations to the Compensation Committee with regard to the optimal form and extent of equity incentives to be granted to employees, including the executive officers.

        Stock option and restricted stock grantsEquity incentive awards are discretionary and may be granted by the Compensation Committee at any time. Historically, we have not awarded equity incentive compensation with performance-based vesting, meaning that individual vesting is not based upon the achievement of any specific goals or objectives. However, increases in stock price provide the only value available to executives from stock options, and increases in shareholder value deliver higher values in restricted stock. The Compensation Committee also considers individual and Company performance in determining the value of total and individual equity awards. The Compensation Committee has determined that equity compensation awards to executives and all other employees should be based upon the economic value of the grant award and should be considered part of the compensation package in determining award levels. In making specific grants to executives, the Compensation Committee evaluates each executive officer's total equity compensation package. The Compensation Committee also generally reviews the option and restricted stock holdings of each of the executive officers as well, including vesting and exercise price and the then current in-the-money value of such options or restricted stock, in addition to the impact of those values under various stock price scenarios. We consider long-term equity compensation to be an integral part of a competitive executive compensation package as both a way to reinforce the individual's commitment to the Company, provide "skin in the game",Bruker, create an ownership mentality and provide an important mechanism to align the interests of management with those of our stockholders.


Table of Contents

Mix of Compensation

        In accordance with our pay-for-performance philosophy, variable compensation in the form of short-term cash incentive compensation and long-term equity incentive awards are intended to be a significant portion of overall compensation, with this at-risk component increasing as a percentage of overall compensation potential as the individual officer's responsibility increases. For example, almost 80%approximately 84% of theour Chief Executive Officer's total compensation is variable or "at risk," meaning these amounts must be re-earned each year. Similarly, almost 60%between 50% and 69% of the total compensation of our other named executive officers is comprised of variable pay.

        Specifically, on a target basis in 2015,2018, approximately 58% of our Chief Executive Officer's total potential cash compensation at the target level was at risk through his short-term cash incentive program. Additionally, recognizing the importance of providing further incentives directly linked to the performance of our common stock and aligned with stockholder interests, in 20152018 the Compensation Committee approved market competitive long-term incentive awards to our named executive officers, including, among others, awards to Dr. Laukien, our Chief Executive Officer, and Mr. Mattacchione, then serving asHerman, our Interim Chief Financial Officer, of stock options and restricted stock grantsRSU awards valued at the time of the respective awardsgrant at over 250%377% and 70%112% of base salary, respectively, subject in each case subject to time-based


vesting over four years and continued employment. Equity awards for our Group presidents on average approximated 165%122% of base salary, signifying strong alignment for our executive team with stockholder interests. Equity compensation comprised approximately half61% of our Chief Executive Officer's total direct compensation and one-thirdapproximately half of our Interim Chief Financial Officer's total direct compensation, which includes base salary, annual bonus and long-term incentives. Long-term incentives as a percent of total direct compensation for our Group presidents also approximated half41% of their total direct compensation. Long-term incentives as a percent of total direct compensation for the named executive officers as a group, excluding former executive officers Mr. Wagner and Mr. Bachmann,including the CEO, ranged from 20%approximately 25% to 50%61%.

        The following charts and table illustrate the mix of base salary at approved 2018 levels, short-term cash incentive bonus at target levels and long-term incentive awards ("LTI") provided in the compensation packages of our Chief Executive Officer ("CEO"), and, on average, our named executive officers other than our Chief Executive Officer and former executive officers Mr. Wagner and Mr. Bachmann ("Other NEOs").


Named Executive Officer Compensation Mix


GRAPHICGRAPHIC

 

GRAPHICGRAPHIC

Table of Contents



 CEO Pay Mix Other NEO Average Pay Mix  CEO Pay Mix Other NEO Average Pay Mix 
Element
 Value % of Total Direct
Compensation
 Value(1) % of Total Direct
Compensation
  Value
($)
 % of Total Direct
Compensation
 Value(1)
($)
 % of Total Direct
Compensation
 

Base Salary(2)

 $625,000 20% $347,337 37% 730,675 16% 408,029 37%

Bonus(3)

 $875,000 29% $172,618 19% 1,031,030 23% 243,984 21%

Long Term Incentives(4)

 $1,562,500 51% $409,447 44% 2,775,027 61% 541,955 42%

Total Direct Compensation

 $3,062,500 100% $929,402 100% 4,536,732   1,193,968   

(1)
The values reported reflect conversionsconversion from euros,Euros (€) and Swiss Francs (CHF) to U.S. Dollars at conversion rates of €1.0 =$1.1809 and CHF 1.0=$1.0224, respectively, reflecting 2018 average midpoint rates.

(2)
Base salaries are as reported in the caseSummary Compensation Table following this CD&A.

(3)
Bonus represents the target level of Mr. Srega, to U.S. dollars at a conversion ratethe short-term cash incentive plan of €1.0 =1.1094, reflecting the 2015 average midpoint rateCEO and Other NEOs.

(4)
Long-term incentive awards are based on the economic values of the awards as published on www.oanda.comapproved by the Compensation Committee.

20152018 Base Salaries

        Annual base salaries approved by the Compensation Committee for each of our named executive officers for 20152018 were as follows:

 
 2015 Base Salary 2014 Base Salary % Change 

Dr. Frank Laukien

 $625,000 $600,000  4.1%

Mr. Mattacchione

 $351,900 $288,400  22.0%

Mr. Srega

 $319,951(1)$372,260(2) 3.0%(3)

Dr. Munch

 $490,000 $400,000  22.5%

Mr. Knell

 $227,500 $223,000  2.0%

Mr. Wagner

 $525,300 $510,000  3.0%

Mr. Bachmann

 $374,796(4)$393,984(5) (6)
 
 2018 Base Salary
($)
 2017 Base Salary
($)(1)
 % Change 

Dr. Frank Laukien

  736,450  715,000  3.0%

Mr. Herman

  420,000     

Mr. Mattacchione(2)

  447,260  447,260   

Dr. Busse

  353,322(3)    

Dr. Munch

  556,432  529,935  5.0%

Mr. Srega

  397,446(4) 369,238(5) 3.0%

(1)
As Mr. Herman and Dr. Busse were not named executive officers in 2017, their 2017 salaries are not included.

(2)
Mr. Mattacchione, our former Chief Financial Officer, resigned from Bruker on March 16, 2018.

(3)
Amount represents the U.S. dollarDollar equivalent value of Dr. Busse's base salary (CHF 345,581), based on the 2018 average midpoint conversion rate of CHF 1.0= 1.0224.

(4)
Amount represents the U.S. Dollar equivalent value of Mr. Srega's base salary (€288,400)326,759), based on the 20152018 average midpoint conversion rate of €1.0 =$1.1094.1.1809.

(2)(5)
Amount represents the U.S. dollarDollar equivalent value of Mr. Srega's base salary (€280,000)326,759), based on the 20142017 average midpoint conversion rate of €1.0 =$1.3295.

1.1300.
(3)

For 2015,2018, the Compensation Committee approved asalary increases ranging from 3% increase in Mr. Srega's base salary denominated in euros,to 5% for our executive named executive officers serving as such at the currencybeginning of payment, from €280,000 to €288,400. The dollar amount reported in the table above is converted from euros and reflects the impact of changes in foreign exchange rates in 2015.

(4)
Amount represents the U.S. dollar equivalent value of Mr. Bachmann's base salary (CHF 360,000), based on the 2015 average midpoint conversion rate of CHF 1.0 =$1.0411.

(5)
Amount represents the U.S. dollar equivalent value of Mr. Bachmann's base salary (CHF 360,000), based on the 2014 average midpoint conversion rate of CHF 1.0 =$1.0944.

(6)
Base salary of Mr. Bachmann did not change in local currency terms from 2014 to 2015. Change reflected in the table result from the impact of changes in applicable exchange rates and conversion of local currencies to U.S. dollars.

        For fiscal 2015, the Compensation Committee approved a 4.1% salary increase for Dr. Laukien, our Chief Executive Officer.2018. The Compensation Committee considered this adjustmentthese increases appropriate based on the updatedits evaluation of competitive market levels, peer group survey data, reviewed by theindividual performance and market conditions. The Compensation Committee as Dr. Laukien's baseadjusted Mr. Herman's salary and total compensation potentialto $322,000 when he was and after the increase continued to be, significantly below the market median for chief executive officers of the Company's compensation peer group.

        Based on Mr. Mattacchione's positive performance evaluation and comparison to market data, the Compensation Committee initially determined that his base salary for fiscal 2015 should be increased by 4.0%, from $288,400 to $299,900. In connection with his appointment to the position of Interimappointed interim Chief Financial Officer in May 2015,on March 17, 2018, an increase of 29%. Upon Mr. Herman's election to Chief Financial Officer by the Board on June 6, 2018, the Compensation Committee approved an additional pre-tax payment of $8,000 per month during his service in that role. The change reported in the table above reflects the cumulative effect of these determinations.

        The Compensation Committee determined that, based on Dr. Munch's performance evaluation and the comparison to compensation paid to executives in comparable positions according to peer group and other market data reviewed by the Compensation Committee, Dr. Munch's base salary for fiscal 2015 should be increased by 10% from $400,000adjustment to $440,000. In August 2015, with retroactive effect to July 2015, the


Table of Contents

$420,000, a further increase of 31%. The Compensation Committee approved an 18% increase into Dr. Munch'sBusse's base salary to


$490,000based on his election to reflectPresident of the Bruker BioSpin Group on May 1, 2018.

        Base salary increases, other than those approved in connection with changes in Mr. Herman's and Dr. Munch's promotion to Executive Vice President and his assumption of additional duties in that capacity. The change reported in the table above reflects the cumulative effect of these determinations. Base salaries established for Messrs. Srega, Knell, Bachmann and Wagner reflect the Compensation Committee's assessment of competitive market levels, individual performance, experience and overallBusse's responsibilities, as well as internal pay equity.became effective April 1, 2018.

Cash Incentive Plans and Review of 20152018 Performance

        Annual cash incentive compensation supports the Compensation Committee's pay-for-performance philosophy and aligns individual goals with those of the Company. Under the annual short-term incentive compensation plans, or ICPs, executive officers are eligible for cash awards based on a combination of the Company'sour attainment of pre-established financial performance metrics and achievement of specific individual qualitativeperformance goals. While still measurable, individual qualitativeperformance goals may not always be as quantifiable as the financial objectives. Thus, and consistent with its past practice, the Compensation Committee structured our executive officers' 2015 cash incentive plans2018 ICPs as follows:

        The Compensation Committee sets the performance metrics as well as the performance thresholds and targets for each metric after consultation with management. The two primary classifications of performance goals utilized in the annual incentive plansICPs are quantitative financial goals and individual qualitative performance goals. Each performance metric represents part of the total incentive award calculation, with the quantitative financial goals accounting for, in the aggregate, 70% of the target award potential and the individual performance goals accounting for, in the aggregate, 30% of the total incentive award potential. Payments for cash incentive bonuses linked to the achievement of pre-established quantitativefinancial performance goals are calculated based on percentage achievement of the quantitativefinancial target goal. While there is no maximum payout for any individual quantitativesingle financial goal, total incentive award payouts, after combining boththe combined payout for the financial and individual portions, are subjectgoals portion of an individual's ICP is limited to a maximum amount of 200% of the individual'sfinancial incentive award target.


        Payments for individual performance goals are made in a range of 0% to 125%, based on evaluation of the named executive officer's performance and determined by the Compensation Committee according to the following schedule:


2015 Cash Incentive2018 Individual Goal Performance Measurement and Payout MeasurementLevels

Performance Descriptor
 Performance Level Payout Percentage 

Significantly Exceeded

  125% 125%

Achieved

  100% 100%

Mostly Achieved

  75% 75%

Partially Achieved

  50% 50%

Not Achieved

  0% 0%
Performance Descriptor
Performance Level
and Payout Percentage

Significantly Exceeded

125%

Achieved

100%

Mostly Achieved

75%

Partially Achieved

50%

Not Achieved

0%

Table of Contents

        Individual qualitativeperformance goals are generally set as stretch but attainable goals, with over-achievement of goals anticipated to occur in very limited circumstances. Additionally, the Compensation Committee may, in its discretion, award cash incentive bonuses above the target level in the event it determines that an executive officer has delivered exceptional performance. Cash incentive compensation plans of our named executive officers operate under a common set of performance metrics and calculation methodologies, with goals adjusted at the Corporate or Group level to reflect individual areas of responsibility. Moreover, each Group president also has a portion of his financial quantitative goals tied to the overall profitability of the Company, creating additional alignment, unity of purpose, and teamwork across the Company.

        Setting Incentive Target Levels.    The Compensation Committee establishes cash incentive plans for our executive officers, including each of our named executive officers, which are designed to provide meaningful performance incentives, relative to both fixed cash compensation in the form of salary and overall potential cash compensation, consistent with the Company's strategic goals and objectives and each individual executive officer's responsibilities. The following table summarizes the 2015 cash incentive2018 ICP target levels approved for each of our named executive officers and the relationship of performance-based cash compensation at target levels to base salary and total potential cash compensation. No cash incentive plan was established for Mr. Bachmann.Mattacchione resigned effective March 16, 2018 and did not participate in the 2018 ICP program.


20152018 Cash Incentive Targets

 
 Target Level % of Base Salary
at Target Achievement
 % of Total Potential
Cash Compensation
at Target Achievement

Dr. Frank Laukien

 $875,000 140% 58%

Mr. Mattacchione

 $164,100 47% 32%

Mr. Srega(1)

 $175,951 55% 35%

Dr. Munch

 $264,000 54% 35%

Mr. Knell

 $86,400 38% 28%

Mr. Wagner

 $525,300 100% 50%
 
 Target Level ($) % of Base Salary
at Target Achievement
 % of Total Potential
Cash Compensation
at Target Achievement
 

Dr. Frank Laukien

  1,031,030  140% 58%

Mr. Herman

  231,000  55% 35%

Dr. Busse(1)

  176,662  50% 33%

Dr. Munch

  347,770  62.5% 38%

Mr. Srega(2)

  228,531  57.5% 37%

(1)
Amounts in the table represent the U.S. dollarDollar equivalent value of Dr. Busse's cash incentive target (CHF 172,791), based on the 2018 average midpoint conversion rate of CHF 1.0= 1.0224.

(2)
Amounts in the table represent the U.S. Dollar equivalent value of Mr. Srega's cash incentive target (€158,600)193,523), based on the 20152018 average midpoint conversion rate of €1.0 =$1.1094.1.1809.

        When setting individual target incentive levels for fiscal 2015,2018 ICPs, the Compensation Committee reviewed, for each named executive officer, individual target awards applicable in fiscal 2014,2017, the total cash compensation established for fiscal 20142017 and the projected cash compensation for fiscal 2015,


2018, considering how the total cash compensation of each named executive officer compared to peer group and related market data, and the responsibilities of each named executive officer. Additionally, the Committee considered long-term incentive target levels, to take into account a total direct compensation view, so that no one element was determined in isolation, but rather the entire total compensation picture was considered.isolation. Based upon this review, as well as the increase in Dr. Laukien's 2015 base salary, the Compensation Committee determined that his cash incentive target should be adjusted to provide both a meaningful increase in his total cash compensation potential and to maintain an appropriate mix of short-term fixed and variable compensation. As a result, Dr. Laukien's cash incentive target was raised to $875,000 from $800,000, or toshould remain at 140% of base salary from 133% of base salary, which represented a modest increase in Dr. Laukien's relative amount of "at risk" potential cash compensation.pay. The Compensation Committee also determined that a greater amount of Mr. Srega'sHerman's potential cash compensation should continue to be tied to performance incentives in light of his responsibilities and determined to maintain Mr. Srega'stherefore increased his cash incentive target atto 55% of base salary for 2015. Additionally,from 40% of base salary in light of2017. Finally, based on its review of peer group data and the overall compensation of each other named executive officer, the Compensation Committee determined to maintain Messrs. Mattacchione and Wagner'sthe cash incentive target at 50%for Dr. Busse and 100%make incremental increases to Dr. Munch's and Mr. Srega's cash incentive targets for 2018 to 62.5% and 57.5% of base salary, respectively, for 2015.respectively.


Table of Contents

        Setting Performance Goals and Thresholds.    The Compensation Committee establishes specific Corporate level quantitative financial performance goals for our executive officers with corporate responsibilities, including named executive officers Dr. Laukien and Messrs. Mattacchione and Wagner,Mr. Herman, and Group level quantitativefinancial performance goals for our executive officers with Group level management responsibilities including Mr. Srega and Dr. Munch, based on key Corporate, Group or divisional business plan goals for the fiscal year. Mr. Bachmann was not eligible to participate in our 2015 short-term incentive program. In addition to goals tied to Group level financial performance, each of our Group Presidents has a portion of his incentive award potential linked directly to our profitability at the Corporate level,non-GAAP earnings per share, creating additional alignment with theour overall strategic objectives of the Company. Quantitativeobjectives.

        Financial performance goals generally reflect targeted growth over the results achieved in the prior year for the relevant metric, with a threshold level of current year performance required for any cash incentive payout that ispayout. Threshold levels are typically equal to the prior year performance. However, in the case of business plan goals for which only modest or no growth is forecast, performance thresholds may be set at 95% of the business plan goal, which may result in a performance threshold that is less than the results achieved in the prior year. For example, because our 2015Our 2018 business plan included goals of lessmore than 5% currency-adjusted revenue growth in our named executive officers' financial targets at the Corporate level and the Bruker BioSpin, Bruker CALID and Bruker Nano Group levels, the performance thresholds for Dr. Laukien's, Mr. Wagner's, Mr. Srega's and Dr. Munch's quantitative targets tied to revenue growth at the Corporate or Group level, as applicable, were set at 95% of the relevant business plan goal.levels. As a result, 2017 performance was the threshold level of 2015 revenue neededachievement for our named executive officers to earn any portion of their goalscash incentive plan targets linked to revenue growth, on a currency-adjusted basis, was slightly below 2014 results.


financial performance goals.

20152018 Corporate Level Performance Goals

Dr. Frank Laukien
Mr. Mattacchione
Mr. Knell
Mr. WagnerHerman


QuantitativeFinancial Performance Goals
(70% of Target Bonus Potential)

2015 Corporate Level Performance
Goals(1)
 Weighting Performance
Threshold
 2015 Performance(2) % of
Incentive
Goal
Achieved
 % of Total
Incentive
Target
Earned

$82.7 million Currency-Adjusted Revenue Growth

  15%95%(3) 

$101.0 million Currency-Adjusted Revenue Growth

 122.2% 18.3%

$16.1 million Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)                         

  20%100%(4) 

$32.4 million increase in
Non-GAAP Operating Profit

 201.1% 40.2%

$0.04 Increase in Non-GAAP Earnings Per Share (adjusted for acquisition and restructuring charges)                         

  15%95%(3) 

$0.18 increase in Non-
GAAP Earnings Per Share

 476.2% 71.4%

$0.018 Reduction in Working Capital Ratio (adjusted for acquisition and restructuring charges)                         

  20%105%(3) 

$0.04 Reduction

 217.0% 43.4%

Total

  70%    247.7% 173.4%
2018 Corporate Level
Performance Goals(1)
 Weighting Performance
Threshold(2)
 2018 Performance(3) % of
Incentive
Goal
Achieved
 % of Total
Incentive
Target
Earned
 

$100.6 million Currency-

       $130.9 million Currency-       

Adjusted Revenue Growth

  15% 100%Adjusted Revenue Growth  130.2% 19.5%

               

$26.9 million Non-GAAP

               

Operating Profit

               

Improvement (adjusted

               

for acquisition and

       $35.6 million increase in       

restructuring charges)

  20% 100%Non-GAAP Operating Profit  132.2% 26.4%

               

$0.032 Reduction in

               

Working Capital Ratio

               

(adjusted for acquisition

       $0.018 reduction in Working       

and restructuring charges)

  20% 100%Capital Ratio  54.7% 10.9%

               

$0.16 Increase in Non-GAAP

               

Earnings Per

               

Share (adjusted for

               

acquisition and restructuring

       $0.18 increase in Non-       

charges)

  15% 100%GAAP Earnings Per Share  112.5% 16.9%

               

Total

  70%      105.4% 73.8%

(1)
The performance goal reflected for each quantitative financial goal is equal to the difference between (x) the Company's 2015our 2018 business plan goal for the respective financial measure and (y) the corresponding threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan.2018 ICP.

(2)
Reflects 2015the performance threshold expressed as a percentage of our 2017 results.

Table of Contents

(3)
Reflects 2018 results, after adjustments for restructuring costs, acquisition-related costs, purchased intangible amortization, information technology transformation costs, impairment and the impactexclusion of the Jordan Valley Semiconductors, Ltd. acquisition,acquisitions not included in our 2018 business plan goal, relative to the threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan2018 ICP for the corresponding financial goal. Adjustments for

Currency-Adjusted Revenue Growth is the Jordan Valley Semiconductors, Ltd. acquisition includeddifference between our 2018 and 2017 actual results. Currency-Adjusted Revenue Growth is determined by applying the 2018 business plan exchange rates to local currency results, which resulted in a $2.0$23.9 million upward adjustment. Currency-Adjusted Revenue Growth also includes a $23.1 million downward adjustment to currency-adjusted revenue, a $1.5 million upward adjustment to Non-GAAP operating profit, a $10.3 million downward adjustment to working capital and a $0.01 upward adjustment to Non-GAAP earnings per share.

(3)
Reflects the performance threshold expressed as a percentage of the Company's 2015associated with acquisitions not included in our 2018 business plan goal. Since working capital ratio

The change in Non-GAAP Operating Profit is a reduction measure, threshold performancethe difference between our 2018 and 2017 non-GAAP results and has been adjusted downward $1.4 million for the impact associated with acquisitions not included in our 2018 business plan goal.

The change in Non-GAAP Earnings Per Share (EPS) is expressedthe difference between the 2018 and 2017 non-GAAP results. Non-GAAP EPS includes the following adjustments to our GAAP EPS as a percentage higher thanreported in our Annual Report on Form 10-K filed with the targeted performance goal.

(4)
Reflects the performance threshold expressed as a percentage of the Company's 2014 results.SEC on March 1, 2019:

 
 2018 2017 

GAAP EPS (Diluted)

 $1.14 $0.49 

Non-GAAP Adjustments:

       

Restructuring Costs

  0.06  0.10 

Acquisition-Related Costs

  0.05  0.06 

Purchased Intangible Amortization

  0.18  0.19 

Other Costs

  0.06  0.03 

Income Tax Rate Differential

  (0.09) 0.33 

Total Non-GAAP Adjustments

  0.26  0.72 

Non-GAAP EPS (Diluted)

 $1.40 $1.21 

        For 2015,2018, the Compensation Committee established quantitative financial performance targets that represented 70% of each named executive officer's total incentive award target. The Corporate level goals for these executive officers emphasized key elements of our strategy for providing value to our stockholders, with a mix of goals that focus on generating revenue growth, improving efficiency and profitability, and working capital reduction. As summarized in the table above, we did not achieve our Corporate level reduction in working capital goal, but significantly exceeded each of


our other Corporate level financial performance goals. Consistent with our pay-for-performance philosophy, the cash incentives earned by Dr. Laukien and Mr. MattacchioneHerman for the quantitative financial performance portion of their 2015 cash incentive plans was equal to2018 ICPs were approximately 247.7%105.4% of their cash incentive targets linked to quantitativefinancial performance goals, or approximately 173.4%73.8% of their respective total cash incentive targets. The cash incentives earned by Mr. Knell for the quantitative financial performance portion


Individual Performance Goals
(30% of his 2015 cash incentive plans was equal to approximately 247.7% of his cash incentive targets linked to quantitative goals, or approximately 173.4% of his total cash incentive targets. Mr. Wagner resigned effective as of June 12, 2015, and therefore was not eligible for consideration for a 2015 cash incentive payment.Target Bonus Potential)

       ��In addition to the quantitative financial performance goals, the Compensation Committee established specific individual qualitative performance goals for each of our executive officers to measure and reward performance with respect to organizational, strategic and other predominantly, although not exclusively, non-financial focuses of corporate or individual development. The individual qualitativeIn determining award payouts for these goals, and weightings established by the Compensation Committee to measure and reward our named executive officers' performance in 2015, as well as the performance achieved relative to these qualitative goals and resulting payout percentages, are described below.


Individual Qualitative Performance Goals
(30% of Target Bonus Potential)

Named Executive Officer
 2015 Individual Qualitative Goals Weighting 2015 Performance % of Total
Incentive
Target
Earned

Dr. Frank Laukien

 •  Management development initiatives 3.6% Achieved 3.6%

 •  BEST strategic initiatives 4.8% Mostly achieved 3.6%

 •  Bruker strategic development 7.2% Achieved 7.2%

 •  Drive efficiencies at BBIO 7.2% Achieved 7.2%

 •  Establish capital allocation strategy 3.6% Achieved 3.6%

 •  Realign BDAL management structure 3.6% Mostly achieved 2.7%

         Total 30%   27.9%

Mr. Mattacchione

 •  Enhancements to accounting and reporting practices 5.0% Achieved 5.0%

 •  Achievement of corporate functions initiatives 2.5% Significantly exceeded 3.1%

 •  Achievement of business effectiveness initiatives 2.5% Achieved 2.5%

 •  Roll out of NA Regional Finance organization 5.0% Achieved 5.0%

 •  Inherit and deliver financial and IT initiatives(1) 15.0% Significantly exceeded 18.75%

 •  Serve as Interim Chief Financial Officer N/A Special bonus awarded N/A

         Total 30%   34.4%

Mr. Knell

 •  Improve financial processes 12.0% Mostly Achieved 9.0%

 •  Internal controls initiatives 9.0% Mostly Achieved 6.75%

 •  Improve BRKR revenue recognition processes 3.0% Achieved 3.0%

 •  Leadership of Corporate accounting and internal control teams and processes 6.0% Achieved 6.0%

         Total 30%   24.75%

Mr. Wagner

 •  Enhance accounting and reporting practices 7.5% N/A 

 •  Achieve corporate functions initiatives 7.5% N/A 

 •  Achieve business effectiveness initiatives 7.5% N/A 

 •  Development of HR organization and practices 7.5% N/A 

         Total 30%   

(1)
Individual goal added for Mr. Mattacchione in May 2015 following his appointment as the Company's Interim Chief Financial Officer.

        The Compensation Committee considered each of the Corporate-level executive officers' achievements in meeting their individual qualitativeperformance goals and the substantial progress made during 20152018 with respect to a variety of strategic, organizational and infrastructure initiatives implemented under their leadership. The individual performance goals for Dr. Laukien's and Mr. Herman's 2018 ICPs are described below.


Table of Contents

        Dr. Laukien's 2018 individual performance goals and his achievement rating for each goal were as follows:

Individual Goal
Rating
Drive Strategic M&AAchieved
Implement Tax Planning InitiativesAchieved
Increase Operational ExcellenceAchieved
Enhance Compliance & ControlsAchieved
Drive Organic Growth InitiativesAchieved
Develop Leadership TeamAchieved
Drive InnovationMostly achieved

        Consistent with this assessment of performance, Dr. Laukien was rewarded for mostly achieving goals linked to management development, as well as the Company's strategic development, new product innovation and divisional performance, in addition to mostly achieving goals linked to BEST strategic initiatives and realigning the Bruker Daltonics management structure. Based on the Compensation Committee's assessment that Mr. Mattacchione fully achieved his qualitative goals, including those relating to consolidation and shared services, as well as tax and audit developments, and effectively led the finance organization upon assuming the role of Interim Chief Financial Officer, Mr. Mattacchione earned 34.4% (or 115% of his target) of his potential incentive payments allocated to individual qualitative goals. In addition, in May 2015, the Compensation Committee approved a one-time discretionary cash incentive award to Mr. Mattacchione in the amount of $150,000, to be earned as of March 31, 2016, in connection with his appointment to the position of Interim Chief Financial Officer. The Compensation Committee considered Mr. Knell's performance with respect to his individual qualitative goals and determined that Mr. Knell mostly achieved his goals relating to financial processes and internal controls initiatives to better meet the Company's evolving needs and fully achieved his goals relating to improving revenue recognition processes and leadership of Corporate accounting. As a result, Mr. Knell earned an incentive award payout equal to 82.5%95.0% of the portion of his cash incentive target attributablelinked to individual qualitative goals. Mr. Wagner resigned effective asperformance goals, or 28.5% of June 12, 2015, and therefore was not eligible for consideration for a 2015his total cash incentive payment.target.

        Mr. Herman's 2018 individual performance goals and his achievement rating for each goal were as follows:

Individual Goal
Rating
Drive Investor Relations InitiativesAchieved
Enhance Compliance & ControlsAchieved
Implement Tax Planning InitiativesMostly Achieved
Drive Transition Activities & Business PartneringSignificantly Exceeded

        Consistent with this assessment of performance, Mr. Herman earned 108.75% of the portion of his cash incentive target linked to individual performance goals, or 32.6% of his total cash incentive target.


2015Table of Contents

2018 Bruker CALIDBioSpin Group Performance Goals

Mr. SregaDr. Busse


Quantitative Financial Performance Goals
(70% of Target Bonus Potential)

2015 Bruker CALID Group
(CALID) Performance Goals(1)
 Weighting Performance
Threshold
 2015 Performance(2) % of
Incentive
Goal
Achieved
 % of Total
Incentive
Target
Earned

• $24.3 million CALID Currency-Adjusted Revenue Growth

 15% 95%(3) $46.0 million Currency-Adjusted Revenue Growth 189.5% 28.4%

• $12.4 Million CALID Non-GAAP Gross Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 95%(4) $16.5 million increase in Non-GAAP Gross Profit 133.3% 20.0%

• $26.4 Million CALID Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100%(4) $35.6 million increase in Non-GAAP Operating Profit 134.7% 20.2%

• $0.018 Reduction in CALID Working Capital Ratio (adjusted for acquisition and restructuring charges)

 15% 105%(3) $0.024 Reduction 138.7% 20.8%

• $16.1 million Corporate Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 10% 100%(4) $32.4 million decrease in Operating Profit 201.0% 20.0%

Total

 70%     156.5% 109.5%
2018 Bruker BioSpin Group
(BBIO)
Performance Goals(1)
 Weighting Performance
Threshold(2)
 2018 Performance(3) % of
Incentive
Goal
Achieved
 % of
Total
Incentive
Target
Earned

• $49.0 million BBIO Currency-Adjusted Revenue Growth

 15% 100% $25.7 million increase in Currency-Adjusted Revenue Growth 52.5% 7.9%

• $27.8 Million BBIO Non-GAAP Gross Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100% $13.7 million increase in Non-GAAP Gross Profit 49.3% 7.4%

• $18.6 Million BBIO Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100% $7.0 million increase in Non-GAAP Operating Profit 37.3% 5.6%

• $0.041 Reduction in BBIO Working Capital Ratio (adjusted for acquisition and restructuring charges)

 15% 100% $0.005 reduction in Working Capital Ratio 13.5% 2.0%

• $0.16 Increase in Non-GAAP Earnings Per Share (adjusted for acquisition and restructuring charges)

 10% 100% $0.18 increase in Non-GAAP Earnings Per Share 112.5% 11.3%

Total

 70%     48.8% 34.1%

(1)
The performance goal reflected for each quantitative financial goal is equal to the difference between (x) the Company's 2015our 2018 business plan goal for the respective financial measure and (y) the corresponding threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan.2018 ICP.

(2)
Reflects 2015the performance threshold expressed as a percentage of our 2017 results.

(3)
Reflects 2018 results, after adjustments for restructuring costs, acquisition-related costs, purchased intangible amortization and the exclusion of acquisitions not included in our 2018 business plan goal, relative to the threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan2018 ICP for the corresponding financial goal.

(3)
Reflects the performance threshold expressed as a percentage of the Company's 2015 Currency-Adjusted Revenue Growth is determined by applying 2018 business plan goal. Since working capital ratio is a reduction measure, threshold performance is expressed as a percentage higher thanexchange rates to local currency results. For additional information regarding our non-GAAP Earnings Per Share results, please see footnote 3 to the targeted performance goal.

(4)
Reflects the performance threshold expressed as a percentageFinancial Performance Goals table on page 34 of the Company's 2014 results.this proxy statement.

Table of Contents

        As President of the Bruker CALIDBioSpin Group, Mr. Srega's incentive planDr. Busse's 2018 ICP included quantitative financial performance goals directly relating to his leadership of the Bruker CALIDBioSpin Group. As summarized in the table above, the Bruker CALID Group exceededBioSpin only partially achieved each of its goals.goals related to 2018 financial performance. As a result, the cash incentive award payout earned by Mr. SregaDr. Busse for the quantitative financial performance portion of his 2015 cash incentive plan2018 ICP opportunity was equal to approximately 157%48.8% of his cash incentive target linked to quantitativefinancial performance goals, or approximately 110%34.1% of his total cash incentive target.


Individual Performance Goals
(30% of Target Bonus Potential)

        Dr. Busse's 2018 individual performance goals and his achievement rating for each goal were as follows:

Individual Goal
Rating
Drive Organic Growth InitiativesNot Achieved
Improve Marketing OrganizationAchieved
Drive Strategic M&AMostly Achieved
Drive Product InnovationMostly Achieved
Drive Gross Profit & Gross Margin Expansion InitiativesSignificantly Exceeded
Enhance Compliance & ControlsSignificantly Exceeded
Improve ProductivitySignificantly Exceeded

        Consistent with this assessment of performance, Dr. Busse earned 94.5% of his cash incentive target linked to individual performance goals, or 28.4% of his total cash incentive target.



Individual Qualitative Performance Goals
(30%Table of Target Bonus Potential)

Named Executive Officer
 2015 Individual
Qualitative Goals
 Weighting 2015 Performance % of Total
Incentive
Target
Earned

Mr. Srega

 

• Drive CALID Group growth

 6% Significantly exceeded 7.5%

 

• Achievement of Bruker Detection division organizational development initiatives

 6% Significantly exceeded 7.5%

 

• Invest in and drive microbiology business unit growth

 6% Achieved 6.0%

 

• Realign BDAL Management and organizational structure

 9% Achieved 9.0%

 

• Leverage Group and drive excellence in supply chain and quality management

 3% Achieved 3.0%

 

Total

 30%   33%

        The Compensation Committee considered Mr. Srega's performance with respect to his individual qualitative goals and determined that Mr. Srega significantly exceeded his goals relating to driving Bruker CALID Group growth and organizational development initiatives of the Bruker Detection division and achieved his other goals. As a result, Mr. Srega earned an incentive award payout equal to 33% of the portion of his cash incentive target attributable to individual qualitative goals, or 110% of his total target potential for individual goals.


Contents

20152018 Bruker Nano Group Performance Goals

Dr. Munch


Quantitative Financial Performance Goals
(70% of Target Bonus Potential)

2015 Bruker Nano Group
(NANO)
Performance Goals(1)
 Weighting Performance
Threshold
 2015 Performance(2) % of
Incentive
Goal
Achieved
 % of
Incentive
Target
Earned

• $23.8 Million NANO Currency-Adjusted Revenue Growth

 15% 95%(3) $18.5 million Currency-Adjusted Revenue 77.7% 11.7%

• $12.0 Million NANO Non-GAAP Gross Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 95%(4) $5.1 million decrease in Non-GAAP Gross Profit 0.0% 0.0%

• $10.6 Million NANO Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100%(4) $3.9 million decrease in Non-GAAP Operating Profit 0.0% 0.0%

• $0.03 Reduction in NANO Working Capital Ratio (adjusted for acquisition and restructuring charges)

 15% 100%(4) $0.001 decrease in Working Capital Ratio 2.2% 0.3%

• $16.1 Million Corporate Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 10% 100%(4) $32.1 increase in Corporate Operating Profit 201.1% 20.1%

Total

 70%     45.9% 32.1%
2018 Bruker Nano Group
(NANO)
Performance Goals(1)
 Weighting Performance
Threshold(2)
 2018 Performance(3) % of
Incentive
Goal
Achieved
 % of
Incentive
Target
Earned

• $36.1 Million NANO Currency-Adjusted Revenue Growth

 15% 100% $46.2 million increase in Currency-Adjusted Revenue 127.9% 19.2%

• $21.2 Million NANO Non-GAAP Gross Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100% $20.3 million increase in Non-GAAP Gross Profit 95.9% 14.4%

• $13.3 Million NANO Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

 15% 100% $9.7 million increase in Non-GAAP Operating Profit 72.6% 10.9%

• $0.062 Reduction in NANO Working Capital Ratio (adjusted for acquisition and restructuring charges)

 15% 100% $0.015 reduction in Working Capital Ratio 24.1% 3.6%

• $0.16 Increase in Non-GAAP Earnings Per Share (adjusted for acquisition and restructuring charges)

 10% 100% $0.18 increase in Non-GAAP Earnings Per Share 112.5% 11.3%

Total

 70%     84.8% 59.3%

(1)
The performance goal reflected for each quantitative financial goal is equal to the difference between (x) the Company's 2015our 2018 business plan goal for the respective financial measure and (y) the corresponding threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan.2018 ICP.

(2)
Reflects 2015the performance threshold expressed as a percentage of our 2017 results.

(3)
Reflects 2018 results, after adjustments for restructuring costs, acquisition-related costs, purchased intangible amortization and the impactexclusion of the Jordan Valley Semiconductors, Ltd. acquisition,acquisitions not included in our 2018 business plan goal, relative to the threshold performance level established by the Compensation Committee for the executive officer's cash incentive plan2018 ICP for the corresponding financial goal. Adjustments for the Jordan Valley Semiconductors, Ltd. acquisition included a $2.0 million downward adjustment to currency-adjusted revenue, a $1.5 million upward adjustment to Non-GAAP operating profit and a $10.3 million downward adjustment to working capital.

(3)
Reflects the performance threshold expressed as a percentage of the Company's 2015Currency-Adjusted Revenue Growth is determined by applying 2018 business plan goal.

(4)
Reflectsexchange rates to local currency results. For additional information regarding our non-GAAP Earnings Per Share results, please see footnote 3 to the performance threshold expressed as a percentageFinancial Performance Goals table on page 34 of the Company's 2014 results.this proxy statement.

        As Executive Vice President, and President of the Bruker Nano Group, Dr. Munch's incentive plan2018 ICP included quantitative financial performance goals directly relating to his leadership of the Bruker Nano Group. As summarized in the table above, Dr. Munch achieved a portion of his goals tied tothe Bruker Nano Group exceeded its goal related to revenue growth and working capital reduction,


Table of Contents

but did not fully achieve his other 2015 quantitativethe rest of its 2018 financial performance goals. Accordingly, the cash incentive award payout earned by Dr. Munch for the quantitative financial performance portion of his 2015 cash incentive plan2018 ICP opportunity was equal to approximately 45.9%84.8% of his cash incentive target linked to quantitativefinancial performance goals, or approximately 32%59.4% of his total cash incentive target.



Individual Qualitative Performance Goals
(30% of Target Bonus Potential)

Named Executive Officer
 2015 Individual
Qualitative Goals
 Weighting 2015 Performance % of Total
Incentive
Target
Earned

Dr. Munch

 

• Drive AXS sales organization development

 6% Achieved 6.0%

 

• Formation and development of BMAT Semi organization

 6% Significantly exceeded 7.5%

 

• Achieve targeted phase gates for NG BioAFM and 2015 revenue plan

 6% Achieved 6.0%

 

• Invest in XRD core

 6% Achieved 6.0%

 

• Establish Life Sciences sales team and organization for BNS FM Business Unit

 6% Achieved 6.0%

 

Total

 30%   31.5%

        The Compensation Committee considered        Dr. Munch's 2018 individual performance with respect to individual qualitative goals relating to marketing and sales, organizational and product development initiatives within the Bruker Nano Group. After consideration ofhis achievement rating for each goal were as follows:

Individual Goal
Rating
Drive Organic Growth InitiativesAchieved
Drive Product InnovationAchieved
Implement Cost Control InitiativesAchieved
Drive Business Unit InitiativesAchieved
Enhance Compliance & ControlsAchieved
Drive IT StrategyAchieved
Drive Strategic M&ASignificantly Exceeded(1)
Drive Product InnovationMostly Achieved

(1)
In determining Dr. Munch's performance relative to his individual qualitative goals,cash incentive award, the Compensation Committee determined thatexercised discretion to increase the payout amount for achievement in respect of his M&A goal based on his exceptional performance identifying acquisition candidates and completing strategic transactions.

        Consistent with this assessment of performance, Dr. Munch significantly exceeded his goal relating to the formation and development of the BMAT Semi organization and achieved each of his other goals. Accordingly, he earned a cash incentive award equal to approximately 105%129.25% of the portion of his target cash incentive bonus potential attributable to his individual qualitativeperformance goals, or 31.5%38.7% of his total targetcash incentive opportunity. In addition, in February 2016,target.


Table of Contents

2018 Bruker CALID Group Performance Goals

Mr. Srega


Financial Performance Goals
(70% of Target Bonus Potential)

2018 Bruker CALID Group
(CALID)
Performance Goals(1)
WeightingPerformance
Threshold
2018 Performance(3)% of
Incentive
Goal
Achieved
% of Total
Incentive
Target
Earned

• $31.9 million CALID Currency-Adjusted Revenue Growth

15%100%$49.7 million increase in Currency-Adjusted Revenue Growth156.0%23.4%

• $23.9 Million CALID Non-GAAP Gross Profit Improvement (adjusted for acquisition and restructuring charges)

15%100%$29.3 million increase in Non-GAAP Gross Profit122.6%18.4%

• $6.5 Million CALID Non-GAAP Operating Profit Improvement (adjusted for acquisition and restructuring charges)

15%100%$16.5 million increase in Non-GAAP Operating Profit255.7%38.4%

• $0.028 Reduction in CALID Working Capital Ratio (adjusted for acquisition and restructuring charges)

15%100%$0.027 reduction in Working Capital Ratio99.3%14.9%

• $0.16 Increase in Non-GAAP Earnings Per Share (adjusted for acquisition and restructuring charges)

10%100%$0.18 increase in Non-GAAP Earnings Per Share112.5%11.3%

Total

70%  151.9%106.3%

(1)
The performance goal reflected for each financial goal is equal to the difference between (x) our 2018 business plan goal for the respective financial measure and (y) the corresponding threshold performance level established by the Compensation Committee approved one-time discretionaryfor the executive officer's 2018 ICP.

(2)
Reflects the performance threshold expressed as a percentage of our 2017 results.

(3)
Reflects 2018 results, after adjustments for restructuring costs, acquisition-related costs, purchased intangible amortization and the exclusion of acquisitions not included in our 2018 business plan goal, relative to the threshold performance level established by the Compensation Committee for the executive officer's 2018 ICP for the corresponding financial goal. Currency-Adjusted Revenue Growth is determined by applying 2018 business plan exchange rates to local currency results. For additional information regarding our non-GAAP Earnings Per Share results, please see footnote 3 to the Financial Performance Goals table on page 34 of this proxy statement.

        As President of the Bruker CALID Group, Mr. Srega's 2018 ICP included financial performance goals directly relating to his leadership of the Bruker CALID Group. As summarized in the table above, Bruker CALID almost achieved its goal related to working capital ratio reduction and significantly exceeded its other 2018 financial performance goals. As a result, the cash incentive award


Table of Contents

payout earned by Mr. Srega for the financial performance portion of his 2018 ICP opportunity was equal to Dr. Munch in the amountapproximately 151.9% of $45,000his cash incentive target linked to financial performance goals, or approximately 106.3% of his total cash incentive target.


Individual Performance Goals
(30% of Target Bonus Potential)

        Mr. Srega's 2018 individual performance goals and his achievement rating for each goal were as follows:

Individual Goal
Rating
Drive Product InnovationAchieved
Enhance Compliance & ControlsAchieved
Drive Strategic M&ASignificantly Exceeded
Drive Commercial Excellence InitiativesSignificantly Exceeded
Drive Service Level ImprovementsSignificantly Exceeded
Drive Organic Growth InitiativesSignificantly Exceeded
Drive Working Capital Reduction InitiativesMostly Achieved
Drive Business Unit InitiativesSignificantly Exceeded

        Consistent with this assessment of performance, Mr. Srega earned 113.75% of his cash incentive target linked to individual performance in connection with the 2015 acquisitiongoals, or 34.1% of Jordan Valley Semiconductors, Ltd.his total cash incentive target.

        DeterminingTotal NEO Incentive Award Payments.    Following review of the performance of our named executive officers in fiscal 2015, other than Mr. Wagner and Mr. Bachmann,2018, the Compensation Committee approved ICP awards to the named executive officers based on their respective percentage achievement of 20152018 financial quantitative and individual qualitative performance goals as follows: Dr. Laukien—200%; Mr. Mattacchione—200%; Mr. Srega—142.5%; Dr. Munch—63.6%; and Mr. Knell—198.1%. Dr. Laukien and Mr. Mattacchione achieved performance goals totaling above 200%, as they earned 201% and 208%, respectively, of their

NEO
 Financial Goal
Achievement
 Individual Goal
Achievement
 Total Cash
Incentive Payment
 

Frank Laukien

  105% 95% 102%

Gerald Herman

  105% 109% 106%

Falko Busse

  49% 94.5% 62.5%

Mark Munch

  85% 129% 98%

Juergen Srega

  152% 114% 140%

        The actual cash incentive targets. However, as the payout maximum under the plan is 200% of the cash incentive targets, Dr. Laukien and Mr. Mattacchione each received 200% maximum cash incentive payouts. The actual award payments to our named executive officers are reported in the "Non-Equity Incentive Plan Compensation" column of the Summary Compensation Table in this proxy statement.

20152018 Long-Term Incentive Awards

        The Compensation Committee uses long-term incentive compensation in the form of equity awards to deliver competitive compensation that recognizes employees for their contributions to the CompanyBruker and aligns the interests of named executive officers with stockholders by focusing them on long-term growth and stock price performance.

        During 2015,2018, upon consideration of a variety of factors, including the individual performance, experience and responsibilities of each of our named executive officers, our stock price, competitive market practices and trends, including stockholder total potential dilution and annual equity burn rate market levels, outstanding equity awards held by our named executive officers and overall Company performance, the


Table of Contents

Compensation Committee approved the following long-term incentive awards to certain of our named executive officers, including:


officers:


20152018 Long-Term Equity Incentive Awards

 
 Economic
Value ($)
 Stock
Options (#)
 Restricted
Stock
Awards (#)
 

Dr. Frank Laukien

  1,541,295  34,774  65,220 

Mr. Mattacchione

  244,999  31,572   

Mr. Srega

  550,001  35,438  13,875 

Dr. Munch

  770,000  49,613  19,425 

Mr. Knell

  72,789  9,380   

Mr. Wagner(2)

  N/A  N/A  N/A 

Mr. Bachmann(2)

  N/A  N/A  N/A 
 
 Aggregate
Economic
Value
($)(1)
 Stock
Options
 Restricted
Stock
Units
 

Dr. Frank Laukien

  2,775,000  68,454  61,178 

Mr. Herman

  470,000  11,594  10,362 

Dr. Busse

  178,000  4,384  3,919 

Dr. Munch

  920,000  22,695  20,283 

Mr. Srega

  600,000  14,801  13,228 

Mr. Mattacchione(2)

  NA  NA  NA 

(1)
Economic Value reflects the combined grant date fair value of option and restricted stockRSU awards, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718.

(2)
Messrs. WagnerMr. Mattacchione resigned effective March 16, 2018 and Bachmann werewas not eligible for a 20152018 long-term incentive award.

        The Company usesWe use a combination of stock options and restricted stockRSU awards to balance the increased performance orientation of stock options to enhance our pay-for-performance culture and the retentive qualities of restricted stock.stock and RSUs. The Compensation Committee believes this mix to be reasonable in light ofconsidering market practices, the overall level of pay for our executives and the long-term orientation of boththe equity award vehicles, given that they both vest over a period of four years. In general, while no specific ratio is targeted, the Compensation Committee endeavors to deliver approximately 50% of2018, the value inof awards to our named executive officers consisted of 25% stock options and 50% of the value in restricted stock. In 2015, Dr. Laukien's awards consisted of 17% stock options and 83%75% restricted stock becauseunits, as is the 2010 Incentive Compensation Plan limits the number of shares that can be granted to an individual to one hundred thousand shares in any one givenCommittee's goal each year. The values of awards to the Group presidents consisted of 50% stock options and 50% restricted stock, while awards to the remaining executive officers were 100% in the form of stock options.

Executive Benefits

        In 2015,2018, our named executive officers were eligible for the same level and offering of benefits made available to other employees, including the Company'sour 401(k) plan and welfare benefit programs in the U.S., or those comparable local benefit programs for our overseas executives. We generally do not provide additional benefits or perquisites to our executive officers, except as follows:


Employment Contracts, Termination of Employment and Change in Control Arrangements

        On March 8, 2018 and June 5, 2012, the Company4, 2018, we entered into a letter agreementagreements with Mr. WagnerHerman which set forth certain terms of Mr. Wagner'sHerman's employment as Executive Vice Presidentour Interim Chief Financial Officer (his prior role) and Chief Financial Officer, respectively. Under the terms of the Company.letter agreements, Mr. Herman's target cash compensation includes the following elements: (i) an annual base salary of $250,000, plus a $6,000 additional monthly payment during the term of his service as Interim Chief Financial Officer from March 16, 2018 to June 6, 2018, and of $420,000 effective June 6, 2018; (ii) a cash incentive bonus plan, with an initial target of (i) $103,500 pro-rated for the period from January 1, 2018 to June 5, 2018 and (ii) $231,000 pro-rated for the period from June 6, 2018 to December 31, 2018. The letter agreement providedagreements further provide that, in connection with his appointment as Chief Financial Officer, Mr. Herman was entitled to receive an equity award with an aggregate value of $420,000 pursuant to our 2016 Incentive Compensation Plan. Additionally, the letter agreements provide that Mr. Wagner'sHerman was eligible to receive a special continuation bonus in the amount of $100,000, payable in April 2019, subject to continuation of employment withand achievement of certain financial reporting goals. During the term of his employment, Mr. Herman will be eligible to participate in all customary employee benefit plans or programs of the Company was at will and could be terminated by either Mr. Wagner generally available to the Company's employees and/or executive officers.

        On May 1, 2018, our wholly-owned subsidiary Bruker BioSpin AG entered into a letter agreement with Dr. Busse which sets forth certain terms of Dr. Busse's employment as President of the Company at any time with or without notice and for any or no reason or cause.Bruker BioSpin Group. Under the terms of the letter agreement, Mr. Wagner was restricted from workingDr. Busse's target cash compensation includes the following elements: (i) an annual base salary set at 345,581 Swiss Francs, or approximately $353,322, for any company that designs, makes2018, subject to annual review and (ii) a cash incentive bonus plan with a target of 50% of base salary, in each case subject to proration for the remainder of 2018. Dr. Busse is also eligible for annual equity awards with a value of 175,000 Swiss Francs, or sells non-clinical magnetic resonance instrumentationapproximately $177,730, pursuant to our 2016 Incentive Compensation Plan. During the term of his employment, Dr. Busse will be eligible to participate in all customary employee benefit plans or mass spectrometry instrumentationprograms generally available to our employees and/or executive officers. Additionally, as an employee of Bruker BioSpin AG, Dr. Busse is entitled to participate in the Bruker BioSpin AG pension fund scheme and other local benefit plans during the term of his employment. In the event of Dr. Busse's death while in our employment, he is entitled to continuation of his base salary for a period of six months following resignation or termination of his employmentmonths. The letter agreement contains customary one-year non-competition and two-year non-solicitation provisions and may be terminated by the Company. Mr. Wagner resigned from employment effective as of June 12, 2015.either party upon six month's written notice.

        On June 25, 2012, the Companywe entered into a letter agreement with Mr. Srega which sets forth certain terms of Mr. Srega's employment as President of the Bruker CALID Group. Under the terms of the letter agreement, Mr. Srega's target cash compensation includes the following elements: (i) an annual base salary, set at 280,000 euros, or approximately $371,896, for 2013, subject to annual review and (ii) a cash incentive bonus plan with target of 50% of base salary.plan. Mr. Srega was also entitled toreceived an initial cash bonus payment of 100,000 euros,Euros, or approximately $132,820, and an initial equity grant consisting of restricted stock valued at $400,000 and options to purchase 90,000 shares of common stock upon commencement of employment, as well as reimbursement of certain relocation expenses. The letter agreement also provides that beginning in 2014, Mr. Srega is entitled to receive an annual equity award with a value of $550,000 pursuant to the Company's 2010 Incentive Compensation Plan.our incentive compensation plans. During the term of his employment, Mr. Srega will be eligible to participate in all customary employee benefit plans or programs of the CompanyBruker generally available to the Company'sour employees and/or executive officers. Additionally, the Companywe assumed a personal pension scheme for Mr. Srega's benefit carried forward in part from his former employer. The personal pension scheme is funded by contributions made by Bruker Daltonik GmbH and voluntary contributions by Mr. Srega, if any, during the term of his employment.

        Mr. Srega will be entitled to a lump sum severance payment equal to six months of his then current base salary, or approximately $159,975$197,277 as of December 31, 2015,2018, in the event there is a change


Table of Contents

in the voting control of the CompanyBruker and his employment is terminated, voluntarily or involuntarily, within six6 months after such change of control.

        On December 3, 2013, Bruker Corporation and Bruker BioSpin AG,In the event of a wholly-owned subsidiary Swiss subsidiarychange in control of Bruker, Corporation, entered into a letter agreement with Mr. Bachmann which set forth certain termsour Board has the authority to accelerate vesting of Mr. Bachmann's employment as President of the Bruker BioSpin Group. The letter agreement contained customary one-year non-competitionany and two-year non-solicitation provisions and was terminable by either party upon six month's written notice. In January 2015, Mr. Bachmann submitted notice of termination to the Company, and his resignation became effective June 30, 2015.

        On April 8, 2015, the Company entered into a letter agreement with Dr. Lenggenhager which sets forth certain terms of Dr. Lenggenhager's employment as President of the Bruker BioSpin Group. Under the terms of the letter agreement, Dr. Lenggenhager's target cash compensation includes the following elements: (i) an annual base salary set at 370,000 Swiss Francs, or approximately $366,300, for


2015, subject to annual review and (ii) a cash incentive bonus plan with target of 35% of base salary. Dr. Lenggenhager was also entitled, within one month of commencement of employment, to an initial equity grant valued at 250,000 Swiss Francs consisting of 50%all unvested option, restricted stock and 50% options to purchase shares of common stock. The letter agreement also provides that, beginning inrestricted stock unit awards granted under the 2016 Dr. Lenggenhager is entitled to receive an annual equity award with a value of 250,000 Swiss Francs, or approximately $254,300, pursuant toIncentive Compensation Plan and the Company's 2010 Incentive Compensation Plan. DuringAccelerated vesting in such circumstances is at the term of his employment, Dr. Lenggenhager will be eligible to participate in all customary employee benefit plans or programs ofBoard's sole discretion. Under the Company generally available to the Company's employees and/or executive officers. Additionally, Dr. Lenggenhager will participate in the Company's pension fund scheme, which provides insurance protection (life and disability) and pension coverage. The letter agreement contains customary one-year non-competition and two-year non-solicitation provisions and may be terminated by either party upon six month's written notice.

        Under thestandard terms of the awards of options, restricted stock and restricted common stock units granted under the 2010 Incentive Compensation Plan,these plans, unvested amounts are forfeited if the grantee's employment or business relationship with our companyBruker is terminated for any reason, other than in the event of death or disability. The board of directors does, however, have the authority to accelerate vesting of any and all unvested amounts in the event of a change in control of Bruker Corporation.

Section 162(m) Limitations

        Section 162(m) of the U.S. Internal Revenue Code limits the tax deductibility by a corporation of compensation in excess of $1,000,000 paid for any year to thecertain "covered employees." Covered employees generally include our Chief Executive Officer, Chief Financial Officer and any othereach of its fourour next three most highly compensated executive officers. Compensation which qualifies as "performance-based" may qualify for exclusion from the $1,000,000 limit if, among other requirements, the compensation is payable only upon attainment of pre-established, objective performance goals under a plan approved by stockholders. Having considered the requirements of Section 162(m), the Compensation Committee believes that stock option grants to date meet the requirement that such grants be "performance-based" and are, therefore, exempt from the limitations on deductibility. Base salaries, awards under our executive officers' cash incentive plans, any other bonus payments and compensation in the form of restricted stock awards, however, are generally subject to the $1,000,000 limit on tax deductible compensation. If the 2016 Incentive Compensation Plan is approved by our stockholdersofficers serving at the 2016 Annual Meeting, the Company believes it will have additional flexibility to structure performance-based compensation, including equity and cash-based awards, intended to qualify for exemption from the limitations of Section 162(m). Please see "Proposal No. 2—Approvalend of the 2016 Incentive Compensation Plan—Description of the 2016 Plan" in this proxy statement for additional information regarding the 2016 Incentive Compensation Plan.taxable year.

        The Compensation Committee and management consider the accounting and tax effects of various compensation elements when designing our annual incentive and equity compensation plans and making other compensation decisions. Although we have undertaken to qualify certain componentsconsidered the impact of Section 162(m) when designing our executive compensation programs and incentive plans, tax deductibility is not a primary consideration in setting compensation to executive officers for the performance exception to non-deductibility, these considerations areand is secondary to meeting the overall objectives of the executive compensation program. The Compensation Committee will continue to monitor the compensation levels potentially payable under our compensation programs butand intends to retain the flexibility necessary to provide total compensation in line with competitive practice and our compensation philosophy. Under certain circumstances,philosophy, even if such as the payment of cash bonus awards and the granting of restricted stock awards, the Committee may decide to award executive compensation in an amount and form that is not deductible under Section 162(m).


Other Benefit Plans

        In October 2009, the board of directors of BEST adopted the Bruker Energy & Supercon Technologies, Inc. 2009 Stock Option Plan, or the BEST Plan. The BEST Plan provides for the issuance of up to 1,600,000 shares of BEST common stock (which is not publicly traded) in connection with awards under the plan. The BEST Plan allows a committee of the BEST board of directors to grant incentive stock options and non-qualified stock options to key employees and directors of the Company. The size of each grant is determined by the value of the BEST stock and BEST stock options at the time, the likely growth in that value and the importance of the individual to growing the value of the Company in the future. The BEST Plan is tied exclusively to increases in BEST's estimated value regardless of the Company'sour performance as a whole. As of December 31, 2015, 475,0002018, 465,000 incentive stock options and non-qualified stock options had been awarded and were outstanding, with vesting periods of three to five years.outstanding. No awards have been granted under the BEST Plan since July 2010. As a director of BEST, Dr. Laukien participates in the BEST Plan. Dr. LaukienPlan and holds options to purchase 10,000 shares of BEST, which have an exercise price of $3.50 per share and expire October 1, 2019.


COMPENSATION COMMITTEE REPORT

        The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, promulgated under the Securities Act of 1933, as amended. Based on such review and discussions, the Compensation Committee recommended to the board of directorsBoard that the Compensation Discussion and Analysis be included in this Proxy Statement on Schedule 14A.

        Submitted by the Compensation Committee of Bruker Corporation's Board of Directors.the Board.

  Richard D. Kniss,A. Packer, Chairman
Wolf-Dieter Emmerich
Stephen W. Fesik
Hermann Requardt
Cynthia Friend


COMPENSATION COMMITTEE INTERLOCKS
AND INSIDER PARTICIPATION

        Mr. Kniss and Drs. Emmerich, Fesik and Requardt serve as members of the Compensation Committee. Mr. Kniss and Drs. Emmerich, Fesik and Requardt were not officers or employees of the Company or any of its subsidiaries during fiscal year 2015. None of our executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our Compensation Committee. In addition, none of our executive officers serves as a member of the compensation committee of any entity that has one or more of its executive officers serving as a member of our board of directors.


Table of Contents


SUMMARY OF EXECUTIVE COMPENSATION

        The following table summarizes the compensation earned by our named executive officers for the years ended December 31, 2015, 20142018, 2017 and 2013.2016.


Summary Compensation Table

Name and
Principal
Position
 Year Salary Bonus Stock
Awards(1)
 Option
Awards(2)
 Non-Equity
Incentive
Plan
Awards
 Change in
Pension
Value and
Non-Qualified
Deferred
Compensation
Earnings
 All Other
Compensation
 Total 

Frank H. 

  2015 $636,250   $1,292,660 $248,634 $1,750,000   $7,950(3)$3,935,494 

Laukien, Ph.D.

  2014 $598,654   $874,991 $596,750 $602,319   $7,800 $2,680,514 

Chairman,

  2013 $547,562   $687,492 $658,859 $316,750   $6,117 $2,216,780 

President and

     ��                      

Chief

                            

Executive

                            

Officer

                            

Anthony L. 

  
2015
 
$

322,520

(5)
 
  
 
$

244,999
 
$

328,241
  
 
$

4,971

(3)

$

900,731
 

Mattacchione

  2014 $273,980     $187,460 $122,087   $3,513 $587,040 

Senior Vice

  2013 $231,538 $25,000   $455,302 $63,088   $2,565 $777,493 

President and

                            

Chief

                            

Financial

                            

Officer(4)

                            

Juergen Srega

  
2015
 
$

310,632
  
 
$

275,003
 
$

274,999
 
$

251,383
  
 
$

87,681

(7)

$

1,199,698
 

President,

  2014 $372,260 $344,943 $275,003 $275,000 $81,712   $105,076 $1,453,994 

Bruker

  2013 $371,896 $132,820 $399,998 $893,700 $112,747   $142,438 $2,069,242 

CALID

                            

Group(6)

                            

Mark R. 

  
2015
 
$

471,846
 
$

45,000

(8)

$

385,004
 
$

384,997
 
$

167,983
  
 
$

17,050

(9)

$

1,471,880
 

Munch, Ph.D.

  2014 $399,462   $350,009 $350,002 $78,842   $16,200 $1,194,515 

Executive Vice

  2013 $380,000 $50,000 $344,600 $665,005 $50,730   $16,400 $1,506,735 

President and

                            

President,

                            

Bruker Nano

                            

Group

                            

Michael G. Knell

  
2015
 
$

231,697
  
  
 
$

72,789
 
$

171,962
  
 
$

7,950

(3)

$

484,398
 

Vice President

                            

and Chief

                            

Accounting

                            

Officer(10)

                            

Charles F. 

  
2015
 
$

261,184
  
  
  
  
  
 
$

7,950

(3)

$

269,134
 

Wagner, Jr.

  2014 $509,488   $535,509 $535,496 $425,416   $7,800 $2,013,709 

Former

  2013 $490,631   $515,549 $515,546 $245,000   $7,500 $1,774,226 

Executive

                            

Vice President

                            

and Chief

                            

Financial

                            

Officer(11)

                            

Thomas W. 

  
2015
 
$

218,631
  
  
  
  
 
$

177,289
 
$

43,546

(13)

$

439,466
 

Bachmann

  2014 $393,984   $283,316 $121,702 $90,193 $42,787 $13,780 $945,762 

Former

                            

President,

                            

Bruker

                            

BioSpin

                            

Group(12)

                            
Name and
Principal
Position
 Year Salary
($)
 Bonus
($)
 Stock
Awards(1)
($)
 Option
Awards(2)
($)
 Non-Equity
Incentive
Plan
Awards
($)
 Change in
Pension
Value and
Non-Qualified
Deferred
Compensation
Earnings
($)
 All Other
Compensation
($)
 Total
($)
 

Frank H. Laukien, Ph.D. 

  2018  730,675    2,081,276  612,663  1,047,035    8,250(3) 4,479,899 

Chairman, President

  2017  704,269    2,062,517  605,540  1,491,583    8,100  4,872,009 

and Chief Executive

  2016  652,477    1,074,995  968,904  737,895    7,950  3,442,221 

Officer

                            

Gerald N. Herman

  
2018
  
360,939
     
352,515
  
117,911
  
186,906
  
  
8,250

(3)
 
1,026,521
 

Chief Financial Officer(4)

                            

Anthony L. Mattacchione

  
2018
  
114,387
  
  
  
  
  
  
8,250

(3)
 
122,637
 

Former Chief Financial

  2017  439,382    618,766  204,432  465,916    8,100  1,736,596 

Officer(5)

  2016  400,744  150,000  325,004  296,580  214,472    7,950  1,394,750 

Falko Busse, Ph.D. 

  
2018
  
339,467
     
133,324
  
44,585
  
103,543
  
30,201
  
48,125

(7)
 
699,245
 

President, Bruker BioSpin

                            

Group(6)

                            

Mark R. Munch, Ph.D. 

  
2018
  
549,298
  
  
690,028
  
230,808
  
334,023
  
  
16,650

(8)
 
1,820,807
 

Executive Vice

  2017  523,141    652,522  215,591  444,182    16,500  1,851,936 

President & President,

  2016  504,474    410,005  410,136  194,652    15,650  1,534,917 

Bruker Nano Group

                            

Juergen Srega

  
2018
  
394,554
  
  
450,017
  
150,526
  
301,178
  
  
94,518

(10)
 
1,390,793
 

President, Bruker CALID

  2017  369,238    431,252  142,491  321,866    90,444  1,355,291 

Group(9)

  2016  351,121    275,001  275,092  84,262    88,587  1,074,063 

(1)
The amounts in this column reflect the grant date fair value of restricted stock awards of RSUs, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. Assumptions used in the calculations



(2)
The amounts in this column reflect the grant date fair value of stock option awards, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. Assumptions used in the calculations of these amounts may be found in Note 2 to our 20152018 audited financial statements included in the Company'sour Annual Report on Form 10-K filed with the SEC on February 29, 2016.March 1, 2019. The actual amount realized by the named executive officer will likely vary based on a number ofseveral factors, including our performance, stock price fluctuations and applicable vesting.

(3)
Amount represents a matching contribution made by the CompanyBruker to a 401(k) plan for the benefit of the named executive officer.

(4)
Mr. MattacchioneHerman was appointed Senior Vice President and Interim Chief Financial Officer effective May 20, 2015in March 2018 and Chief Financial Officer effective February 18, 2016.June 6, 2018.

(5)
Amount includes an incremental monthly payment of $8,000 during Mr. Mattacchione's tenure as Interim Chief Financial Officer.Mattacchione resigned from Bruker effective March 16, 2018.

(6)
Dr. Busse was appointed President of the Bruker BioSpin Group effective May 1, 2018. The amounts reflected for 2018 compensation, other than amounts reported under the headings "Stock Awards," "Option Awards" and "Non-Equity Incentive Plan Awards," are based on actual payments in Euros converted to U.S. Dollars at a conversion rate of €1.0 =$1.1281 from January to April 2018 and in Swiss Francs converted to U.S. Dollars at a conversion rate of CHF 1.0 =$1.0224 from May to December 2018, which in each case represents the 2018 average midpoint rate. The amounts reflected under the heading "Non-Equity Incentive Plan Awards" are converted from Swiss Francs to U.S. Dollars at a conversion rate equal to the midpoint rate on the date of approval by the Compensation Committee of CHF 1.0 =$0.9928.

(7)
Amounts reported in 2018 include contributions in the amount of $40,672 made by Bruker BioSpin AG to the Swiss Pension Plan for Dr. Busse and an automobile allowance of $7,453.

Table of Contents

(8)
Amounts reported include matching contributions made by Bruker to a 401(k) plan for the benefit of Dr. Munch and an automobile allowance.

(9)
The amounts reflected for 20152018 compensation, other than amounts reported under the headings "Stock Awards,"" "Option Awards" and "Non-Equity Incentive Plan Awards," are based on actual payments in eurosEuros converted to U.S. dollarsDollars at a conversion rate of €1.00 = $1.1094€1.0 =$1.1809, which represents the 20152018 average midpoint rate as published on www.oanda.com.rate. The amounts reflected under the headingsheading "Non-Equity Incentive Plan Awards" are converted from eurosEuros to U.S. dollarsDollars at a conversion rate equal to the midpoint rate as published on www.oanda.com on the date of approval by the Compensation Committee.

(7)(10)
Amounts reported in 20152018 include contributions in the amount of $73,775$78,530 made by Bruker Daltonik GmbH to the personal pension scheme established for Mr. Srega and an automobile allowance of $13,906.

(8)
Amount reported represents a discretionary award approved by the Compensation Committee for 2015 performance in connection with the acquisition of Jordan Valley Semiconductors, Ltd.

(9)
Amounts reported include matching contributions made by the Company to a 401(k) plan for the benefit of Dr. Munch and an automobile allowance.

(10)
Mr. Knell was not a named executive officer in 2013 or 2014. Accordingly, compensation data is presented only for 2015.

(11)
Mr. Wagner resigned from employment with the Company effective June 12, 2015.

(12)
Mr. Bachmann was not a named executive officer of the Company prior to 2014. Accordingly, compensation data is presented only for 2014 and 2015. Mr. Bachmann resigned from employment with the Company effective June 30, 2015. The amounts reflected for 2015 compensation are based on actual payments in Swiss Francs (CHF) converted to U.S. dollars at a conversion rate of CHF 1.00 = $1.0411, which represents the 2015 average midpoint rate as published on www.oanda.com. The amount reflected under the heading"Change in Pension Value and Non-Qualified Deferred Compensation Earnings" represents the actuarial increase during 2015 of the accumulated pension benefit provided Mr. Bachmann under the pension plan for Swiss employees, or the Swiss Pension Plan, reduced by the aggregate amount of Company contributions and Mr. Bachmann's contributions, converted to U.S. dollars at the midpoint conversion rate of CHF 1.0 =$1.0075 as of December 31, 2015. Company contributions to the Swiss Pension Plan are reported under the heading "All Other Compensation."

(13)
Amounts reported include contributions made by Bruker BioSpin AG to the Swiss Pension Plan for Mr. Bachmann. All Swiss employees are eligible to participate in this plan on the same general terms and conditions. Bruker BioSpin AG does not provide any additional supplemental executive pension contributions.$15,988.


20152018 Grants of Plan-Based Awards

        The following table sets forth certain information with respect to individual grants of plan-based awards to our named executive officers during the fiscal year ended December 31, 2015.2018.


  
 Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards
 All Other
Stock Awards:
Number of
Shares of
Stock or
Units
(#)
 All Other
Option Awards:
Number of
Securities
Underlying
Options
(#)
  
 Grant Date
Fair Value
of Stock
and Option
Awards
($)(2)
   
 Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards
 All Other
Stock Awards:
Number of
Shares of
Stock or
Units
(#)
 All Other
Option Awards:
Number of
Securities
Underlying
Options
(#)
  
 Grant Date
Fair Value
of Stock
and Option
Awards
($)(2)
 

  
 Exercise or
Base Price
of Option
Awards
($/SH)(2)
   
 Exercise or
Base Price
of Option
Awards
($)(2)
 
Name
 Grant Date Threshold
($)(1)
 Target
($)(1)
 Maximum
($)(1)
Grant Date
Fair Value
of Stock
and Option
Awards
($)(2)
 Grant Date Threshold
($)(1)
 Target
($)(1)
 Maximum
($)(1)
Grant Date
Fair Value
of Stock
and Option
Awards
($)(2)

Frank H. Laukien

   0 875,000 1,750,000         8/09/2018 0 1,023,625 2,047,250 61,178 68,454 37.42 2,693,939

 8/07/2015       65,220 34,774(3) 21.80 1,541,295

Anthony L. Mattacchione

   0 164,121 328,242         

 8/07/2015        31,572 19.82 244,999 

Gerald N. Herman

 
8/09/2018
 
0
 
175,643
 
351,286
 
10,362
 
11,594
 
34.02
 
470,426
 

Falko Busse

 
8/09/2018
 
0
 
170,619
 
341,238
 
3,919
 
4,384
 
34.02
 
177,910
 

Mark R. Munch

 
8/09/2018
 
0
 
340,419
 
680,838
 
20,283
 
22,695
 
34.02
 
920,836
 

Juergen Srega

   0 175,950 351,902          
8/09/2018
 
0
 
224,511
 
449,023
 
13,228
 
14,801
 
34.02
 
600,543
 

 8/07/2015       13,875 35,438 19.82 550,001 

Mark R. Munch

   0 264,000 528,000         

 8/07/2015       19,425 49,613 19.82 770,000 

Michael G. Knell

   0 86,435 172,870         

 8/07/2015        9,380 19.82 72,789 

Charles F. Wagner, Jr.

   0 525,300 1,050,600         

Anthony L. Mattacchione(4)

 
N/A
 
0
 
N/A
 
N/A
 
N/A
 
N/A
 
N/A
 
N/A
 

(1)
Represents estimated possible payouts on the grant date for annual cash incentive bonus awards granted for 20152018 performance under the 20152018 cash incentive bonus plans of our named executive officers. The amounts reflected for Mr. Srega and Dr. Busse, which were basedpayable in local currency,Euros and Swiss Francs, respectively, are converted from euros to U.S. dollars at a conversion rate of €1.00 = $1.1094, which represents the 20152018 average midpoint rate.conversion rates of €1.0 =$1.1809 and CHF 1.0=1.0224.

(2)
Represents the grant date fair value of restricted stockRSU and stock option awards granted under the Company's 2010our 2016 Incentive Compensation Plan, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. Assumptions used in the calculations of these amounts may be found in Note 2 to our 20152018 audited financial statements included in the Company'sour Annual Report on Form 10-K filed with the SEC on February 29, 2016. Unless otherwise noted: (i)March 1, 2019. Stock option and RSU awards vest in equal annual installments on the first, second, third and fourth anniversaries of the grant date,date. Except as noted in footnote 3 below, stock option awards are exercisable upon vesting at a price equal to the closing price of our common stock on the date of the grant and expire on the ten yearten-year anniversary of the grant date; and (ii) restricted stock awards vest in equal annual installments on the first, second, third and fourth anniversaries of the grant date.

(3)
Options granted to Dr. Laukien vest in equal annual installments on the first, second, third and fourth anniversaries of the grant date, are exercisable upon vesting at a price equal to 110% of the closing price of our common stock on the date of the grant and expire on the five yearfive-year anniversary of the grant date.

(4)
Mr. Mattacchione resigned effective March 16, 2018 and was not granted a plan-based award in 2018.

Table of Contents


Outstanding Equity Awards at December 31, 20152018

        The following table provides information concerning outstanding equity incentiveequity-based plan awards, including unexercised options and stock that has not vested, for each of our named executive officers as of the end of our most recently completed fiscal year.2018.


 Option Awards Stock Awards  Option Awards Stock Awards 
Name
 Option
Grant Date
 Number of
Securities
Underlying
Unexercised
Options
Exercisable
 Number of
Securities
Underlying
Unexercised
Options
Unexercisable
 Option
Exercise
Price
 Option
Expiration
Date
 Stock
Award
Grant Date
 Number of
Shares of Stock
That Have Not
Vested
 Market
Value of
Shares of Stock
That Have
Not Vested(1)
  Option
Grant Date
 Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
 Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
 Option
Exercise
Price
($)
 Option
Expiration
Date
 Stock
Award
Grant
Date
 Number of
Shares of
Stock
That Have
Not Vested
(#)
 Market
Value of
Shares of
Stock
That Have
Not Vested
($)(1)
 

Frank H. Laukien(2)

 9/09/2011 3,750 0 $13.805 09/09/2016 8/13/2012 40,000(3) $970,800  8/08/2014 57,657  22.748 8/08/2019 8/07/2015 16,305(3) 485,400 

 8/30/2013 31,138 31,136(4) $22.04 08/30/2018 8/30/2013 17,152(3)$416,279  8/07/2015 26,080 8,694(4) 21.80 8/07/2020 10/04/2016 24,223(5) 721,119 

 8/08/2014 14,415 43,242(5) $22.748 8/08/2019 8/08/2014 31,733(6) $770,160  10/04/2016 77,142 77,142(6) 24.409 10/04/2021 8/10/2017 57,144(7) 1,701,177 

 8/07/2015  34,774(7) $21.80 8/07/2020 8/07/2015 65,220(8) $1,582,889  8/10/2017 21,084 63,253(8) 29.777 8/10/2022 8/09/2018 61,178(9) 1,821,269 

Anthony L. Mattacchione.

 
2/25/2013
 
20,000
 

20,000(4)

 
$

17.41
 
2/25/2023
       

 8/30/2013 3,737 3,736(4) $20.04 08/30/2023        8/09/2018  68,454(10) 37.42 8/09/2023       

Gerald N. Herman

 12/01/2016 4,002 4,002(6) 22.51 12/01/2026 12/01/2016 1,241(5) 36,945 

 8/09/2018  11,594(10) 34.02 8/09/2028 8/10/2017 3,591(7) 106,904 

           8/09/2018 10,362(9) 308,477 

Falko Busse

 8/07/2015 8,987 3,013(4) 19.82 8/07/2025 10/04/2016 1,115(5) 33,194 

 8/08/2014 4,324 12,969(5) $20.68 8/08/2024        10/04/2016 3,548 3,549(6) 22.19 10/04/2026 8/10/2017 3,758(7) 111,876 

 8/07/2015  31,572(7) $19.82 8/07/2025        8/09/2018  4,384(10) 34.02 8/09/2028 8/09/2018 3,919(9) 116,669 

Mark R. Munch

 
11/01/2010
 
75,000
 

 
$

14.80
 
11/01/2020
 
5/07/2013
 

12,000(6)

 
$

291,240
  8/30/2013 15,059  20.04 8/30/2023 8/07/2015 4,857(3) 144,593 

 8/30/2013 30,118 30,118(4) $20.04 08/30/2023 8/08/2014 12,693(6) $308,053  8/08/2014 16,144  20.68 8/08/2024 10/04/2016 9,239(5) 275,045 

 8/08/2014 8,072 24,216(5) $20.68 8/08/2024 8/07/2015 19,425(8) $471,445  8/07/2015 24,806 12,404(4) 19.82 8/07/2025 8/10/2017 18,079(7) 538,212 

 8/07/2015  49,613(7) $19.82 8/07/2025        10/04/2016 29,421 29,422(6) 22.19 10/04/2026 8/09/2018 20,283(9) 603,825 

 8/10/2017 6,670 20,012(8) 27.07 8/10/2027       

 8/09/2018  22,695(10) 34.02 8/09/2028       

Juergen Srega

 
4/03/2013
 
36,000
 

54,000(5)

 
$

18.57
 
04/03/2023
 
4/03/2013
 

12,924(6)

 
$

313,665
  4/03/2013 90,000  18.57 4/03/2023 8/07/2015 3,469(3) 103,272 

 8/08/2014 6,343 19,026(5) $20.68 8/08/2024 8/08/2014 9,973(6) $242,045  8/08/2014 25,369  20.68 8/08/2024 10/04/2016 6,197(5) 184,485 

 8/07/2015  35,438(7) $19.82 8/07/2025 8/07/2015 13,875(8) $336,746  8/07/2015 26,578 8,860(4) 19.82 8/07/2025 8/10/2017 11,949(7) 355,722 

Michael G. Knell

 
3/01/2012
 
21,000
 

14,000(4)

 
$

16.05
 
3/01/2022
       

 8/30/2013 3,638 3,636(4) $20.04 08/30/2023        10/04/2016 19,734 19,734(6) 22.19 10/04/2026 8/09/2018 13,228(9) 393,798 

 8/08/2014 1,646 4,937(5) $20.68 8/08/2024        8/10/2017 4,408 13,227(8) 27.07 8/10/2027       

 8/07/2015  9,380(7) $19.82 8/07/2025        8/09/2018  14,801(10) 34.02 8/09/2028       

Charles F. Wagner, Jr.(9)

                 

Thomas W. Bachmann (10)

                 

Anthony L. Mattacchione(11)

         

(1)
The amounts in this column were calculated by multiplying $24.27,$29.77, the closing price of our common stock on the NASDAQNasdaq Global Select Market as of December 31, 2015,2018, by the number of unvested shares.

(2)
In addition to the awards reported for equity securities of Bruker Corporation, Dr. Laukien held options to purchase 10,000 shares of BEST, which options were fully vested as of December 31, 2015.BEST. The BEST options have an exercise price of $3.50 per share, are fully vested and expire October 1, 2019.

(3)
The unvested shares of restricted stock vest on the anniversary of the grant date in 2019.

(4)
The options become exercisable on the anniversary of the grant date in 2019.

(5)
The unvested RSUs vest in equal annual installments on the anniversary of the grant date in 20162019 and 2017.2020.

(4)(6)
The options become exercisable in equal annual installments on the anniversary of the grant date in 20162019 and 2017.2020.

(5)(7)
The unvested RSUs vest in equal annual installments on the anniversary of the grant date in 2019, 2020 and 2021.

(8)
The options become exercisable in equal annual installments on the anniversary of the grant date in 2016, 20172019, 2020 and 2018.2021.

(6)(9)
The unvested shares of restricted stockRSUs vest in equal annual installments on the anniversary of the grant date in 2016, 20172019, 2020, 2021 and 2018.2022.

(7)(10)
The options become exercisable in equal annual installments on the anniversary of the grant date in 2016, 2017, 20182019, 2020, 2021 and 2019.2022.

(8)
The unvested shares of restricted stock vest in equal annual installments on the anniversary of the grant date in 2016, 2017, 2018 and 2019.

(9)(11)
As a result of Mr. Wagner'sMattachione's resignation which was effective June 12, 2015,as of March 16, 2018, no equity awards were outstanding as of December 31, 2015.

(10)
As a result of Mr. Bachmann's resignation, which was effective June 30, 2015, no equity awards were outstanding as of December 31, 2015.2018.

Table of Contents


20152018 Option Exercises and Stock Vested

        The following table provides information regarding the number of shares acquired by our named executive officers upon the exercise of options or vesting of restricted stock awards and restricted stock units and the value realized at that time before payment of any applicable withholding taxes and brokerage commission.


 Option Awards Stock Awards  Option Awards Stock Awards 
Name
 Number of Shares
Acquired on Exercise
(#)
 Value Realized
on Exercise
($)(1)
 Number of Shares
Acquired on Vesting
(#)
 Value Realized
on Vesting
($)(2)
  Number of Shares
Acquired on Exercise
(#)
 Value Realized
on Exercise
($)(1)
 Number of Shares
Acquired on Vesting
(#)
 Value Realized
on Vesting
($)(2)
 

Frank H. Laukien

 11,250 57,431 39,155 773,709  62,274 635,818 58,041 1,983,137 

Anthony L. Mattacchione.

     

Gerald N. Herman

   1,817 61,515 

Falko Busse

   1,809 60,976 

Mark R. Munch

   23,730 611,725 

Juergen Srega

   7,633 152,708    18,180 601,766 

Mark R. Munch

   8,232 169,645 

Michael G. Knell

     

Charles F. Wagner, Jr.

     

Thomas W. Bachmann

     

Anthony L. Mattacchione

 93,474 1,036,659 3,276 103,922 

(1)
Represents the difference between the exercise price of the options exercised and the closing price of Bruker Corporation common stock as of the date of exercise. As of December 31, 2015, Dr. Laukien continued to hold all of the shares reported as acquired upon exercise in 2015.

(2)
Represents the aggregate value of shares vested in 20152018 based on the closing price of Bruker Corporation common stock as of the date of vesting or, if the NASDAQNasdaq Global Select Market was closed on such date, the next trading date thereafter. As of December 31, 2015,2018, our named executive officers continued to hold all of the shares reported as acquired upon vesting of restricted stock awards and restricted stock units in 2015,2018, except as follows: 3,2641,055 of the shares reported as acquired by Dr. Munch,Mr. Mattacchione, with an aggregate value of $67,533,$33,264, were withheld to satisfy tax withholding obligations upon vesting; and 3,43818,552 of the shares reported as acquired by Dr. Laukien,Mr. Munch, of which 11,517 shares, with an aggregate value of $69,379,$388,134, were withheld to satisfy tax withholding obligations upon vesting.


Pension Benefits

        Swiss Pension Plan.    As an employee of our BioSpin AG subsidiary in Switzerland, Dr. Busse is eligible to participate in a defined benefit plan available to all employees of our subsidiaries in Switzerland, which we refer to as the Swiss Pension Plan. Dr. Busse participates in the plan on the same terms and conditions as all other Swiss employees and does not receive any additional supplemental executive pension contributions. The Swiss Pension Plan is a cash balance-based pension arrangement, under which we contribute an annual amount based on a percentage of salary and bonus and the participant's age. Employees may also make contributions based on a percentage of salary and bonus and age. Additionally, participants are allocated annual savings and interest credits based on age and account value, respectively. Payments to participants are based on accumulated capital in the participant's plan account and may be taken as a lump sum or annuity at normal retirement, beginning at age 65. Participants may also elect to receive a reduced benefit beginning at age 58 in the event of early retirement. In the event of premature death and disability, the Swiss Pension Plan also provides for payments in the form of an annuity based on a percentage of the participant's salary or as a lump sum based on accumulated plan account assets.

        Retirement Plan for Mr. Srega.    A personal pension scheme established for Mr. Srega's benefit, which was in part carried forward from his former employer, is funded by contributions made by Bruker Daltonik GmbH and voluntary contributions by Mr. Srega, if any, during the term of his employment. The personal pension scheme has three components: a contribution-based plan of Bruker Daltonik GmbH (the "Bruker Daltonik Plan"); a pension fund guarantee (the "Guarantee Plan"); and


Table of Contents

a cash value life insurance policy (the "Life Insurance Policy"). The Bruker Daltonik Plan provides for monthly Company contributions in the amount of €5,500€5,541 (approximately $5,999$6,342 per month or $71,988$76,104 per year) and a lifetime monthly retirement benefit based on the value of accumulated capital beginning at age 67 or a lump-sum payment. In the event of termination of employment or death prior to age 67, the Bruker Daltonik Plan provides for a reduced benefit to be determined based on the cash assets of the plan at such time. Mr. Srega may also elect to receive a reduced benefit beginning at age 62 in the event of early retirement. The Guarantee Plan provides an inflation hedge and an additional monthly retirement benefit, commencing December 1, 2019, with an annually increasing benefit based on Guarantee Plan earnings or, at Mr. Srega's election, a lump-sum payment. The Guarantee Plan is funded by annual Company contributions during the term of employment in amounts which increase annually by the same percentage as the upper earnings limit established under German law for pension insurance contributions. In the event of death prior to December 1, 2019, the Guarantee Plan provides for a lump-sum payment in an amount to be determined based on the plan assets at such time. In the event of death on or after December 1, 2019, benefits will terminate effective November 30, 2024. If Mr. Srega's employment terminates prior to the eligible retirement age,


Mr. Srega may elect to continue funding through personal contributions or the Guarantee Plan may be transferred to a subsequent employer. Under the Life Insurance Policy, which matures on November 1, 2019, Mr. Srega is entitled to receive at the earlier of death or maturity a payment in the amount of €53,028 (approximately $57,838)$60,691), adjusted for increases in the value of accumulated surplus and reserves, if any. In the event Mr. Srega's employment terminates prior to the maturity date, other than by reason of death, the Life Insurance Policy and continued funding obligations are to be transferred to Mr. Srega. Amounts payable in eurosEuros are converted to U.S. dollarsDollars at the midpoint conversion rate of €1.0=$1.09071.1445 as of December 31, 2015.2018. Mr. Srega may also make voluntary contributions to the personal pension scheme during the term of his employment.

        Swiss Pension Plan.    As an employee of our BioSpin AG subsidiary in Switzerland, Mr. Bachmann was eligible to participate in a defined benefit plan available to all employees of our subsidiaries in Switzerland, which we refer to as the Swiss Pension Plan. Mr. Bachmann participated in the plan on the same terms and conditions as all other Swiss employees and did not receive any additional supplemental executive pension contributions. The Swiss Pension Plan is a cash balance based pension arrangement, under which we contribute an annual amount based on a percentage of salary and bonus and the participant's age. Employees may also make contributions based on a percentage of salary and bonus and age. Additionally, participants are allocated annual savings and interest credits based on age and account value, respectively. Payments to participants are based on accumulated capital in the participant's plan account and may be taken as a lump sum or annuity at normal retirement, beginning at age 65. Participants may also elect to receive a reduced benefit beginning at age 58 in the event of early retirement. In the event of premature death and disability, the Swiss Pension Plan also provides for payments in the form of an annuity based on a percentage of the participant's salary or as a lump-sum based on accumulated plan account assets.

        Information about our contributions to the Swiss Pension Plan in which Dr. Busse is a participant and the personal pension scheme of Mr. Srega and the Swiss Pension Plan in which Mr. Bachmann was a participant is provided in the Summary Compensation Table above under the column entitled "All"All Other Compensation"Compensation" and the related footnotes.


20152018 Pension Benefits Table

        The following table provides information about the benefits provided for Mr. BachmannDr. Busse under the Swiss Pension Plan. The amount reported represents the U.S. dollarDollar equivalent of the benefits distributed to Mr. Bachmann upon his termination of employmentprovided for Dr. Busse in Swiss Francs, based on the midpoint conversion rate of CHF 1.0 =$1.00751.0=$1.0162 as of December 31, 2015.2018.

Name
 Plan Name Number of
Years of
Credited
Service(#)
 Payments
During Last
Fiscal Year
  Plan Name Number of
Years of
Credited
Service
(#)
 Present Value
of Accumulated
Benefit
($)
 

Thomas W. Bachmann(1)

 Swiss Pension Plan 1.92 $402,244 

Falko Busse(1)

 Swiss Pension Plan 0.7 108,154 

(1)
The number of years of credited service is equal to Mr. Bachmann'sDr. Busse's length of service with the Company. The reported amount reflects the distribution to Mr. Bachmann upon termination of his employment.as Bruker BioSpin Group President.

        During 2015, Mr. Bachmann2018, Dr. Busse made contributions to the Swiss Pension Plan of $34,505,$37,282, which amounts areamount is included in the "Salary" column of the Summary Compensation Table, andTable. During 2018, Dr. Busse did not make any additional voluntary contribution to the Swiss Pension Plan nor did he receive any benefits. Company contributions in 2018 for the benefit of $302,621. FollowingDr. Busse totaled $40,672. For the distributioneight month period ended December 31, 2018, the effect of benefits to Mr. Bachmann upon his termination, there is no remainingchanges in actuarial assumptions and the measurement date on the present value of the accumulated benefit obligation or survivorwas $30,201. The present value of accumulated benefit is calculated using the methodology and assumptions under Accounting Standards Codification Topic 715:Compensation—Retirement Benefitsfor Mr. Bachmann under the Swiss Pension Plan.fiscal year-end measurement (as of


Table of Contents

December 31, 2018). The present value is based on a discount rate of 1.10%, an expected return on plan assets of 1.60%, an expected rate of compensation increase of 1.00% and the BVG 2015 Generational mortality tables.


20152018 Non-Qualified Deferred Compensation Table

        The following table provides information about 20152018 activity relating to the personal pension scheme established for Mr. Srega. All amounts reported are as of December 31, 20152018 and are converted from eurosEuros to U.S. dollarsDollars at the 20152018 average midpoint conversion rate of €1.0 =$1.1094.€1.0=$1.1809.

Name
 Executive
Contributions
in Last
Fiscal Year ($)
 Registrant
Contributions
in Last
Fiscal Year ($)(1)
 Aggregate
Earnings
in Last
Fiscal Year ($)(2)
 Aggregate
Balance at
Last Fiscal
Year-End ($)(3)
  Executive
Contributions
in Last
Fiscal Year ($)
 Registrant
Contributions
in Last
Fiscal Year ($)(1)
 Aggregate
Earnings
in Last
Fiscal Year ($)(2)
 Aggregate
Balance at
Last Fiscal
Year-End ($)(3)
 

Juergen Srega

 4,488 73,775 2,263 323,056  5,025 78,530 188,713 616,475 

(1)
The reported amount is included in the "All Other Compensation" column in the Summary Compensation Table.

(2)
The reported amount includes earnings attributable to plan assets amounts contributed by Mr. Srega and Mr. Srega's former employer, which amounts were carried forward into the personal pension scheme following commencement of Mr. Srega's employment in 2013. The reported amount also reflects the impact of changes in exchange rates and currency translation from eurosEuros to U.S. dollars.Dollars. Aggregate earnings in local currency were 49,910 euros,143,886 Euros, or approximately $66,355 on a constant currency basis.$169,915.

(3)
The reported amount includes $4,488$5,025, $4,729 and $4,478 reported as 20152018, 2017 and 2016 compensation, respectively, in the "Salary"Salary"" column in the Summary Compensation Table, which was contributed by Mr. Srega from fiscal year 2015 compensation.his compensation in those years. Also included in the reported amount is the value of contributions to and earnings on amounts contributed by Mr. Srega and Mr. Srega's former employer prior to his employment with the Company,Bruker, which amounts were carried forward into the personal pension scheme following commencement of Mr. Srega's employment in 2013.

        There were no withdrawals or distributions from Mr. Srega's personal pension scheme during 2015.2018. Further information on the personal pension scheme established for Mr. Srega is included above under the heading"Pension Benefits—Retirement Plan."


Potential Payments upon Termination or Change-in-Control

        The following information describes and quantifies certain compensation and benefits that would have been payable under existing agreements, plans, and arrangements if the named executive officer's employment had terminated on December 31, 2015,2018, given his compensation and service levels as of that date. These benefits are in addition to the benefits to which the named executive officer was already entitled or in which he was vested as of such date, as well as certain benefits that are generally available to salaried employees. Due to the number of factors that affect the nature and amount of the compensation and benefits potentially payable upon the events described below, any amounts actually paid or distributed may be different than those shown in the table. Factors that could affect these amounts include the nature of or basis for such termination, the timing during the year of any such event, whether and when a named executive officer decides to exercise stock options and our stock price on that date and the exercise of discretion by the Board or Compensation Committee regarding the payment of compensation and benefits.

        Severance Benefits.    The cash severance benefits contained in the employment agreementagreements for Mr. Srega and Dr. Busse, and the amounts heeach would be paid in connection with a termination of


Table of Contents

employment within six months of a change in voting control of the CompanyBruker are described in the Compensation and Discussion &and Analysis section of this proxy statement under the heading "Employment Agreements, Termination of Employment and Change in Control Arrangements." Other than as contained in such agreement,agreements, we do not have arrangements with any of our other named executive officers, including


Dr. Laukien, Mr. Mattacchione,Herman and Dr. Munch, and Mr. Knell, which provide cash severance benefits in the event of termination of employment or a change in control of the Company.Bruker.

        Equity Awards.    The unvested equity awards held by each of the named executive officers as of December 31, 20152018 are described above in the 20152018 Outstanding Equity Awards table. We made eachEach of thosethe stock option and restricted stock awards granted prior to May 20, 2016 were granted pursuant to our 2010 Incentive Compensation Plan, or 2010 Plan. Each of the equity-based awards granted on or after May 20, 2016 were granted pursuant to our 2016 Plan. In accordance with that planthe terms of the 2010 Plan and the 2016 Plan and our related award agreements, except as noted below, no accelerated vesting of stock options, RSUs or restricted stock awards would have occurred as of December 31, 20152018 in the event of a voluntary termination by a named executive officer or an involuntary termination by us, whether with or without cause. Generally, upon termination of employment, (a) any unvested restricted stock is forfeited and (b) the participant has a period of 90 days from termination to exercise any vested option awards (or, if earlier, until the option expiration date). However, in the event of termination for cause, including as a result of dishonesty with respect to the CompanyBruker or any of itsour affiliates, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or refusal to comply with Company'sour published policies generally applicable to all employees or conduct materially harmful to the business of the CompanyBruker or any of itsour affiliates, all vested and unexercised options and unvested RSU or restricted stock awards are forfeited immediately upon termination. Additionally, in the event of death or disability of a plan participant, including any named executive officer, (a) any unvested RSUs or restricted stock awards will become vested and (b) all vested stock options will remain exercisable for a period of 90 days following such event (or, if earlier, until the stock option expiration date).

        The Compensation Committee has discretion to revise or amend outstanding equity awards and may, at its discretion, accelerate vesting of any unvested option, RSU or restricted stock awards, including in connection with a "Change in Control" of the Company,Bruker, as defined in our 2010 Plan.Plan or 2016 Plan, as applicable. Under that plan,these plans, a "Change in Control" occurs if: (a) within one year of any merger, consolidation, sale of a substantial part of the Company'sour assets, or contested election, the persons who were directors of the CompanyBruker immediately before such transaction cease to constitute a majority of the boardBoard of directors of the CompanyBruker or itsa successor to the Company;Bruker; (b) if, as a result of any such transaction, the Company doeswe do not survive as an entity, or itsour shares are changed into the shares of another corporation unless the stockholders of the CompanyBruker immediately prior to the transaction own a majority of the outstanding shares of such other corporation immediately following the transaction; (c) any person or group who owned less than twenty percent of theour outstanding common stock of the Company at the time of adoption of the 2010 Plan or 2016 Plan, as applicable, acquires ownership of fifty percent or more of the Company'sour outstanding common stock; (d) the dissolution or liquidation of the CompanyBruker is approved by its stockholders; or (e) the members of the board of directorsBoard as of the date the 2010 Plan or 2016 Plan, as applicable, was adopted cease to represent at least two-thirdstwo thirds of the Board, subject to certain exceptions.

        Additionally, with respect to awards granted pursuant to the 2016 Plan, in the event of a Change in Control, if (a) an award is assumed or continued (including through conversion or substitution for a substantially similar award of the successor) and, within twenty four (24) months following the Change in Control (or such shorter period as specified in the applicable award agreement), the executive officer's employment is terminated without cause or is voluntarily terminated for good reason (a "double-trigger" provision), or (b) an award is not assumed or continued, then any then outstanding awards of stock options will vest and become fully exercisable and any outstanding unvested awards of restricted stock units that are not performance-based will be treated as vested.


Table of Contents

        The values of (i) unvested in-the-money stock options that would have been received by each of the named executive officers in the event the Compensation Committee chose to accelerate the vesting of outstanding option awardsacceleration upon a Change in Control, assuming the Change in Control was effective December 31, 20152018 and (ii) unvested restricted stock that would have been received by each of the named executive officers in the event (a) the Compensation Committee chose to accelerate the vesting of outstanding restricted stock awardsacceleration upon a Change in Control, assuming the Change in Control was effective December 31, 20152018 or (b) of the death or disability of the respective named executive officer


are set forth in the following table. All calculations are based on a price per share equal to the NASDAQ Global Select MarketNasdaq closing price of $24.27$29.77 per share on December 31, 2015.2018.

Name
 Unvested
In-the-Money
Stock Options ($)
 Unvested
Restricted
Stock ($)
  Unvested
In-the-Money
Stock Options ($)
 Unvested
Restricted
Stock ($)
 Unvested
Restricted
Stock Units ($)
 

Frank H. Laukien

 221,139 3,740,128  482,849 485,400 4,243,565 

Anthony L. Mattacchione.

 340,057  

Gerald N. Herman

 29,055  452,325 

Falko Busse

 56,881  261,738 

Mark R. Munch

 400,471 144,593 1,417,082 

Juergen Srega

 533,802 892,456  273,454 103,272 934,004 

Mark R. Munch

 435,112 1,070,744 

Michael G. Knell

 189,925  

Anthony L. Mattacchione

    

        Retirement Plans.    The retirement planplans provided for Mr. Srega isand Dr. Busse are described under the heading "Pension Benefits" above.

        In the event of termination of employment as of December 31, 20152018 by reason of death, Mr. Srega's beneficiary would be entitled to receive an estimated lump-sum payment of $318,903,$579,751, which amount is payable in eurosEuros and converted to U.S. dollarsDollars based on the midpoint conversion rate of €1.0 =$1.0907€1.0=$1.1445 as of December 31, 2015.2018.

        Upon hisIn the event of termination of employment Mr. Bachmann receivedas of December 31, 2018, other than for reason of death or disability, Dr. Busse would be entitled to receive a distributionlump-sum payment in the amount of $65,796. In the event of disability as of December 31, 2018, Dr. Busse would be entitled to receive an annual disability pension in the amount of $263,385. In the event of death as of December 31, 2018, Dr. Busse's beneficiary would be entitled to annual survivor benefits under the Swiss Pension Plan of $402,244. The amount$158,031. Amounts reported for Dr. Busse, which wasare payable in Swiss Francs, isare converted to U.S. dollarsDollars based on the midpoint conversion rate of CHF 1.0 =$1.00751.0=$1.0162 as of December 31, 2015.2018.

Pay Ratio Disclosure

        As required by Section 953(b) of the Dodd-Frank Wall Street Reform Act and Consumer Protection Act of 2010, and Item 402(u) of Regulation S-K, we are providing the following disclosure about the ratio of the annual total compensation of Dr. Frank Laukien, our President and Chief Executive Officer (CEO), to the annual total compensation of our median employee.

        For 2018, the annual total compensation of our median employee was $87,097. The 2018 annual total compensation of our CEO, as reported in the Summary Compensation Table included in this proxy statement, was $4,479,898. Based on this information, the ratio of our CEO's annual total compensation to the annual total compensation of our median employee in 2018 was 51:1. This ratio is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K.

        For purposes of reporting annual total compensation and the ratio of annual total compensation of the CEO to the median employee, both the CEO and median employee's annual total compensation were calculated consistent with the disclosure requirements of executive compensation under the Summary Compensation Table.

        For 2018, we used the same median employee as used for 2017 as there have been no material changes in our employee population or employee compensation arrangements that we believe would


Table of Contents

result in a significant change to the pay ratio. There also were no material changes to this employee's compensation that would significantly affect the pay ratio.

        To identify the median employee, we examined the 2017 target total cash compensation, including annualized base salaries plus target performance bonus, incentive pay and commissions, for all individuals, excluding our CEO, who were employed by us as of October 31, 2017, as reflected in our payroll records. In accordance with Item 402(u) and instructions thereto, we included all 6,125 full-time, part-time, temporary and seasonal employees. We selected target total cash compensation for all employees as a consistently applied compensation measure because we do not widely distribute annual equity awards to employees and because we believe that this measure reasonably reflects the total annual compensation of our employees. For purposes of calculating the target total cash compensation of our non-U.S. employees, we converted local currencies at the applicable 2017 average exchange rates as of October 31, 2017.


COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

        None.


RELATED PERSONS TRANSACTIONS

Review and Approval of Transactions with Related Persons

        We have adopted a written Related Person Transactions Policy that prohibits transactions involving the CompanyBruker and any related person, except in accordance with the policy. For purposes of this policy, related persons include (a) our executive officers, directors, director nominees or greater than 5% shareholders,stockholders, or any of their immediate family members and (b) any firm, academic entity or other entity in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has more than a 10% beneficial ownership interest. The Related Person Transactions Policy applies to any transaction or series of transactions, other than product or service sales or purchases entered into in the ordinary course of business involving aggregate amounts of less than $50,000 annually, in which the Company iswe are a participant and in which any related person has a direct or indirect interest.

        Our Related Person Transactions Policy provides for standing pre-approval of certain categories of transactions with related persons, including:

        Under our Related Person Transactions Policy, any related person transaction not in one of the preceding categories must be submitted to our Chief Financial Officer for review and approval. Related person transactions involving amounts of $500,000 or less, as well as all product or service sales and purchases in the ordinary course of business, are subject solely to review and approval, ratification, amendment, termination or rescission by our Chief Financial Officer. Any transaction in excess of


$500,000, $500,000, other than a transaction involving product or service sales or purchases in the ordinary course of business, must be forwarded to the Audit Committee for review and approval, ratification, amendment, termination or rescission, at the discretion of the Audit Committee. In reviewing such transactions, our Chief Financial Officer or Audit Committee, as applicable, evaluates all material facts


Table of Contents

relating to the transaction and takes into account, among other factors deemed appropriate, the related person's relationship to the CompanyBruker and interest in the transaction, the terms of the transaction, including its aggregate value, whether the transaction is in the best interests of the Company,Bruker, the impact on a director's independence in the event the related person is a director, a family member of a director, or an entity in which a director is a partner, shareholderstockholder or executive officer and, if applicable, the availability of other sources of comparable products or services and whether the transaction is on terms comparable to the terms available to an unrelated third party. Neither the Chief Financial Officer nor any member of the Audit Committee may participate in the review of any transaction involving such person or any of his or her immediate family members.

        Our Chief Financial Officer must report to the Audit Committee any approval or other action taken with respect to a related party transaction at or prior to the next audit committee meeting following such approval or other action. Additionally, Companyour management must provide to the Audit Committee an annual report of any amounts paid or payable to, or received or receivable from, any related person. The Audit Committee is responsible for reviewing such reports and may make inquiries or take such actions as it deems appropriate upon consideration of all of the relevant facts and circumstances.

Transactions with Related Persons

        Under twoa lease agreements,agreement, Bruker BioSpin Corporation rents laboratory, manufacturing and office space from trustsa trust controlled equally by certain Laukien family members, including Dr. Frank Laukien. During 2015, Dr. Frank Laukien wasand Dr. Dirk Laukien. During 2018, Dr. Frank Laukien and Dr. Dirk Laukien were each paid $390,300$252,983 as a beneficiary of the trusts. Thetrust. Payments under the terms of the lease terms were equal to the estimated fair market value of the rentals.rental.

        Our Bruker Optics subsidiary rents various office space from        Dr. Dirk Laukien, a director and employee of the Company until July 10, 2012 and half-brother of Dr. Frank Laukien, is also a party to a lease agreement under lease agreements pursuant to which Bruker BioSpin AG rents certain office space. During 2018, we paid Dr. Dirk Laukien was paid $509,200 in 2015. Under two$114,107 under this lease agreements, Bruker BioSpin Corporation rents laboratory, manufacturingagreement. Payments under the terms of the lease were equal to the estimated fair market value of the rental.

        Isolde Laukien-Kleiner is the stepmother of Dr. Frank Laukien and office space from trusts controlled by certainMr. Joerg Laukien family members, includingand the mother of Dr. Dirk Laukien. During 2015, Dr. Dirk Laukien was paid $390,300 as a beneficiary of the trusts. Dr. Dirk Laukien is also a partyand Ms. Laukien-Kleiner are parties to a lease agreement with Bruker BioSpin AG under which Bruker BioSpin AG rents certain office and laboratory space. During 2015, Dr. Dirk Laukien2018, Ms. Laukien-Kleiner was paid $116,000$342,321 under that agreement. Ms. Laukien-Kleiner is party to an additional lease agreement with Bruker BioSpin AG under which Bruker BioSpin AG rents certain office space. During 2018, Ms. Laukien-Kleiner was paid $234,447 under that agreement. Payments under the terms of each of the leases referenced above were equal to the estimated fair market value of the respective rental.

        Joerg C. Laukien, a director of the Company, is Executive Chairman of Bruker BioSpin Corporation. During 2015, Joerg Laukien earned aggregate cash compensation of 235,217 euros in salary, or $260,950 based on a conversion rate of €1.00 = $1.1094, which represents the 2015 average midpoint rate.

        Isolde Laukien-Kleiner is the stepmother of Dr. Frank Laukien and Mr. Joerg Laukien and the mother of Dr. Dirk Laukien. With Dr. Dirk Laukien, Ms. Laukien-Kleiner is a party to a lease agreement with Bruker BioSpin AG under which Bruker BioSpin AG rents certain office space. During 2015, Ms. Laukien-Kleiner was paid $143,000 under that agreement. Ms. Laukien-Kleiner is party to an additional lease agreement with Bruker BioSpin AG under which Bruker BioSpin AG rents certain office space. During 2015, Ms. Laukien-Kleiner was paid $238,400 under that agreement. Payments under the terms of each of the leases referenced above were equal to the estimated fair market value of the respective rental.


Dr. Gilles Martin, a director of the Company,Bruker, is the Chairman, Chief Executive Officer and controlling shareholder of the Eurofins Scientific Group, a provider of analytical testing services, and a director of various of its affiliates. During 2015, the Company2018, we received approximately $697,000$3,047,196 from, and paid approximately $12,000$97,785 to, entities affiliated with the Eurofins Scientific Group in connection with purchases and sales of goods and services entered into in the normal course of business. We believe that the terms of such transactions are comparable to those that would have been reached by unrelated parties in arm's-length transactions. We expect to engage in similar commercial transactions with affiliates of the Eurofins Scientific Group during fiscal 2016.2019.

        Dr. MiekeMeike Hamester, the wife of Bruker CALID Group President Juergen Srega, is employed by our Bruker Daltonik GmbH subsidiary as the Director of Small Molecule Pharma & CRO. During 2015,2018, Dr. Hamester received a base salary in the amount of $104,257$106,621 and she is eligible to receiveearned an annual performance-based cash incentive bonus for 20152018 performance based on a target level of $22,188 (base salary and bonus are payable in euros; amounts are converted to U.S. dollars at a conversion rate of €1.00 = $1.1094, which represents the 2015 average midpoint rate as published on www.oanda.com). The amount of her 2015 cash incentive bonus payment has not yet been determined.$37,551. She also received a bonus payment in the amount of $21,660,$30,826 which was earned in 20142017 but paid in 2015.2018. Dr. Hamester's base salary and bonus are payable in Euros; amounts are converted to U.S. Dollars at a conversion rate of €


Table of Contents

1.0=$1.1809, which represents the 2018 average midpoint rate. Her compensation is consistent with the total compensation provided to other employees of the same level with similar responsibilities. Dr. Hamester continues to be an employee of Bruker Daltonik GmbH and she may receive compensation and other benefits in 20162019 in amounts similar to those she received during 2015.2018.


SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

        Section 16(a) of the Securities Exchange Act of 1934 and the rules promulgated thereunder require our officers and directors and persons owning more than 10% of theour outstanding common stock of the Company to file reports of ownership and changes in ownership with the Securities and Exchange Commission and to furnish us with copies of all these filings. We believe, based solely upon a review of those reports and amendments thereto furnished to us during and with respect to our fiscal year ended December 31, 2015,2018, that all of our directors and executive officers complied with the reporting requirements of Section 16(a) of the Exchange Act during fiscal 2015,2018, with the exception of one transaction reported in a late Form 4 filing by Dr. MunchMr. Richard Packer due to an administrative error.delay in report processing.


Table of Contents


AUDIT COMMITTEE REPORT

        The Audit Committee, which operates pursuant to a written charter, assists the board of directorsBoard in fulfilling its oversight responsibilities by reviewing Bruker Corporation's financial reporting process on behalf of the board.Board. Management is responsible for Bruker Corporation's internal controls, the financial reporting process and compliance with laws and regulations and ethical business standards. Ernst & YoungPricewaterhouseCoopers LLP ("Ernst & Young"PwC"), Bruker Corporation's independent registered public accounting firm, is responsible for expressing opinions on the conformity of Bruker Corporation's consolidated financial statements with generally accepted accounting principles and on the effectiveness of Bruker Corporation's internal control over financial reporting. The Audit Committee is responsible for overseeing and monitoring these practices. It is not the duty or responsibility of the Audit Committee to conduct auditing or accounting reviews or procedures.

        In this context, the Audit Committee reviewed and discussed with management and Ernst & Young,PwC, among other things, the scope of the audit to be performed, the results of the audit performed, Ernst & Young'sPwC's evaluation of Bruker Corporation's internal control over financial reporting and the independent registered public accounting firm's fees for the services performed. Management represented to the Audit Committee that Bruker Corporation's consolidated financial statements were prepared in accordance with generally accepted accounting principles. Discussions about Bruker Corporation's audited financial statements included the auditors' judgments about the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in its financial statements.

        The Audit Committee also discussed with Ernst & YoungPwC other matters required by Auditing Standard No. 16,1301,Communications with Audit Committees, as adopted by the Public Company Accounting Oversight (PCAOB), including the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of the disclosures in the financial statements. Ernst & YoungPwC also provided to the Audit Committee written disclosures and the letter required by applicable requirements of the PCAOB regarding communications with the Audit Committee concerning independence. The Audit Committee discussed with Ernst & YoungPwC the registered public accounting firm's independence from Bruker Corporation and considered the compatibility of non-audit services with Ernst & Young'sPwC's independence.

        Based on the Audit Committee's discussion with management and Ernst & Young,PwC, and the Audit Committee's review of the representations of management and the report of Ernst & YoungPwC to the Audit Committee, the Audit Committee recommended to the boardBoard that that the audited financial statements be included in the Company's Annual Report on Form 10-K for the year ended December 31, 20152018 filed with the Securities and Exchange Commission.

        Submitted by the Audit Committee of Bruker Corporation's Board of Directors.the Board.

  Brenda J. Furlong,John Ornell, Chair
John OrnellAdelene Q. Perkins
Richard A. Packer
Chris van IngenRobert Rosenthal

Table of Contents


PROPOSAL NO. 2
APPROVAL OF THE 2016 INCENTIVEADVISORY VOTE ON EXECUTIVE COMPENSATION PLAN

Overview

        Our board of directors is seeking stockholder approval of the Bruker Corporation 2016 Incentive Compensation Plan (the "2016 Plan") at the 2016 Annual Meeting. The 2016 Plan will become effective when and if approved by the Company's stockholders. The 2016 Plan is attached asAppendix A to this proxy statement and the following summary is qualified in its entirety by reference to the full text of the 2016 Plan.

        The 2016 Plan is intended to continue and extendBoard recognizes the type of incentives thatinterest our stockholders have been provided underin the Company's 2010 Incentive Compensation Plan (the "2010 Plan") and its predecessor. As of April 1, 2016, a total of 3,868,630 shares of common stock were subject to outstanding awards under the 2010 Plan, and an additional 2,888,174 sharescompensation of our common stock were available for new awards underexecutives. In recognition of that interest and as required by the 2010 Plan. AlthoughDodd-Frank Wall Street Reform and Consumer Protection Act and SEC rules, we are providing our stockholders the opportunity to cast a non-binding advisory vote on the compensation of our named executive officers, as disclosed pursuant to the compensation disclosure rules of the SEC.

        The compensation of our named executive officers is disclosed in the Compensation Discussion and Analysis, or "CD&A," the compensation tables, and the related disclosures contained in this proxy statement. As described in our CD&A, we have adopted an executive compensation philosophy designed to deliver competitive total compensation, upon the achievement of financial and/or strategic performance objectives, which we believe will attract, motivate and retain leaders who will drive the creation of stockholder value. In order to implement that philosophy, the Compensation Committee may grant awards underhas established a disciplined and rigorous process for the 2016 Plan prior to stockholder approval, any such awards shall be conditioned on such approvaladoption of executive compensation programs and accordingly, may not be vested, exercised or paid prior to such approval. If the 2016 Plan is approved by our stockholders, we will not grant any new awards under the 2010 Plan after the 2016 Annual Meeting. Outstanding awards under the 2010 Plan, however, will continue to be governed by the 2010 Plan and the agreements under which they were granted.

        If our stockholders do not approve the 2016 Plan, the 2010 Plan will continue in effect until its stated expiration date of March 9, 2020, unless the 2010 Plan is otherwise amended, and we will continue to have the authority to, and expect that we will, continue to grant option and restricted stock awards under the 2010 Plan.

Backgroundindividual executive officer pay actions.

        We believe that cash- and equity-based incentive awards are fundamental to our ability to attract, motivate and retain highly qualified and dedicated employees, directors and other service providers. We also believe that the use of equity-based compensation awards provides a strong link to our long-term performance, creates an ownership culture and generally aligns the interests of our directors, executives and other employees with our stockholders. We have worked closely with our compensation consultant to designpolicies and decisions are focused on pay-for-performance principles, are strongly aligned with the 2016 Plan to meet our internal compensation objectives, as well as thelong-term interests of our stockholders and provide an appropriate balance between risk and incentives. Stockholders are urged to read the CD&A section of this proxy statement, which discusses in greater detail how our compensation policies and procedures implement our executive compensation philosophy. We are asking our stockholders to indicate their support for our named executive officer compensation, as more fully described below.

        On February 18, 2016 upon the recommendation andin this proxy statement, by approval of the Compensation Committee, our board of directors adoptedfollowing resolution:


Background for Requested Share Authorization

        The number of shares of common stock reserved for issuance under the 2016 Plan was determined after consideration of a number of factors, including (i) the number of shares available under the 2010 Plan, (ii) the Company's historical equity grant practices, including its "burn rate," which is below the that of the Company's peer group and index thresholds established by certain major proxy advisory firms, (iii) potential future awards that may be granted to attract and retain critical talent, and (iv) expected dilution to existing stockholders. We are seeking to include additional shares of common stock under the 2016 Plan beyond the shares of stock that remain available for future awards under the 2010 Plan in order to provide us, with flexibility in structuring our compensation arrangements going forward and to enable us to grant equity compensation at a level that allows us to continue to attract and retain employees in the competitive labor markets in which we compete. We are also expanding the types of vehicles available under our incentive plan to include award types such as restricted stock units in order to reflect evolving competitive practices, offer tax-effective equity vehicles, provide additional flexibility to align our equity incentives with our overall philosophy of attracting, rewarding, and also retaining our talented employees and further help to align our employee interests with those of our stockholders through accumulation of a long-term stake in the Company.

Description of the 2016 Plan

        The following is a description of the principal terms of the 2016 Plan. The summary is qualified in its entirety by the full text of the 2016 Plan, which is attached asAppendix A to this proxy statement.

Purpose

        The 2016 Plan is intended to encourage ownership of Company common stock by management, employees, directors, consultants and advisors of the Company and its subsidiaries, to induce qualified personnel to enter and remain in the employ of the Company or its subsidiaries and otherwise to provide incentives to promote the success of our business.

Administration and Term

        The 2016 Plan will be administered by the Compensation Committee, or such other committeethe Board. However, our Board and our Compensation Committee value input from stockholders and will consider the outcome of the board of directors as the board of directors may from time to time designate (the "Committee"). The Committee will consist of not fewer than two directors of the Company, each of whom will be (i) an independent director in accordance with the rules of any stock exchange on which the Company's shares are listed, (ii) a "non-employee director" within the meaning of Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and (iii) an "outside director" within the meaning of Section 162(m) of the Code.

        The Committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2016 Plan. The Committee may delegate the administrative responsibilities of the 2016 Plan and also delegate to one or more members of management all or a portion of its responsibilities to grant awards, subject to specified limitations. The Committee may also determine whether, to what extent, andvote when an award may be canceled, forfeited, exchanged or surrendered, and may waive any conditions or rights under,


amend, modify or supplement the terms of, or amend, alter, suspend, discontinue or terminate an award, but may not, except in connection with a corporate transaction involving the Company: (i) amend the terms of outstanding options or SARs to reduce the exercise price of such outstanding options or SARs; (ii) exchange outstanding options or SARs for options or SARs with an exercise price that is less than the exercise price of the original options or SARs; or (iii) cancel outstanding options or SARs with exercise prices above the current fair market value of a share in exchange for cash or other securities, in each case, unless such action is subject to and approved by the Company's stockholders. To the extent permitted by Rule 16b-3 of the Exchange Act and applicable laws, the Committee may delegate to one or more members of management all or a portion of its authority to grant awards under the 2016 Plan.

        The 2016 Plan will become effective upon stockholder approval at the 2016 Annual Meeting and will terminate on the first to occur of (i) February 18, 2026 or (ii) the date determined in accordance with the Board's authority to amend, alter, suspend, discontinue, or terminate the 2016 Plan.

        On April 1, 2016, the closing price of the Company's common stock on the NASDAQ Global Select Market was $29.26 per share.

Eligibility

        Eligible participants under the 2016 Plan include officers, employees, consultants, advisors and directors of the Company and its subsidiaries, as selected from time to time by the Committee. As of April 1, 2016, approximately 6,000 employees, and all of the Company's non-employee directors, are eligible to participate in the 2016 Plan. In determining a person's eligibility to be granted an award under the 2016 Plan, and the number of shares to be granted to any person, the Compensation Committee takes into account, in its sole discretion, the person's position and responsibilities, the nature and value to the Company or its subsidiaries of the person's service and accomplishments, the person's present and potential contribution to the success of the Company, and such other factors as the Compensation Committee deems relevant.

Shares Available

        A total of 9,500,000 shares of the Company's common stock are authorized for issuance under the 2016 Plan, consisting of (i) approximately 6,611,826 shares plus (ii) approximately 2,888,174 shares expected to be available for issuance under the 2010 Plan immediately prior to effectiveness of the 2016 Plan.

        If any awards under the 2016 Plan are forfeited, canceled, terminated, exchanged or surrendered, or such award is settled in cash or otherwise terminates without a distribution of shares to the participant, then the number of shares counted against the share reserve with respect to such award will, to the extent of such forfeiture, settlement, termination, cancellation, exchange or surrender, again be available formaking future issuance under the 2016 Plan.

        The number of shares of stock available for issuance under the 2016 Plan will not be increased by the number of shares (i) tendered, withheld or subject to an award granted under the 2016 Plan surrendered in connection with the purchase of shares upon exercise of an option, (ii) that were not issued upon the net settlement or net exercise of a share-settled SAR granted under the 2016 Plan, (iii) deducted or delivered from payment of an award granted under the 2016 Plan in connection with the Company's tax withholding obligations, or (iv) purchased by the Company with proceeds from option exercises.

        The number of authorized shares will be proportionately adjusted to reflect a merger, reorganization, consolidation, recapitalization, share exchange, stock dividend, stock split, reverse stock split, split-up, spin-off, issuance of rights or warrants, or other similar event.


Award Limitations and Minimum Vesting Period

        The 2016 Plan provides certain limits on the number of shares or, as applicable, value subject to equity-based award types and the value of cash-based awards that an individual may receive in any one fiscal year. More than one award may be granted to an individual participant, at the discretion of the Committee.

        The maximum aggregate number of shares of common stock subject to stock options granted to any participant in any fiscal year is 500,000. The maximum aggregate number of shares of common stock subject to stock appreciation rights granted to any participant in any fiscal year is 500,000. The maximum aggregate number of shares of common stock subject to awards of restricted stock, unrestricted stock or restricted stock units granted to any participant in any fiscal year is 500,000. The maximum aggregate grant of performance shares or performance units made to any participant in any fiscal year is 500,000 (if stock-settled) or the value of such number of shares (if cash-settled). For cash-based awards, the maximum aggregate amount awarded to any participant in any fiscal year is $5,000,000.

        The maximum aggregate dollar amount of cash or fair market value of shares of common stock subject to awards that may be granted to a non-employee director under the 2016 Plan during any fiscal year is $500,000 (not including cash-based director fees that the non-employee director elects to receive in the form of shares or share equivalents equal in value to such cash-based director fees).

        Except with respect to a maximum of 5% of the shares of common stock reserved under the 2016 Plan, as may be adjusted pursuant to the terms of the 2016 Plan, awards that vest solely based on service will be subject to a minimum vesting period requiring at least one year of service.

Types of Awards

        Under the 2016 Plan, the Committee may award options (nonqualified stock options or incentive stock options), SARs, restricted stock, unrestricted stock, restricted stock units, performance shares and performance units, as well as grant cash-based awards.

        Options.    A stock option represents the right to purchase a share of common stock at a predetermined exercise price. The 2016 Plan permits the grant of stock options that are intended to qualify as incentive stock options, or "ISOs," and options that are not intended to qualify as ISOs, which are commonly referred to as "nonqualified" stock options. ISOs may be granted only to employees of the Company and its subsidiaries. The maximum aggregate number of shares of common stock that may be delivered pursuant to ISOs granted under the 2016 Plan is 9,500,000.

        The terms of each stock option award, including the number of shares, option duration, exercise price, vesting period and any other restrictions or conditions on exercise, will be set forth in an award agreement.

        The exercise price of each option will be determined by the Committee, provided that the exercise price per share will be no less than 100% of the fair market value of one share of stock on the grant date. If a participant is a 10% stockholder, the exercise price of an option granted to such participant that is intended to be an incentive stock option will be not less than 110% of the fair market value of one share of stock on the grant date. The 2016 Plan generally prohibits the repricing of outstanding stock options and the exchange of cash or other securities for out-of-the money awards, without prior stockholder approval.

        Subject to certain limitations set forth in the 2016 Plan, each option granted under the 2016 Plan will become vested and/or exercisable at such times and under such conditions as determined by the Committee. The Committee will determine the time or times at which the option may be exercisable, the methods by which the exercise price may be paid or deemed paid (including broker-assisted


exercise arrangements), the form of such payments (including cash or shares of stock), and the methods by which the shares of stock will be delivered or deemed delivered.

        The term of each option will be determined by the Committee, but will not be longer than ten years from the date of grant, provided that, in the event that a participant is a 10% stockholder, an option granted to such participant that is intended to be an incentive stock option will not be exercisable after five years from the date of grant. Unexercised stock options will generally expire on the earlier of the expiration date of the stock option (as set forth in the applicable award agreement) or 90 days after the participant's termination of employment or other business relationship. Upon termination of a participant's employment or other relationship for cause (as defined in the applicable award agreement) unexercised stock options held by the participant will terminate immediately.

        Share Appreciation Rights (SARs).    The holder of a SAR will be entitled to receive, upon exercise thereof, an amount measured by the difference between (i) the fair market value of one share of Company common stock on the date the SAR is exercised and (ii) the SAR exercise price as determined by the Committee as of the date of grant.

        The terms of each SAR award, including the number of shares subject to the award, the grant price, duration, payment terms and any restrictions or conditions on exercise, will be set forth in an award agreement. The exercise price of each SAR will be determined by the Committee, provided that the exercise price per share will be no less than 100% of the fair market value of one share of common stock subject to the SAR on the date of grant. The 2016 Plan generally prohibits the repricing of stock appreciation rights or the exchange of cash or other securities for out-of-the-money awards, without prior stockholder approval. The appreciation distribution payable upon exercise of a stock appreciation right may be paid in shares of our common stock, in cash, or in a combination of cash and stock, at the election of the Committee. Stock appreciation rights are subject to the same transferability restrictions as stock options.

        Restricted Stock and Stock Awards.    Restricted stock awards are grants of shares of stock to a participant that are subject to forfeiture during a pre-established period of restriction if certain conditions (for example, continued employment or attainment of pre-determined performance goals) are not met.

        The terms of each restricted stock award, including the period of restriction, number of shares and other terms and conditions, will be determined by the Committee and set forth in an award agreement. Restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered while the shares are subject to a substantial risk of forfeiture or otherwise restricted as to transfer. Unless provided otherwise in an award agreement, holders of restricted stock generally will have all the rights of a holder of common stock, including the rights to receive any dividends and to vote, during the period of restriction. The Committee may apply any restrictions to the payment of dividends declared with respect to restricted stock as it deems appropriate to maintain eligibility for the performance-based exception from the tax deductibility requirements of Section 162(m) of the Code.

        Upon the termination of a participant's service during the period of restriction, any shares of restricted stock held by such participant to which all applicable restrictions and conditions have not lapsed will be deemed forfeited, unless the Committee provides otherwise.

        Except as otherwise provided in an award agreement, all shares of restricted stock covered by any restricted stock award made under the 2016 Plan will become freely transferable by the participant after the last day of the applicable period of restriction.

        Under the 2016 Plan, the Committee may also grant awards of shares of our common stock that are not subject to periods of restriction but which may be subject to such other conditions or provisions as the Committee may deem advisable. The Committee will determine the terms and conditions of such awards at the time of grant.


        Restricted Stock Units, Performance Units and Performance Shares.    Restricted stock units, performance units and performance share awards represent a conditional right to receive shares of the Company's common stock or cash at the end of a specified performance period. The terms of each award of restricted stock units, performance units or performance shares, including the initial value, duration, applicable performance measures or service requirements and other terms and conditions, will be determined by the Committee and may be set forth in an award agreement.

        Each performance unit shall have an initial value that is established by the Committee at the time of grant. Each restricted stock unit and performance share shall have an initial value equal to the fair market value of a share of common stock on the date of grant. Generally, a participant's right to receive amounts under a restricted stock unit award will be based on the participant's satisfaction of a service requirement and such other terms and conditions as the Committee may specify. Generally, a participant's right to receive amounts under a performance unit or performance share award will be based on the satisfaction of a performance requirement and such other terms and conditions as the Committee may specify.

        Upon expiration of the performance period specified by the Committee, the holder of an award of restricted stock units, performance units, or performance will be entitled to payment of earned amounts in cash, shares of the Company's common stock (or a combination of cash and shares) having an aggregate fair market value equal to the value of the earned restricted stock units, performance units, and performance shares at the close of the applicable performance period.

        To the extent provided by the Committee in an award agreement, participants holding restricted stock units, performance units, or performance shares may be entitled to receive dividend units with respect to dividends declared with respect to the shares underlying such awards; provided that no dividend units may be paid on performance units or performance shares that are not earned. The Committee may apply any restrictions to the payment of dividends declared with respect to shares underlying such awards as it deems appropriate to maintain eligibility for the performance-based exception from the tax deductibility requirements of Section 162(m) of the Code.

        Except as otherwise provided in an award agreement, restricted stock units, performance units, and performance shares granted under the 2016 Plan may not be transferred by the participant other than by will or the laws of descent and distribution.

        Cash-Based Awards.    Awards denominated and payable in cash may be granted to participants in such amounts and upon such terms as determined by the Committee. The Committee may set performance and/or service requirements in its discretion which, depending on the extent to which they are met, will determine the amount in respect of such award that will be paid out to the participant following expiration of the applicable performance or service period. Payment of earned cash-based awards will be in cash or in shares of the Company's common stock (or a combination of cash and shares) having an aggregate fair market value equal to the value of the earned cash-based awards at the close of the applicable performance or service period.

        Cash-based awards granted under the 2016 Plan may not be transferred by the participant other than by will or the laws of descent and distribution.

Performance Criteria and Targets

        For equity or cash-based awards under the 2016 Plan that are intended to satisfy the exception for qualified performance-basedexecutive compensation under Section 162(m) of the Code, the Committee will establish specific objective performance targets for specified performance periods. The 2016 Plan provides the following permissible performance criteria for such awards:decisions.


        Performance measures may be set either at the consolidated level, segment level, division level, group level, or business unit level. Additionally, performance measures may be measured either annually or cumulatively over a period of years, on an absolute basis or relative to pre-established targets, to a previous year's results or to a designated comparison group, in each case as specified by the Committee.

        Generally, the amount paid under any award or portion of an award intended to qualify as performance-based compensation for purposes of Section 162(m) of the Code must be determined based on the attainment of written, objective performance goals approved by the Committee for a performance period established by the Committee while the outcome for that performance period is substantially uncertain within the meaning of Section 162(m) of the Code. The Committee will determine whether, with respect to a performance period, the applicable performance goals have been met by the participant and the amount of the applicable award, if any. Such awards that are held by "covered employees" (within the meaning of Section 162(m) of the Code) may not be adjusted upward but may be adjusted downward at the discretion of the Committee. The Committee may adjust the terms and conditions of, and the performance criteria included in, such awards in recognition of unusual or nonrecurring events affecting the Company or the financial statements of the Company, such as, but not limited to, effects of changes in foreign exchange, an unbudgeted material expense incurred by or at the direction of the board of directors or a committee of the board of directors, a material litigation judgment or settlement, mergers, acquisitions, divestitures, spin-offs, consolidation, acquisition of property or stock, reorganizations, restructuring charges, or joint ventures, or of changes in applicable laws, regulations, or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the 2016 Plan, unless such adjustment shall would be


inconsistent with the award's satisfaction of the requirements for treatment as a performance-based award under Section 162(m) of the Code or would cause an award not otherwise subject to the non-qualified deferred compensation rules of Section 409A of the Code to become so subject.

        The Committee may also award compensation that is not exempt from the limits of deductibility under Section 162(m) of the Code.

Recoupment

        To the extent provided in the applicable award agreement, the Committee may require a participant to forfeit cash-based or equity-based awards, repay all or a portion of cash-based or equity-based awards or otherwise make payments under certain circumstances if such participant engages in activity detrimental to the business of the Company. Additionally, any award granted pursuant to the 2016 Plan may be subject to forfeiture, cancellation or repayment upon such terms as may be required by the Committee or any applicable rules and regulations promulgated by the SEC or any securities exchange on which the Company's shares are traded.

Change in Control

        Awards granted under the 2016 Plan are generally subject to double-trigger vesting provisions upon a change in control (as defined in the 2016 Plan). This means that rather than vesting automatically upon a change in control, such awards will be subject to accelerated vesting only in the event of a qualifying termination following a change in control or in the event the acquiring company does not assume the awards.

        Under the 2016 Plan, in the case of a change in control, unless provided otherwise by the Committee or prohibited by applicable law, rule or regulation:


        Stock options or SARs that are not continued or assumed may also be terminated or canceled:

Amendment and Termination

        The board of directors may at any time amend, modify or terminate the 2016 Plan or outstanding awards issued under the 2016 Plan, except that the board of directors generally will not be able to alter the terms of an award if it would materially and adversely affect the rights of a participant without the consent of the affected participant. Stockholder approval will be required for any amendment to increase the maximum number of shares for which awards may be granted, change the designation of the class of persons eligible to receive awards under the 2016 Plan, or make any other change in the 2016 Plan which requires stockholder approval under applicable law or regulations.

Material Federal Income Tax Consequences under the 2016 Plan

        The federal income tax consequences of awards under the 2016 Plan for participants and the Company will depend on the type of award granted. The following description of tax consequences is intended only for the general information of stockholders. This discussion is general in nature; we have not taken into account a number of considerations which may apply in light of the circumstances of a particular participant. A participant in the 2016 Plan should not rely on this description and instead should consult his or her own tax advisor.

        The deductibility by the Company of all awards is subject to the limits on deductibility under Section 162(m), as described above.

        Options.    Under current law the grant of an option generally will have no federal income tax consequences for the participant or the Company. Upon the exercise of an option, the participant will recognize ordinary income in an amount equal to the excess of the fair market value of the stock on the exercise date over the exercise price. Generally, the Company will be entitled to a deduction equal to the amount of ordinary income recognized by the participant and at the time the participant recognizes such income for tax purposes, if the Company complies with applicable reporting requirements.

        Incentive Stock Options.    Under current law, the grant of an incentive stock option will not be a taxable event for the participant or for the Company. In addition, a participant generally will not recognize taxable income upon exercise of an incentive stock option. A participant's alternative minimum taxable income, however, will be increased by the amount by which the aggregate fair market value of the shares of the stock underlying the option, which is generally determined as of the date of exercise, exceeds the aggregate exercise price of the option. Any gain realized upon a disposition of the shares of stock received pursuant to the exercise of an incentive stock option will be taxed as long-term capital gain if the participant holds the shares for at least two years after the date of grant and for one year after the date of exercise (the "holding period requirement"). The Company will not be entitled to


any income tax deduction with respect to the exercise of an incentive stock option, except as discussed below.

        For the exercise of an incentive stock option to qualify for the foregoing tax treatment, the participant generally must be an employee of the Company or a subsidiary from the date the option is granted through a date within three months before the date of exercise of the option. If all of the foregoing requirements are met except the holding period requirement mentioned above, the participant will recognize ordinary income upon the disposition of the shares of stock in an amount generally equal to the excess of the fair market value of the shares of stock at the time the incentive stock option was exercised over the option exercise price (but not in excess of the gain realized on the sale). The balance of the realized gain, if any, will be capital gain.

        The Company will generally be allowed an income tax deduction to the extent the participant recognizes ordinary income, subject to the Company's compliance with Section 162(m) and to certain reporting requirements.

        Share Appreciation Rights (SARs).    Under current law, the grant of a SAR generally will have no federal income tax consequences for the participant. Upon the exercise of a SAR, the participant will recognize ordinary income equal to the amount measured by the difference between (i) the fair market value of one share of stock on the date the SAR is exercised over (ii) the SAR exercise price as determined by the Committee as of the date of grant. Generally, the Company will be entitled to a deduction equal to the amount of ordinary income recognized by the participant and at the time the participant recognizes such income for tax purposes, if the Company complies with applicable reporting requirements.

        Restricted Stock.    Under current law, the grant of restricted stock generally will have no federal income tax consequences to the participant or the Company. The participant will generally recognize ordinary income on the date the award vests, in an amount equal to the value of the shares of stock on the vesting date. Under Section 83 of the Code, a participant may elect to recognize income on the date of grant rather than the date of vesting in an amount equal to the fair market value of the shares of stock on the date of grant (less the purchase price for such shares of stock, if any). Generally, the Company will be entitled to a deduction equal to the amount of ordinary income recognized by the participant and at the time the participant recognizes such income for tax purposes, if the Company complies with applicable reporting requirements and subject to the limit on the deductibility under Section 162(m), as described above.

        Unrestricted Stock Awards.    Under current law, upon the grant of an award of unrestricted shares, a participant will be required to recognize ordinary income in an amount equal to the fair market value of the shares of stock on the date of grant, reduced by the amount, if any, paid for such shares. Upon a participant's disposition of such shares of stock, any gain realized in excess of the amount reported as ordinary income will be reportable by the participant as a capital gain, and any loss will be reportable as a capital loss. Capital gain or loss will be long-term if the participant held the shares of stock for more than one year (otherwise, the capital gain or loss will be short-term). Generally, the Company will be entitled to a deduction equal to the amount of ordinary income recognized by the participant and at the time the participant recognizes such income for tax purposes, if the Company complies with applicable reporting requirements.

        Restricted Stock Units, Performance Shares, Performance Units, and Performance Cash Awards.    Under current law, the grant of a restricted share unit award, performance share, performance unit or performance cash award generally will have no federal income tax consequences to the participant or the Company. The participant generally will recognize ordinary income when payment is actually or constructively received by the participant in satisfaction of the restricted share unit award, performance share, performance unit or performance cash award, in an amount equal to the amount of cash paid, if


any, and the fair market value of any shares of stock delivered to the participant. Generally, the Company will be entitled to a deduction equal to the amount of ordinary income recognized by the participant and at the time the participant recognizes such income for tax purposes, if the Company complies with applicable reporting requirements.

        Certain payments made to employees and other service providers in connection with a change in control may constitute "parachute payments" subject to tax penalties imposed on both the Company and the recipient under Sections 280G and 4999 of the Code. In general, when the value of parachute payments equals or exceeds three times the employee's "base amount," the employee is subject to a 20% nondeductible excise tax on the excess over the base amount and the Company is denied a tax deduction for the excess payments. The base amount is generally defined as the employee's average compensation for the five calendar years prior to the date of the change in control. The value of accelerated vesting of options, SARs, restricted shares, restricted stock units, performance shares, performance units, performance cash awards, dividend equivalent rights or other awards in connection with a change in control, as well as the full value of any such awards granted within one year preceding a change in control, can constitute a parachute payment.

New Plan Benefits

        At the 2016 Annual Meeting, stockholders are being asked to approve the adoption of the 2016 Plan. Stockholders are not being asked to approve any specific awards under the 2016 Plan. Except as described below, no awards have been made under the 2016 Plan as of the date of this proxy statement. Because benefits under the 2016 Plan are discretionary and will depend on the actions of the Committee, the performance of the Company and the value of our common stock, it is not possible to determine the benefits that will be received if stockholders approve the 2016 Plan.

        In March 2016, the Committee approved, contingent on stockholder approval of the 2016 Plan, 2016 cash incentive award levels and performance goals for the Company's executive officers, including the named executive officers, under the 2016 Short-Term Incentive Compensation Program (the "2016 Short-Term ICP") which are intended to qualify as cash-based awards under the 2016 Plan. Because adoption of the 2016 Short-Term ICP and grants of the individual cash-based awards are contingent on stockholder approval of the 2016 Plan, the 2016 Short-Term ICP and individual grants will be effective only if the Company's stockholders approve the 2016 Plan. If the Company's stockholders do not approve the 2016 Plan, the Committee may, at its discretion, establish 2016 short-term incentive plans for the Company's executive officers containing similar or different terms than those approved under the 2016 Short-Term ICP on a contingent basis, including, without limitation, target levels and performance conditions which may differ from those reported in this proxy statement.

        The 2016 short-term incentive award target levels approved for the Company's executive officers are as set forth below:

Name and Position
  
 Dollar Value(1) 

Frank H. Laukien, Ph.D. 

 President and Chief Executive Officer $952,000 

Anthony L. Mattacchione

 Senior Vice President and Chief Financial Officer $271,700 

Mark R. Munch, Ph.D. 

 Executive Vice President and President, Bruker Nano Group $302,800 

Juergen Srega

 President, Bruker CALID Group $195,370(2)

Rene Lenggenhager, Ph.D. 

 President, Bruker BioSpin Group $133,432(3)

Michael G. Knell

 Vice President and Chief Accounting Officer $93,300 

(1)
Represents dollar value at target award level. Actual award amounts earned may be greater or less than the target level reported based on Company and individual performance.

(2)
Represents U.S. Dollar value of Mr. Srega's 2016 incentive award target of €174,500, based on a conversion rate of €1:$1.1196 as of March 23, 2016 as reported on www.oanda.com.

(3)
Represents U.S. Dollar value of Dr. Lenggenhager's 2016 incentive award target of CHF 130,000, based on a conversion rate of CHF 1:$1.0264 as of March 23, 2016 as reported on www.oanda.com.

        The Board of Directors recommends a vote FOR the approval, on an advisory basis, of the Bruker Corporation 2016 Incentive2018 compensation paid to the named executive officers, as disclosed in the Compensation Plan.Discussion and Analysis, the compensation tables, and related narratives in this proxy statement.


Table of Contents


PROPOSAL NO. 3
RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

        ThePricewaterhouseCoopers LLP has been our independent registered public accounting firm since June 1, 2016, and has been selected by the Audit Committee of our board of directors is engaged in the process of selecting the Company'sBoard as our independent registered public accounting firm for the fiscal year ending December 31, 2016. Accordingly,2019. Although we are not recommendingrequired to seek stockholder approval of this appointment, the Board believes it to be sound corporate governance to do so. In the event that the stockholders anfail to ratify the appointment, the Audit Committee will investigate the reasons for stockholder rejection and will reconsider the appointment. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm for ratification atduring the 2016 Annual Meeting. Ernst & Young LLP served asyear if the Audit Committee believes that such a change would be in the best interests of Bruker and our independent registered public accounting firm for the fiscal year ended December 31, 2015 and has been our independent registered public accounting firm since 1998.stockholders.

        A representative of Ernst & YoungPricewaterhouseCoopers LLP is expected to be present at the 20162019 Annual Meeting and will have the opportunity to make a statement if he or she so desires to do so and will be available to respond to appropriate stockholder questions.

        Fees billed toThe Board recommends a vote FOR the Company by itsratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2019.


Table of Contents

Independent Registered Public Accounting Firm

        Fees billed to us by our independent registered public accounting firms for fiscal years 20142018 and 2015,2017, all of which were approved by the Audit Committee, were comprisedconsisted of the following:

 
 2018($) 2017($) 

Audit Fees

  6,617,693  6,555,369 

Audit Related Fees

    30,720 

Tax Fees

  2,803,103  2,078,281 

All Other Fees and Expenses

  2,700  42,286 

Total Fees

  9,423,495  8,706,656 

        Audit Fees.    Ernst & Young'sAudit fees for itsthe years ended December 31, 2018 and 2017 were for the audit of the Company'sour annual consolidated financial statements, including the integrated audit of internal control over financial reporting, itsthe review of the consolidated financial statements included in our quarterly reports on Form 10-Q, audits of statutory filings, comfort letter procedures and review of other regulatory filings for 2014 and 2015 were $5,431,280 and $5,244,918, respectively.filings.

        Audit-Related Fees.    Ernst & Young billed $3,000 in each of 2014Audit-related fees for the years ended December 31, 2018 and 2015 for audit-related services.2017 include amounts related to accounting consultations and services provided due to other statutory requirements.

        Tax Fees.    Ernst & YoungTax fees for the years ended December 31, 2018 and 2017 were for tax services provided to us, including tax compliance, tax advice and planning, totaled $176,611 in 2014 and $170,000 in 2015.planning.

        All Other Fees.    In 2014 and 2015, noAll other fees for servicesthe years ended December 31, 2018 and 2017 relate to license fees for a web-based accounting research tool as well as other than as indicated above were billed to us by Ernst & Young.advisory non-audit services.

Audit Committee Pre-Approval Policies and Procedures

        In order to ensure that audit and non-audit services proposed to be performed by the Company'sour independent registered public accounting firm do not impair the auditor's independence from the Company,Bruker, the Audit Committee has adopted, and the board of directorsBoard has ratified, the following pre-approval policies and procedures.

Policies

        Before engaging the independent registered public accounting firm to render the proposed service, the Audit Committee must either (i) approve the specific engagement ("specific pre-approval") or (ii) enter into the engagement pursuant to pre-approval policies and procedures established by the Audit Committee ("general pre-approval"), provided the policies and procedures are detailed for the particular service, the Audit Committee is informed of each service, and such policies and procedures do not include delegation of the Audit Committee's responsibilities to management. The Audit Committee annually reviews and pre-approves the services that may be provided by the independent registered public accounting firm without obtaining specific pre-approval. The Audit Committee will add to or subtract from this list of general pre-approved services from time to time, based on subsequent determinations.

        Unless a type of service has received general pre-approval, it requires specific pre-approval by the Audit Committee if it is to be provided by the independent registered public accounting firm. Any proposed services exceeding pre-approved cost levels or budgeted amounts also require specific pre-approval by the Audit Committee.


        For both types of pre-approval, the Audit Committee considers whether such services are consistent with the SEC's and the PCAOB's rules on auditor independence. The Audit Committee also considers whether the independent registered public accounting firm is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company'sour business, people, culture,


Table of Contents

accounting systems, risk profile and other factors, and whether the service might enhance the Company'sour ability to manage or control risk or improve audit quality. All such factors are considered as a whole, and no one factor will necessarily be determinative.

        The Audit Committee also considers the relationship between fees for audit and non-audit services in deciding whether to pre-approve any such services and may determine, for each fiscal year, the appropriate ratio between the total amount of fees for Audit, Audit-related and Tax services and the total amount of fees for certain permissible non-audit services classified as All Other services.

        The Audit Committee may delegate either type of pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.

Procedures

        Pre-approval fee levels or budgeted amounts for all services to be provided by the independent registered public accounting firm are established annually by the Audit Committee. Any proposed services exceeding these levels or amounts require specific pre-approval by the Audit Committee, even if previously generally pre-approved.

        All requests or applications for services to be provided by the independent registered public accounting firm that do not require specific approval by the Audit Committee are submitted to the Chief Financial Officer and must include a detailed description of the services to be rendered.

        Requests or applications to provide services that require specific approval by the Audit Committee must be submitted to the Audit Committee by both the independent registered public accounting firm and the Chief Financial Officer, and must include a joint statement as to whether, in their view, the request or application is consistent with the SEC's rules on auditor independence.

        The Audit Committee monitors the performance of all services provided by the independent auditor and assesses whether such services are in compliance with this policy.


STOCKHOLDER COMMUNICATIONSOTHER INFORMATION

Stockholder Communications

        The boardBoard will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as appropriate. Absent unusual circumstances or as contemplated by committee charters and subject to any required assistance or advice from legal counsel, Mr. Stein,Kristin Caplice, the Secretary of the Company,Bruker, is primarily responsible for monitoring communications from stockholders and for providing copies or summaries of such communications to the other directors as heshe considers appropriate.

        Communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments that Mr. SteinMs. Caplice considers to be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we may receive repetitive or duplicative communications.

        Stockholders who wish to send communications on any topic to the boardBoard should address such communications to Richard M. Stein,Kristin Caplice, Secretary, at Nixon Peabody LLP, 100 Summer Street, Boston,Bruker Corporation, 40 Manning Road, Billerica, MA 02110.01821.


Table of Contents

TIME FOR SUBMISSION OF STOCKHOLDER PROPOSALS
Time for Submission of Stockholder Proposals

        Pursuant to Rule 14a-8 under the Exchange Act, stockholders may present proper proposals for inclusion in a company's proxy statement and for consideration at the next annual meeting of its stockholders by submitting their proposals to Bruker Corporation in a timely manner.

        Stockholders interested in submitting a proposal for inclusion in the proxy materials for the annual meeting of stockholders in 20172020 may do so by following the procedures set forth in Rule 14a-8 of the Securities Exchange Act of 1934, as amended. To be eligible for inclusion, stockholder proposals must be received by us no later than December 23, 2016.19, 2019.

        Additionally, under our bylaws, no business may be brought before an annual meeting unless it is specified in the notice of meeting by or at the direction of the board of directorsBoard or by a stockholder entitled to vote who has delivered notice to Kristin Caplice, Secretary, at Bruker Corporation 40 Manning Road, Billerica, MA 01821 (containing certain information specified in the bylaws) not less than 90 or more than 120 days prior to the first anniversary of the preceding year's annual meeting.


OTHER MATTERS
Other Matters

        Management knows of no matters which may properly be and are likely to be brought before the meeting other than the matters discussed herein.in this proxy statement. However, if any other matters properly come before the meeting, the persons named in the enclosed proxy will vote in accordance with their best judgment.


ANNUAL REPORT
Annual Report

        A copy (without exhibits) of our Annual Report on Form 10-K for the fiscal year ended December 31, 20152018 is included in the 20152018 Annual Report provided to stockholders with this proxy statement.We will provide an additional copy of the 20152018 Annual Report (without exhibits) to any stockholder, without charge, upon written request of such stockholder. Such requests should be addressed to the attention of Investor Relations at Bruker Corporation, 40 Manning Road, Billerica, Massachusetts 01821.


VOTING PROXIES

        The board of directors recommends an affirmative vote on all proposals specified. Proxies will be voted as specified. If signed proxies are returned without specifying an affirmative or negative vote on any proposal, the shares represented by such proxies will be voted in favor of the board of directors' recommendations.

  By order of the board of directorsBoard

 

 


GRAPHIC
  Frank H. Laukien, Ph.D.
Chairman, President and Chief Executive Officer

April 22, 2016



Appendix A

BRUKER CORPORATION
2016 INCENTIVE COMPENSATION PLAN

        1.    Purpose of the Plan.    

        This incentive compensation plan (the "2016 Plan") is intended to encourage ownership of the stock of Bruker Corporation (the "Company") by management, employees, directors, consultants and advisors ("Participants") of the Company and its subsidiaries, to induce qualified personnel to enter and remain in the employ of the Company or its subsidiaries and otherwise to provide additional incentive for Participants to promote the success of its business. The 2016 Plan permits the grant of Non-qualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, unrestricted Stock Awards, Restricted Stock Units, Performance Shares, Performance Units, and Cash-Based Awards (each an "Award" and collectively "Awards").

        2.    Stock Subject to the 2016 Plan.    

        3.    Administration of the 2016 Plan.    

        The 2016 Plan shall be administered by the Board or a committee thereof (the "Compensation Committee") consisting of two or more persons appointed to such Compensation Committee from time to time by the Board; provided, however, that (i) such persons shall satisfy the independence or other applicable requirements of any exchange on which Shares are listed, (ii) to the extent necessary in order to permit officers and directors of the Company to be exempt from the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended (the "1934 Act") with respect to transactions pursuant to the 2016 Plan, each of such persons shall be a "Non-Employee Director" within the meaning of Rule 16b-3 promulgated by the Securities and Exchange Commission under the 1934 Act and (iii) if such qualification is deemed necessary in order for the grant, settlement or


exercise of Awards made under the 2016 Plan to qualify for any tax or other material benefit to participants of the Company under applicable regulations under Section 162(m) of the Internal Revenue Code of 1986, as amended (the "Code"), each of such persons shall be an "outside director" (as defined in applicable regulations thereunder). The term "Compensation Committee" shall, for all purposes of the 2016 Plan be deemed to refer to the Board if the Board is administering the 2016 Plan. If the 2016 Plan is administered by a Compensation Committee, the Compensation Committee shall from time to time select a Chairman from among its members and shall adopt such rules and regulations as it shall deem appropriate concerning the holding of meetings and the administration of the 2016 Plan. A majority of the entire Compensation Committee shall constitute a quorum and the actions of a majority of the members of the Compensation Committee present at a meeting at which a quorum is present, or actions approved in writing by all of the members of the Compensation Committee, shall be the actions of the Compensation Committee; provided, however, that if the Compensation Committee consists of only two members, both shall be required to constitute a quorum and to act at a meeting or to approve actions in writing. Except as otherwise expressly provided in the 2016 Plan, the Compensation Committee shall have all powers with respect to the administration of the 2016 Plan, including, without limitation, full power and authority to interpret the provisions of the 2016 Plan and any Award agreement granted hereunder, and to resolve all questions arising under the 2016 Plan. In addition, subject to applicable law, the Compensation Committee may delegate to one or more members of the management of the Company (as determined in the discretion of the Compensation Committee) the authority to grant Awards to Participants who are not officers or directors of the Company subject to Section 16 of the Exchange Act or Covered Employees (within the meaning of Section 162(m) of the Code), and any such delegatee(s) shall be considered the "Compensation Committee" hereunder with respect to Awards to such Participants. All decisions of the Compensation Committee shall be conclusive and binding on all participants in the 2016 Plan.

        4.    Award Limitations.    


        5.    Eligibility.    


        6.    Award Agreement.    

        Each Award shall be evidenced by an award agreement, as applicable (each an "Award Agreement"), duly executed on behalf of the Company and by the Participant to whom such Award is granted, which Award Agreement shall comply with and be subject to the terms and conditions of the 2016 Plan. The Award Agreement may contain such other terms, provisions and conditions which are not inconsistent with the 2016 Plan as may be determined by the Compensation Committee; provided that Awards designated as incentive stock options shall meet all of the conditions for incentive stock options as defined in Section 422 of the Code. In order to fulfill the purposes of the Plan and without amending the Plan, the Compensation Committee may modify Awards and the form of Award Agreements to Participants who are foreign nationals or employed outside of the United States in order to recognize differences in local law, tax policies, or customs. The date of grant of an Award shall be as determined by the Compensation Committee. More than one Award may be granted to an individual. Awards that vest solely based on service will be subject to a minimum vesting period requiring at least one year of service; provided that the Compensation Committee may adopt shorter vesting periods or provide for accelerated vesting after less than one year for Awards involving an aggregate number of Shares not exceeding five percent (5%) of the total number of Shares available for issuance under Section 2(a): (i) in connection with terminations of employment or service due to death, disability, retirement or other circumstances (not including voluntary pre-retirement termination) that the Compensation Committee determines to be appropriate; (ii) in connection with a Change in Control in which the Award is not continued or assumed (e.g., the Award is not equitably converted or substituted for a substantially similar award of the successor company); (iii) for grants made in connection with an acquisition by the Company or its Subsidiaries in substitution for pre-existing awards; (iv) for new hire inducement awards or off-cycle awards; or (v) to comply with contractual rights in effect on the date of approval of the Plan by the Board.

        7.    Options.


        To the extent that the right to purchase Shares under an option has accrued and is in effect, options may be exercised in full at one time or in part from time to time, by giving written notice, signed by the Participant exercising the option, to the Company, stating the number of Shares with respect to which the option is being exercised, accompanied by payment in full for such Shares as provided above. Upon such exercise, delivery of a certificate for paid-up non-assessable Shares shall be made at the principal office of the Company to the Participant exercising the option at such time, during ordinary business hours, not more than thirty (30) days from the date of receipt of the notice by the Company, as shall be designated in such notice, or at such time, place and manner as may be agreed upon by the Company and the person or persons exercising the option. Upon exercise of the option and payment as provided above, the Participant shall become a shareholder of the Company as to the Shares acquired upon such exercise.

        To the extent that an option to purchase Shares is not exercised by a Participant when it becomes initially exercisable, it shall not expire but shall be carried forward and shall be exercisable, on a cumulative basis, until the expiration of the exercise period. The Compensation Committee has power to establish restrictions, including but not limited to restrictions on partial exercise, in Award Agreements.



        8.    Stock Appreciation Rights.

        9.    Restricted Stock and Stock Awards.


        10.    Restricted Stock Units, Performance Units, and Performance Shares.    



        11.    Cash-Based Awards.    

        12.    Performance-Based Awards and Performance Measures.

        Awards that are designed to qualify for the performance-based exception from the tax deductibility provisions of Code Section 162(m) ("Performance-Based Awards") may be granted to a Participant who, as of the date of vesting and/or payout of such Award, or the date the Company or any of its subsidiaries is entitled to a tax deduction as a result of the Award, as applicable, is or may be one of the group of "covered employees," as defined in the regulations promulgated under Code Section 162(m), or any successor statute ("Covered Employees"). Unless and until the Compensation Committee proposes for shareholder vote and the Company's shareholders approve a change in the general performance measures set forth in this Section 12, the attainment of which may determine the degree of payout and/or vesting with respect to any Performance-Based Awards, the performance measure(s) to be used for purposes of such grants shall be chosen from among:


        Performance measures may be set either at the consolidated level, segment level, division level, group level, or business unit level. Additionally, performance measures may be measured either annually or cumulatively over a period of years, on an absolute basis or relative to pre-established targets, to a previous year's results or to a designated comparison group, in each case as specified by the Compensation Committee.

        Awards that are designed to qualify as Performance-Based Awards shall conform to the requirements of Section 162(m) of the Code. Generally, this requires that the amount paid under such an Award be determined based on the attainment of written, objective performance goals approved by the Compensation Committee for a performance period established by the Compensation Committee (i) while the outcome for that performance period is substantially uncertain and (ii) no more than 90 days after the commencement of the performance period to which the performance goal relates or, if less, the number of days which is equal to 25 percent of the relevant performance period. The Compensation Committee shall determine whether, with respect to a performance period, the applicable performance goals have been met by the Participant and, if they have, shall so certify and determine the amount of the applicable Award. Such Awards that are held by Covered Employees may not be adjusted upward. The Compensation Committee shall retain the discretion to adjust such Awards downward. No amount will be paid for any performance period until such certification is made by the Compensation Committee.

        The material terms of the performance measures shall be disclosed and reapproved by shareholders no later than the first shareholder meeting occurring in the fifth year following the year in which shareholders previously approved the performance measures. However, if applicable tax and/or securities laws change to permit Compensation Committee discretion to alter the governing performance measures without obtaining shareholder approval of such changes, the Compensation Committee shall have sole discretion to make such changes without obtaining shareholder approval.


        The Compensation Committee may make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events affecting the Company or the financial statements of the Company, such as, but not limited to, effects of changes in foreign exchange, an unbudgeted material expense incurred by or at the direction of the Board or a committee of the Board, a material litigation judgment or settlement, mergers, acquisitions, divestitures, spin-offs, consolidation, acquisition of property or stock, reorganizations, restructuring charges, or joint ventures, or of changes in applicable laws, regulations, or accounting principles, whenever the Compensation Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan; provided that, with respect to any Performance-Based Awards, no such adjustment shall be authorized to the extent that such adjustment would be inconsistent with the Award's satisfaction of the requirements for treatment as a Performance-Based Award under Section 162(m) of the Code or cause an Award not otherwise subject to the non-qualified deferred compensation rules of Section 409A of the Code to become so subject.

        13.    Recapitalizations, Reorganizations and the Like.

All such Awards shall be paid out to Participants within thirty (30) days following such qualifying termination, provided that there shall be no acceleration of the time for payment of any Award subject to Code Section 409A the acceleration of payment of which would result in additional taxes under Section 409A.


All such Awards shall be paid out to Participants within thirty (30) days following such Change in Control, provided that there shall be no acceleration of the time for payment of any Award subject to Code Section 409A the acceleration of payment of which would result in additional taxes under Section 409A.

        The Compensation Committee may also terminate Options or SARs provided that each Participant is first notified of and given the opportunity to exercise his/her vested Options or SARs for a specified period of time (of not less than 15 days) from the date of notification and before the Option or SAR is terminated. In addition, the purchaser(s) of the Company's assets or stock may, in his, her or its discretion, deliver to the Participant the same kind of consideration that is delivered to the shareholders of the Company as a result of such sale, conveyance or Change in Control, or the Board may cancel outstanding options or SARs in exchange for consideration in cash or in kind which consideration in both cases shall be equal in value to the value of those Shares or other securities the Participant would have received had the option or SAR been exercised (to the extent then exercisable) and no disposition of the Shares acquired upon such exercise been made prior to such sale, conveyance or Change in Control, less the exercise price therefor. Upon receipt of such consideration by the Participant, his or her option or SAR shall immediately terminate and be of no further force and effect. The Compensation Committee may also implement any combination of the foregoing or implement any other action with respect to an Award that it deems appropriate.




such dissolution or liquidation, to exercise his or her Options and SARs to the extent then exercisable.

        14.    No Special Employment or Other Rights.

        Nothing contained in the 2016 Plan or in any Award granted under the Plan shall confer upon any Participant any right with respect to the continuation of his or her employment or other relationship by the Company (or any subsidiary) or interfere in any way with the right of the Company (or any subsidiary), subject to the terms of any separate employment or other agreement, at any time to terminate such employment or other relationship or to increase or decrease the compensation of the Participant from the rate in existence at the time of the grant of an Award. Whether an authorized leave of absence, or absence in military or government service, shall constitute termination of employment or another relationship shall be determined by the Compensation Committee at the time.

        15.    Withholding.

        The Company's obligation to deliver Shares under the 2016 Plan and any payments or transfers under Section 13 hereof shall be subject to the Participant's satisfaction of all applicable Federal, state and local income, excise, employment and any other tax withholding requirements. If and to the extent permitted by the Compensation Committee, the Participant may satisfy, totally or in part, the Participant's tax obligations pursuant to this Section by electing to have Shares withheld from an Award upon grant or vesting, to redeliver Shares acquired under an Award, or to deliver previously owned Shares. All non-U.S. Participants must pay all applicable employee and employer wage and other withholding taxes in advance of receiving Shares.

        16.    Restrictions on Issue of Shares.

        17.    Purchase for Investment; Rights of Holder on Subsequent Registration.

        Unless the Shares to be issued pursuant to an Award granted under the 2016 Plan have been effectively registered under the Securities Act of 1933, as now in force or hereafter amended (the "1933 Act"), the Company shall be under no obligation to issue any Shares covered by any Award


unless the Participant, in whole or in part, shall give a written representation and undertaking to the Company which is satisfactory in form and scope to counsel for the Company and upon which, in the opinion of such counsel, the Company may reasonably rely, that he or she is acquiring the Shares issued pursuant to such Award for his or her own account as an investment and not with a view to, or for sale in connection with, the distribution of any such Shares, and that he or she will make no transfer of the same except in compliance with any rules and regulations in force at the time of such transfer under the 1933 Act, or any other applicable law, and that if Shares are issued without such registration, a legend to this effect may be endorsed upon the securities so issued. In the event that the Company shall, nevertheless, deem it necessary or desirable to register under the 1933 Act or other applicable statutes any Shares with respect to which an option shall have been exercised, or to qualify any such Shares for exemption from the 1933 Act or other applicable statutes, then the Company may take such action and may require from each Participant such information in writing for use in any registration statement, supplementary registration statement, prospectus, preliminary prospectus or offering circular as is reasonably necessary for such purpose and may require reasonable indemnity to the Company and its officers and directors and controlling persons from such holder against all losses, claims, damages and liabilities arising from such use of the information so furnished and caused by any untrue statement of any material fact therein or caused by the omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made.

        18.    Modification of Outstanding Awards; Shareholder Approval for Certain Plan Amendments.

        The Compensation Committee may authorize the amendment of any outstanding Award with the consent of the Participant when and subject to such conditions as are deemed to be in the best interests of the Company and in accordance with the purposes of this 2016 Plan. The foregoing notwithstanding, the Compensation Committee may not authorize any amendment of an outstanding Award, and shareholder approval obtained in the manner described in Section 19 will be required for any amendment of the Plan, that does any of the following: (a) permits the grant of any Option with an exercise price less than the fair market value (determined as provided in Section 7) of the Shares on the date of grant; (b) reduces the exercise price of an outstanding Option, either by lowering the exercise price or by canceling an outstanding Option and granting a replacement Option with a lower exercise price; (c) permits the grant of any SAR with a grant price that is less than the fair market value (determined as provided in Section 7) of the Shares on the date of grant; (d) reduces the grant price of an outstanding SAR, either by lowering the grant price or by canceling an outstanding SAR and granting a replacement SAR with a lower exercise price; (e) provides for cancelation in exchange for a cash payment of an Award the exercise price of which is greater than the then fair market value (determined as provided in Section 7) of the Shares; or (f) accelerates vesting in manner more favorable to a Participant than that provided by the last sentence of Section 6 or, with respect to an Award that is continued or assumed upon a Change in Control, than that provided by Section 13(b)(1).

        19.    Approval of Stockholders.

        The 2016 Plan shall be subject to approval by the vote of stockholders holding at least a majority of the voting stock of the Company present, or represented, and entitled to vote at a duly held stockholders' meeting, or by written consent of the stockholders as provided for under applicable state law, within twelve (12) months after the adoption of the 2016 Plan by the Board of Directors and shall take effect as of the date of adoption by the Board of Directors upon such approval. The Compensation Committee may grant Awards under the 2016 Plan prior to such approval, but any such Awards shall be become effective as of the date of grant conditioned upon such approval and, accordingly, prior to such approval, no option may be exercised nor any Award be vested or settled in vested Common Stock or cash.


        20.    Termination and Amendment.

        Unless sooner terminated as herein provided, the 2016 Plan shall terminate ten (10) years from the date upon which the 2016 Plan was duly adopted by the Board. The Board may at any time terminate the 2016 Plan or make such modification or amendment thereof as it deems advisable; provided, however, that except as provided in this Section 20, the Board may not, without the approval of the stockholders of the Company obtained in the manner stated in Section 19, increase the maximum number of Shares for which Awards may be granted or change the designation of the class of persons eligible to receive Awards under the 2016 Plan, or make any other change in the 2016 Plan which requires stockholder approval under applicable law or regulations.

        21.    Reservation of Stock.

        The Company shall at all times during the term of the 2016 Plan reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the 2016 Plan and shall pay all fees and expenses necessarily incurred by the Company in connection therewith.

        22.    Limitation of Rights in Shares Covered by Awards; Voting and Dividend Rights in Shares of Restricted Stock.

        23.    Detrimental Activity and Recapture Provisions.


        24.    Notices.

        Any communication or notice required or permitted to be given under the 2016 Plan shall be in writing, and mailed by registered or certified mail or delivered by hand, if to the Company, to its principal place of business, attention: Treasurer, and, if to a Participant, to the address as appearing on the records of the Company.

        25.    Substitute Awards.


        26.    Deferrals.

        Subject to the requirements of Section 409A, the Compensation Committee may in its sole discretion permit or require a Participant to defer such Participant's receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant by virtue of the lapse or waiver of restrictions with respect to Restricted Stock, payment of a Stock Award or the satisfaction of any requirements or goals with respect to Restricted Stock Units, Performance Units/Shares and Cash-Based Awards. If any such deferral election is required or permitted, the Compensation Committee shall, in its sole discretion, establish rules and procedures for such payment deferrals provided that such rules must comply with the requirements of Section 409A.

        27.    Governing Law.

        This Plan shall be governed by the internal laws of the State of Delaware, without giving effect to the conflicts of laws principles thereof.

        28.    Certain Definitions.

        Whenever used in this Plan, the following terms shall have the meanings set forth below, and when the meaning is intended, the initial letter of the word shall be capitalized:

        "Cash-Based Awards" are Awards denominated and payable in cash.

        "Incentive Stock Option" means an "incentive stock option" within the meaning of Code Section 422.

        "Non-qualified Stock Option" means an option that is not an Incentive Stock Option.

        "Option" means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to Section 7.

        "Performance Share" means an Award granted to a Participant the value of which is denominated in Shares and is earned by satisfaction of specified performance goals and such other terms and conditions that the Compensation Committee may specify pursuant to Section 10 hereof.

        "Performance Unit" means an Award granted to a Participant the value of which is specified by the Compensation Committee and is earned by satisfaction of specified performance goals and such other terms and conditions that the Compensation Committee may specify pursuant to Section 10 hereof.

        "Restricted Stock" means an Award of Shares subject to a Period of Restriction granted to a Participant pursuant to Section 9 hereof.

        "Restricted Stock Units" means an Award granted to a Participant the value of which is denominated in Shares and is earned by satisfaction of specified service requirements and such other terms and conditions that the Compensation Committee may specify pursuant to Section 10 hereof.

        "Stock Appreciation Right" or "SAR" means an Award denominated in appreciation in value of a Share and designated as an SAR pursuant to the terms of Section 8 hereof.

        "Stock Award" means an Award of Shares granted pursuant to the terms of Section 9(g) hereof.17, 2019


 

VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have the proxy card in hand when accessing the web site and follow the instructions to obtain records and to create an electronic voting instruction form. BRUKER CORPORATION C/O AMERICAN STOCK TRANSFER 6201 FIFTEENTH AVENUE BROOKLYN, NY 11219 VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have the proxy card in hand when calling and then follow the instructions. VOTE BY MAIL Mark, sign and date the proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E09888-P78642E74820-P22653 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. BRUKER CORPORATION The Board of Directors recommends you vote FOR each of the nominees listed below:following: For Withhold For All Withhold All For All ExceptAllAllExcept To withhold authority to vote for any individual nominee(s), mark “For"For All Except”Except" and write the number(s) of the nominee(s) on the line below. ! ! ! 1. Election of fourthree Class I directors to serve for a three-year termterms expiring in 2019.2022. Nominees: 01) Frank H. Laukien 02) John Ornell 03) Richard A. Packer 04) Robert Rosenthal Election of one Class IIIII director to serve for a one-yeartwo-year term expiring in 2017.2021. Nominee: 05) Cynthia M. Friend04) Robert Rosenthal For Against Abstain The Board of Directors recommends you vote FOR proposal 2. For Against Abstainproposals 2 and 3. ! ! ! ! ! ! 2. To approve on an advisory basis the adoption2018 compensation of our named executive officers, as discussed in the Proxy Statement. 3. Ratification of the Bruker Corporation 2016 Incentive Compensation Plan.appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2019. NOTE: The undersigned also authorizesIn their discretion, the named Proxiesproxies are authorized to vote in their discretion uponon such other business as may properly come before the meeting or any adjournment or postponement thereof. ! For address changes/comments, mark here. (see reverse for instructions) ! Yes ! No ! Please indicate if you plan to attend this meeting. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date

GRAPHIC

 


Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Annual Report and Notice and Proxy Statement are available at www.proxyvote.com. E09889-P78642E74821-P22653 BRUKER CORPORATION THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Frank H. Laukien and Richard M. Stein,Gerald N. Herman, or either of them, with power of substitution, Proxies to vote at the Bruker Corporation Annual Meeting of Stockholders on May 20, 2016,2019, and any adjournments or postponements thereof, all shares of common stock of Bruker Corporation that the undersigned is entitled to vote at such meeting on matters which may come before the Annual Meeting in accordance with and as more fully described in the Noticenotice of Annual Meeting of Stockholders and the Proxy Statement. The undersigned acknowledges receipt of the Noticenotice of the 20162019 Annual Meeting of Stockholders and the accompanying Proxy Statement and revokes any proxy heretofore given with respect to such meeting. The votes entitled to be cast by the undersigned will be cast as instructed. If this proxy is executed, but no instruction is given, the votes entitled to be cast by the undersigned will be cast “FOR”"FOR" each of the nominees for director in Proposal 1, "FOR" Proposal 2, and "FOR" Proposal 2,3, each of which is set forth on the reverse side hereof. The votes entitled to be cast by the undersigned will be cast in the discretion of the named Proxies on any other matter that may properly come before the meeting and any adjournment or postponement thereof. (If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on reverse side Address Changes/Comments:

GRAPHIC

 



QuickLinks

BRUKER CORPORATION 40 Manning Road Billerica, MA 01821 (978) 663-3660
BRUKER CORPORATION NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
BRUKER CORPORATION PROXY STATEMENT
RECORD DATE AND VOTING SECURITIES
CORPORATE INFORMATION
PROPOSAL NO. 1 ELECTION OF DIRECTORS
BOARD LEADERSHIP STRUCTURE
BOARD MEETINGS, COMMITTEES AND COMPENSATION
DIRECTOR NOMINATIONS
ROLE OF THE BOARD IN RISK OVERSIGHT
COMPENSATION OF DIRECTORS
2015 Director Compensation Table
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
EXECUTIVE OFFICERS
COMPENSATION DISCUSSION AND ANALYSIS
2015 Cash Incentive Performance and Payout Measurement
2015 Cash Incentive Targets
Quantitative Performance Goals (70% of Target Bonus Potential)
Individual Qualitative Performance Goals (30% of Target Bonus Potential)
Quantitative Performance Goals (70% of Target Bonus Potential)
Individual Qualitative Performance Goals (30% of Target Bonus Potential)
Quantitative Performance Goals (70% of Target Bonus Potential)
Individual Qualitative Performance Goals (30% of Target Bonus Potential)
2015 Long-Term Equity Incentive Awards
COMPENSATION COMMITTEE REPORT
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
SUMMARY OF EXECUTIVE COMPENSATION
Summary Compensation Table
2015 Grants of Plan-Based Awards
Outstanding Equity Awards at December 31, 2015
2015 Option Exercises and Stock Vested
Pension Benefits
2015 Pension Benefits Table
2015 Non-Qualified Deferred Compensation Table
Potential Payments upon Termination or Change-in-Control
RELATED PERSONS TRANSACTIONS
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
AUDIT COMMITTEE REPORT
PROPOSAL NO. 2 APPROVAL OF THE 2016 INCENTIVE COMPENSATION PLAN
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
STOCKHOLDER COMMUNICATIONS
TIME FOR SUBMISSION OF STOCKHOLDER PROPOSALS
OTHER MATTERS
ANNUAL REPORT
VOTING PROXIES
BRUKER CORPORATION 2016 INCENTIVE COMPENSATION PLAN